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Abstract
The objective of this thesis is to establish design rules for nanoparticle properties that enable
their in vivo transport to target destinations. Gold nanoparticles containing surface-engrafted
polyethylene glycol (PEG) chains are prepared with controlled physicochemical properties (hy-
drodynamic size, surface charge, targeting ligand density). Upon systemic injection into mice,
the transport of nanoparticles is monitored by blood pharmacokinetics as well as distribution at
the organ, tissue, and subcellular levels from the same injection in an individual animal.
At a constant, slightly negative surface charge (ca. −10 mV), most PEGylated gold nanopar-
ticles (PEG-AuNPs) deposit in the liver, spleen, and kidney of normal mice 24 hours after in-
jection. Increasing retention in the liver (Kupffer cells) and spleen correlate positively with
increasing nanoparticle diameter over the range of 25-165 nm, largely due to phagocytic uptake.
Accumulation in the kidney is size-dependent, but shows a maximum uptake at ca. 75 ± 25 nm
that also gives the highest deposition in the mesangium (uptake by mesangial cells).
Tumor-bearing mice received injections of PEG-AuNPs of near-constant size (ca. 75 nm)
and surface charge (ca. −10 mV) but with variable amounts of ligands that target cancer cells
(0-144 ligands per nanoparticle). Independent of ligand content, nanoparticles accumulate in the
tumor by the enhanced permeation and retention effect to the same magnitude, and adjacent
to leukocytes. Nanoparticles only enter cancer cells in significant amounts when they contain
viii
targeting ligands above a threshold amount (between 18 and 144 ligands per nanoparticle).
Mechanistic studies from model nanoparticles provide insights for the delivery of therapeu-
tic nanoparticles. Systemic administrations of targeted, cyclodextrin-based, siRNA-containing
nanoparticles are investigated in animals and humans (Phase I clinical trial). A fluorescent
chemical stain with exposed adamantane molecules for binding into the cyclodextrin cups of the
targeted nanoparticles is created, allowing for the examination of tumor tissue sections from
animals and patient biopsies. Results from both animal and human tissues reveal intracellular,
dose-dependent accumulation of targeted nanoparticles in cancer cells of the tumor.
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1Chapter 1
Introduction
Chemical engineering (ChE) as an academic discipline has undergone much revision and inno-
vation over the past decades, characterized by its rapid expansion from petroleum sciences into
new frontiers such as medicine, microelectronics, and environmental sciences. With advances
in computing, instrumentation, and synthesis and characterization of nanomaterials (e.g., bio-
logical [1], colloidal [2]), modern ChE has switched its focus from studying large-scale reactions
or mechanisms to processes at the molecular/atomic level in the past three decades [3]. Armed
with knowledge across multiple time and length scales, modern chemical engineers can contribute
more to the emerging field of nanotechnology.
General interest in nanotechnology is enormous. Nanoscale objects can have properties (e.g.,
strength, electric conductivity, melting point, color, and magnetic moment) different from those
of their macroscopic equivalents, owing to fundamental principles of quantum physics, and have
seen their widespread application in many commercial prodicts. Giant magnetoresistive heads
found in computer hard drives have nanoscale structural dimensions to reduce the size required
for storing memory bits. Textiles blended with nanoparticles are in vogue due to their impressive
stain-proof, water-proof, and wrinkle-resistant properties.
2Bionanotechnology
Like ChE, biological sciences have also adopted a more “reductionist” approach [4], with their
pedagogical focus shifting away from the “ensemble perspective” (e.g., anatomy and physiology)
to “individual perspective” (e.g., cellular biology and molecular pharmacology). The manipula-
tion of biological processes, mechanisms, and pathways (all building blocks that contribute to the
integrated process of life [5]) have been conducted at the nanoscale level [6]. More exquisite tools
from physics and chemistry are available to image and control the properties of cell membranes,
proteins, nucleic acids, or even atoms (all of nanoscale dimensions).
Integration of nanotechnology with biotechnology, as well as with information technology and
cognitive science, is expected to accelerate in the next decade [7]. In particular, “bionanotechnol-
ogy” integrates nanoscale principles and techniques with biological systems in the development
of biomimetic nanostructures, design tools and devices to facilitate biomedical research, and gen-
erate new therapeutics [8]. Active nano-based research by biomedical engineers began around
1999, accompanied by the concomitant increase in government support.
The ability to control material properties on the nanoscale catalyzes the development of novel
diagnostics and imaging agents for detecting diseases [9]. Silicon-based nanowires can electrically
detect femtomolar concentrations of marker proteins overexpressed in cancer cells present in blood
serum [10]. Gold nanoparticles conjugated with DNA strands can identify marker proteins at a
sensitivity of a million times higher than conventional ELISA assys [11], and have been extended
to detect nucleic acid sequences, small molecules, and inorganic ions as well [12]. When injected
in mice, cadmium-selenium quantum dots can reveal sentinel lymph nodes [13] and recently lung
tissues [14] located at centimeters beneath the skin under near-infrared light.
Reasons for the widespread use of nanosized objects in biomedical applications are multifold.
Despite their smallness, nanosized objects (1-1000 nm in diameter) are still considerably larger
3than molecules, and hence can receive surface engraftment of different types of moieties to achieve
multiple functions simultaneously (e.g., target receptors, image cells, and inhibit gene). The
smallness also translates to a high surface area to volume ratio, allowing more dense and compact
packing of moieties on their periphery. Finally, the nanoscale dimension corresponds to the
typical size of fenestrations and tight junctions of most tissues and cells.
As of 2006, drug delivery represents the most popular branch within the field of nanomedicine,
netting the highest number of publications, patents, and commericalized products compared to
biomaterials, active implants, in vitro diagnostics, and in vivo imaging agents [15]. As therapeutic
delivery systems, nanoparticles allow targeted delivery and controlled release. For diagnostic
applications, nanoparticles allow detection on the molecular scale.
Nanoparticle-based drug delivery
A historical perspective
The key objective of a delivery system is to release therapeutics at the desired anatomical site, at a
suitable concentration and for a desired duration, independent of the route of administration (e.g.,
oral, parenteral, pulmonary, transdermal, systemic). For the past five decades, techniques such
as compression, spray and dip coating, and encapsulation are widely used in the pharmaceutical
industry to imbibe therapeutics with polymers [16]. Since the first report of sustained drug
release systems in the 1970s [17], the field of drug delivery witnessed the development of new
classes of polymer-based drug delivery devices, including diffusion-controlled, solvent-activated
(swelling- [18] or osmotically controlled [19]), chemically controlled (biodegradable) [20], and
environmentally induced systems (e.g., pH, temperature) [21].
Therapeutic nanoparticles are now under intense development for the treatment of diseases
such as cancer, inflammatory disorders, and cardiovascular disease [22] [23]. Upon their admin-
4istration, they can selectively accumulate in biological sites, enhance the delivery of the drug
payload in the most non-invasive and cost-effective manner (i.e., utilizing minimal dosage to
achieve maximal potency). Two archetypal therapeutic nanoparticles that laid the cornerstone
for modern nanoparticle-based drug delivery are liposomes and polymer–drug conjugates.
Initially discovered in the 1960s [24], liposomes are spherical vesicles with a phospholipid bi-
layer membrane structure that can encapsulate both hydrophilic and hydrophobic agents. They
are biologically inert and weakly immunogenic, and thus constitute attractive vehicles for deliver-
ing different types of therapeutic cargo (e.g., small molecules, nucleotides, proteins). Drug-loaded
liposomes were first reported in 1973 [25], yet their in vivo delivery suffered from severe uptake by
mononuclear macrophages and serum complement components. Their interaction with lipopro-
teins also led to the premature release of the cargo in blood [26]. Such limitations prompted the
development of “stealth” liposomes [27] and “long-circulating” liposomes [28], both with longer
circulation half-lives and reduced toxicity than the free drug. The first liposome-based therapeu-
tic, liposome-encapsulated doxorubicin (Doxil), received FDA approval in 1995 for the treatment
of HIV-related Kaposis sarcoma. The basic concept of liposomes spurred the development of
new-generation nanocarriers (e.g., virosomes [29], polymersomes [30]) and new liposome-based
applications (e.g., photothermal therapy [31], diagnostic imaging [32]). By modifying the lipid
structure, liposomes can also contain targeting ligands (e.g., monoclonal antibodies or fragments,
peptides, glycoproteins, carbohydrates, or receptor ligands) and form “immunoliposomes”, to en-
hance the selective accumulation in desired tissue and cellular locations [33] [34].
As a point of digression, other nanocarrier systems for drug delivery also appeared at the same
time as drug-containing liposomes, although they did not receive as much attention as liposomes.
One notable exception is albumin-bound paclitaxel (Abraxane) [35] [36], the first protein-based
nanoparticle to receive FDA approval for the treatment of metastatic breast cancer in 2005.
Polymeric nanoparticles, micelles, nanoshells, dendrimers, viral nanoparticles, metallic nanopar-
5ticles, and ceramic nanoparticles have also shown therapeutic potential in multiple branches of
medicine, such as oncology, immunology, neurology, ophthalmology, and orthopedics [37].
Polymer-drug conjugates, the second important class of nanoparticle-based therapetics be-
sides liposomes, first appeared in the 1970s [38]. Since their conception, polymer coating has
immediately become an indispensable component of modern nanoparticle-based therapeutics to
regulate their in vivo behavior. For sustained drug release applications, biodegradable poly-
mers (e.g., poly(-caprolactone), poly(lactic acid) (PLA), poly(glycolic acid) (PGA), and their
copolymers) have been under development for over two decades [39] [40] [41]. To prolong blood
pharmacokinetics, hydrophilic and non-immunogenic polymers such as poly (ethylene glycol)
(PEG) and N-(2-hydroxypropyl)methacrylamide (HPMA) have proven to be very effective. The
next section features an overview of PEG in nanoparticle forumulations.
Poly (ethylene glycol)
Poly (ethylene glycol) (PEG) has a general structure of HO–(CH2CH2O)n–CH2CH2-OH (poly-
dispersity = 1.01), encompassing a chemically inert polyether backbone, with terminal hydroxyl
groups that can be activated for conjugation to different types of polymers and drugs. It has
high solubility in both organic and aqueous solvents. Despite its gradual decomposition in vivo
by enzymolysis [42] and hydrolysis [43], PEG still represents the most common and validated
polymer used in drug delivery formulations compared to other alternatives, such as dextran,
chitosan, heparin, poly (amino acids), and vinyl polymers.
PEG has long been utilized as a modification agent of individual proteins, peptides, antibod-
ies (and their fragments). Many therapeutic proteins have limited bioavailability due to their
continuous enzymatic degradation by serum proteins. They require high doses to maintain effi-
cacy, which can impart immunological risks. In 1977, Abuchowski et al. pioneered the covalent
attachment of methoxy-PEG (mPEG) to bovine liver catalase, and reported marked improve-
6ments in blood circulation and reduced immunogenicity [44]. Most importantly, PEGylation (the
covalent attachment of PEG) did not drastically hamper the biological activity of the enzyme.
As a significant breakthrough in drug delivery, this study sparked the development of a plethora
of PEG-protein conjugates [45] [46] [47] for various biomedical applications in the 1980s. Ow-
ing to its bulkiness and hydrophilicity, PEG augments the hydrodynamic size of the conjugated
proteins far beyond the increase in molecular mass [48]. Due to their flexibility, PEG chains
can shield protein sites from recognition by the immune system, cellular receptors, or proteases.
Thus, PEG-protein conjugates are more resistant to non-specific uptake by the organs (e.g., liver,
spleen) of the reticuloendothelial system (RES), and can remain in blood circulation in a pro-
longed manner to reach as well as accumulate in the target organs [49]. With multiple PEG5000
strands connected to each molecule of therapeutic protein, PEGylation enhanced the circulation
of the protein by 3-4 times. Representative PEG-protein conjugates that met FDA approval
include Adagen (bovine adenosine deaminase-PEG) [50] and Oncaspar (L-asparaginase-PEG)
[51]. Despite the increase in blood circulation and solubility, PEGylation can adversely affect
protein binding, leading to the concomitant reduction in functional activity (e.g., internaliza-
tion, intracellular transport, and lyzosomal degradation) [52]. The recent creation of site-specific
PEG modification techniques has shown promise in ameliorating the undesirable loss in protein
function associated with random PEGylation [53] [54].
In contrast to therapeutic proteins, small-molecule drugs suffer from limited bioavailability
due to poor aqueous solubility, high toxicity, rapid excretion, and untargeted biodistribution. To
improve their solubility and extend their blood circulation, PEGylation typically entails polymer
chains of at least 40,000 in molecular weight to avoid renal clearance [55] [56]. The conjugation
chemistry for non-protein drugs is facile because of less functional groups present on a small
molecule, absence of conformational constrains, and simpler purification and characterization
procedures for the conjugates [57]. Examples of PEG-small molecule conjugates include PEG-
7paclitaxel [58] and Prothecan (PEG-camptothecin) [59], and PEG-doxorubicin [60]. A key draw-
back with PEGylation of small molecules lies on the low loading of PEG, with only 1-2 hydroxyl
terminal groups per strand for activation. The recent development of multi-arm PEG-containing
dendrimers permits the engraftment of multiple copies of PEG-small molecule conjugates on the
same structure to increase loading [61] [62]. Dendrimers are highly branched, globular structures
with an initiator core and mulitple layers of polymer strands.
In general, reaction with PEG derivatives does not alter the mechanism of action of a thera-
peutic protein/ small molecule. It enhances its therapeutic effect by altering its pharmacokinetics.
Thesis objectives
Spurred by advances in wet chemistry and fabrication techniques, nanosized objects can now
assume different physical properties (e.g., hydrodynamic size, geometry, rigidity, porosity), sur-
face properties (e.g., surface functionality, charge, hydrophobicity, polymer type and grafting
density), targeting ligands (e.g., proteins, peptides, aptamers, small molecules, antibodies), and
chemical composition (e.g., carbon nanotubes and bucky balls, quantum dots, supramagnetic
oxide nanoparticles, nanocrystals, nanowires, nanocages, polymeric micelles). Such “modular-
ity” allows for the creation of an infinite assortment of nanoparticles of various properties. Each
class of nanoparticles will demonstrate distinct in vivo profiles (e.g., blood clearance, drug-release
kinetics, tissue accumulation, intracellular localization, toxicity, and drug stability) [63] [64].
This thesis elucidates the structure-function relationships between nanoparticle proper-
ties and their in vivo behavior. Its objective is to seek new mechanistic understanding in
factors that govern the systemic delivery of nanoparticles to biological desinations in vivo. Below
features sample mechanistic approaches to examine the effects of two nanoparticle properties,
particle size and targeting ligand density, for drug delivery applications.
8Various physiological mechanisms are responsible for nanoparticle clearance from blood cir-
culation. Rigid quantum dots smaller than 5 nm experience renal filtration via urine. On the
other hand, metallic nanoparticles larger than 100 nm face severe removal by phagocytosis of the
liver and spleen. Mechanistic studies that examine in vivo behavior as a function of particle
size (Chapters 2 and 4) permit the optimization of nanocarriers with longer blood circulation.
Upon diffusion into the target tissues, systemically delivered nanoparticles must enter cells to
exert their desired therapeutic action by crossing the cell membrane. With decoration of ligands,
targeted nanoparticles can bind to receptors on the cell membrane with enhanced affinity and
specificity. Internalization of the receptor/ligand complexes leads to receptor-mediated endocy-
tosis of the targeted nanoparticles. Alternatively, nanoparticles can interact with the membrane
via hydrophobic and electrostatic interactions and enter the cell through pinocytosis. For the first
approach, mechanistic studies that examine in vivo behavior as a function of ligand density
(Chapter 3) enables the design of nanoparticles with elevated intracellular accumulation.
Brief pharmarcology
The illustration of in vivo nanoparticle behavior warrants an introduction to the fundamental
concepts in pharmacology, a field that examines the interactions between a living organism and
chemicals that affect biochemical functions [65], such as drug composition, toxicity, and therapy.
The two main areas of pharmacology are pharmacokinetics and pharmacodynamics.
Pharmacokinetics (PK) determines the in vivo fate of substances administered externally to
a living organism [66]. It analyzes the extent and rate of liberation (release of chemicals from
the formulation), absorption (entry into blood circulation), distribution (dispersion or dissemi-
nation in fluids and tissues), metabolism (irreversible decomposition into daughter metabolites),
and excretion (elimination of the substances from the body). Some recurrent PK parameters
9discussed throughout this thesis are dose (D; quantity of injected drug), concentration (Cp; drug
concentration in plasma), volume of distribution (VD = D/C0, where C0 is the initial concen-
tration), area under the curve (AUC =
∫∞
0 Cpdt; integral of the plasma drug concentration (Cp)
after injection), clearance (CL = D/AUC = VD ×Ke; volume of plasma cleared of the drug per
unit time, where Ke is the elimination rate constant), and biological half-life (t1/2 = ln 2/Ke;
time required for the drug concentration to reach half of its original value).
Pharmacokinetics (PD) determines the biochemical and physiological effects of drugs on the
body, mechanisms of drug action, and relationship between drug concentration and effect [67].
Several PD concepts mentioned in this work include toxicity, dose-response relationships (e.g.,
efficacy, potency, cellular uptake), and ligand-receptor binding interaction.
Gold nanoparticles
For all mechanistic studies, this thesis involves the intravenous administration of model nanopar-
ticles into mice to analyze their in vivo nanoparticle behavior. Below summarizes the rationales
behind the use of PEGylated gold nanoparticles as model probes.
Due to their electronic, optical, fluorescent, and magnetic properties, metallic nanoparticles
have found diverse applications in catalysis, energy, medicine, electronics, and the environment.
Most applications of metallic nanoparticles stem from two principles: (1) surface functionaliza-
tion to attain desirable in vivo properties (e.g., colloidal stability, biocompatibility, molecular
targeting); (2) excitation of the surface plasmons to explore their unique optical properties
across the vis-NIR band [68]. A significant portion of this thesis entails the use of PEGylated
gold nanoparticles to interrogate the in vivo targeting of biological sites.
Gold nanoparticles (AuNPs) have a long history of use, dating back to the 5th century B.C.
for making ruby glass and adding a reddish tinge to ceramics. Hindu chemists for Ayurveda, the
10
Figure 1.1: Properties of gold nanoparticles. (A) The large surface plasmon peak at 530 nm allows
for easy quantification of bulk gold particle (diameter = 50 nm) content by UV-Vis spectrometry. (B)
The high electron density of gold nanoparticles by transmission electron microscopy (TEM). (C) Negative
staining by 1% phosphotungstic acid reveals the faint halo of PEG5000 layer (marked by black arrows)
covalently grafted on the periphery of 80 nm gold nanoparticles under TEM. Scale bar = 100 nm.
ancient system of Indian medicine, prepared “longevity” concoctions based on gold colloids [69].
Significant experimental progress made from the 19th and 20th centuries aimed at deciphering
the nature of colloidal matter. Faraday first examined the optical properties of metallic colloids
(including AuNPs), within the context of aggregation and sedimentation [70]. Zsigmondy con-
structed an ultramicroscope to visualize the size and mobility of colloidal dispersions, and later
developed the “seed-mediated” method to create AuNPs [71]. Svedberg pioneered the use of elec-
trochemical methods to make AuNPs, and later invented analytical ultracentrifugation to size
AuNPs [72]. Meanwhile, theoretical advances by Einstein [73], Smoluchowski [74], and Langevin
[75] enriched the understanding of the continuous Brownian motion of colloidal suspensions.
Nanosized gold constitutes the most popular class of nanoparticles used in biomedical ap-
plications, ranging from targeted delivery (small molecule drugs, genetic materials, antigens),
cellular imaging, medical diagnostics, to treatment of diseases (tumors or rheumatoid arthritis)
[76] [77]. Several intravenous applications using nanosized gold for cancer treatment are currently
under early clinical development, such as AurImmune [78], AuriTol, and AuroLase [79].
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AuNPs provide a well-defined, rigid core for surface modification with ligands. Scalable
synthesis of monodisperse AuNPs with tunable dimensions is straightforward [80] [81]. The
strong surface plasmon peak of AuNPs allows easy detection by UV-Vis spectrometry (Fig.
1.1A). For surface modification, purification of AuNPs from unreacted ligands by centrifugation
is facile owing to the high density of gold (ρ = 19.3 g/cm3). Dynamic light scattering (DLS) can
characterize the hydrodynamic size and surface charge, by treating AuNPs as a dilute suspension
of spherical spheres that exhibit strong Mie scattering [82]. Without non-spherical contaminants
or aggregates (which can drastically skew the scattering intensity), DLS can provide reasonably
accurate mean values for the physicochemical parameters of a single AuNP.
The examination of in vivo targeting necessitates the detection of nanoparticles in biolog-
ical structures. The current “gold standards” to quantify bulk gold concentrations of tissues
are inductively coupled plasmonic mass spectrometry (ICP-MS) [83] and instrumental neutron
activation analysis (INAA), with an about 0.02-1 ppb detection limit. Atomic absorption spec-
troscopy (AAS) can also measure bulk gold content, albeit at a lower sensitivty. AuNPs can
catalyze the selective reduction of silver ions to metallic silver and the subsequent deposition
of metallic silver onto the particle surface. This “silver enhancement” method allows for their
visualization of AuNPs as size-enhanced entities in tissue sections (prepared from routine his-
tological procedures) under light microscopy (LM) [84]. Electron microscopy (e.g., transmission
electron microscopy (TEM) and scanning electron microscopy (SEM)) can ascertain localization
of AuNPs in cells and subcellular compartments, owing to the high electron density of AuNPs
(Fig. 1.1B). When used together with energy dispersive X-ray spectroscopy (EDX) and X-ray
absorption spectroscopy (XAS), EM can provide additional information about elemental data
and structural information of gold and sulfur atoms, respectively. This thesis employs ICP-
MS, histology with silver enhancement, and TEM to provide a top-down elucidation of in vivo
distribution of AuNPs on organ, tissue, and (sub)cellular levels from the same animal (Fig. 1.2).
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Like their bulk metal counterpart, AuNPs generally have low in vitro toxicity independent of
size and geometry [85], opening the door for their i.v. injection and examination of their in vivo
pharmacological behavior. When exposed to AuNPs with negative or neutral capping agents
(e.g., citrate, biotin, glucose, cysteine), cells internalized AuNPs up to 100 µM with no apparent
sign of toxicity. At minute concentrations (10 nM), the same cells showed toxicity for AuNPs
capped with cetyltrimethylammonium bromide (CTAB), a structure directing agent with a quar-
ternary amine group [86]. While cationic AuNPs induce toxicity than anionic AuNPs (perhaps
due to the electrostatic interaction between positive particles and negative cell membranes [87]),
this phenomenon depends on the specific cell lines under investigation [88].
Particle stability is crucial to maintain the physicochemical parameters (e.g., size, surface
charge, targeting ligand density) of nanoparticles constant in vivo. Such parameters must be
optimal to achieve effective delivery to the target site as individual entities and thus elicit the
desirable biological response. While most naked nanoparticles are inherently stable in deionized
water due to charge repulsion, the addition of salt induces charge screening and protein adsorp-
tion, respectively, shielding their surface charge and leading to particle aggregation. Unmodified
nanoparticles (e.g., metallic, liposomes, latex) are also subject to non-specific binding by blood
serum proteins (most notably fibrinogen, albumin, trypsin, apoproteins, immunoglobulins, and
complement factors [89] [90] [91]) onto their periphery, causing their enlargement in size and
elevated ability to cause blood clotting [92]. By grafting with PEG chains that serve as extended
brush layers, adjacent nanoparticles are less vulnerable to salt- and serum-induced aggregation
by maintaining considerable separation distance between particles.
The decoration of AuNPs with a monolayer of thiolated PEG (PEG-SH) via the formation of
covalent gold-thiol linkages (bond energy = 30-40 kJ/mol [93]) is a popular approach to confer
steric stability to AuNPs. For each AuNP grafted with alkanethiols, crystallization and X-ray
structure determination studies show that all sulfur atoms bind in a bridge conformation to two
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Figure 1.2: Levels of biodistribution. Inductively coupled plasma mass spectrometry (ICP-MS), light mi-
croscopy (LM) with silver enhancement, and transmission electron microscopy (TEM) collectively monitor
the in vivo distribution of PEGylated gold nanoparticles at the organ, tissue, and cellular levels, respec-
tively. Representative data of each imaging method is provided to illustrate this top-down approach in
tracking particle localization in the kidney.
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Figure 1.3: Assembly of Aux-PEGy NPs. Unmodified gold nanoparticles of different core sizes (x) (Aux
NPs) were reacted with methoxy-PEG-SH of different molecular weights (y) in deionized water for 30 min
at RT under constant stirring to form PEGylated gold nanoparticles (Aux-PEGy NPs).
gold atoms, at least one of which binding to two sulfurs, forming a “staple” motif [94]. Due
to the soft character of gold and sulfur, sulfur ligands (e.g., alkanethiols, xanthates, disulfides,
mercaptoalkanoic acids) can chelate to gold atoms to form thiolated AuNPs of reduced dispersity,
controlled size, and stability in air and against heat [95]. Fig. 1.1C illustrates a 80 nm AuNP
with covalent engraftment of mexthoxy-PEG5000-thiol chains on the surface.
Thesis structure
Chapters 2-4 represent mechanistic studies in mice that received i.v. administration of PEGylated
gold nanoparticles as in vivo model probes. Chapter 5 reports a technical development in ex
vivo detection methods that employs PEGylated gold nanoparticles as the contrast agent.
Chapter 2 ascertains the mechanistic effects of passive tumor targeting. Using tumor-bearing
mice, it studies the effect of particle size on tumor retention, clearance by the liver, and ac-
cumulation in the kidney. Results from passive targeting define the optimal particle size for
subsequent analysis of active targeting using liganded nanoparticles.
Chapter 3 examines the mechanistic effects of active tumor targeting. Using probes with
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surface decoration of human transferrin (a popular ligand for cancer targeting), it investigates
the effects of targeting ligand density attached onto the nanoparticle as well as receptor expression
levels of cancer cells on the intracellular accumulation of nanoparticles in the tumor.
Investigations until now entailed the development of targeted delivery strategies for cancer
applications. Chapter 4 demonstrates the translation of insights derived from tumor targeting to
the targeting of other biological sites. In particular, it presents a novel approach that selectively
targets the kidney mesangium, via the adjustment of nanoparticle properties (e.g., size and
surface charge) in accordance to the unique characteristics of renal physiology.
Chapter 5 deviates from the design of delivery strategies using model nanoparticle probes. In-
stead, it evaluates the effectiveness of drug delivery by tracking the in vivo distribution of actual
therapeutic nanoparticles. Through the creation of a novel chemical stain that can specifically
recognize cyclodextrin-polymer (CDP) conjugates in cells, animal tumors, and patient tumor
biopsies, this chapter reveals pharmacological insights of CDP-based therapeutic nanoparticles.
Appendix A details the materials and methods for common techniques, including dynamic
light scattering (DLS), inductively coupled plasma mass spectrometry (ICP-MS), histology with
silver enhancement, confocal immunofluorescence microscopy, and transmission electron mi-
croscopy (TEM). Protocols specific for individual studies are listed at the end of each chapter.
Appendix B provides theoretical justifications of using model PEGylated gold nanoparticles
to mimic the in vivo flow patterns of actual therapeutic nanoparticles with reference to simple
arguments from fluid mechanics. It lends support to the applicability of the data from Chapters
3 and 4 to interpret clinical results from Chapter 5.
NOTES
Table 1.1 presents abbreviations and their associated meanings used throughout this thesis.
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Abbreviation Meaning
RT Room temperature
1× PBS 1× Phosphate buffered saline
(150 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2 mM K3PO4, pH = 7.4)
D5W 5% Dextrose in water
PFA Paraformaldehyde
DMEM Dulbecco’s Modification of Eagle’s Medium
FBS Fetal bovine serum
i.v. Intravenous
s.d. Standard deviation
PEGy Poly (ethylene glycol) (Molecular weight: y Da)
Aux NP Gold nanoparticle (Core diameter: x nm)
Aux-PEGy NP PEGylated gold nanoparticle
Tf Transferrin
TfR Transferrin receptor
% ID Percent injected dose
LM Light microscopy
TEM Transmission electron microscopy
ICP-MS Inductively coupled plasma mass spectrometry
DLS Dynamic light scattering
HD Hydrodynamic diameter
ZP ζ-potential
EPR Enhanced permeation and retention
RES Reticuloendothelial system
siRNA Small interfering ribonucleic acid
N2A Neuro2A cells (mouse neuroblastoma)
Table 1.1: List of abbreviations.
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Chapter 2
Optimizing the Nanoparticle Size for
Passive Tumor Targeting
2.1 Abstract
As nanoparticles are receiving enormous attention as drug delivery agents for cancer applica-
tions, mechanistic analysis of the effect of physicochemical parameters on the in vivo fate of
nanoparticles can lead to the more targeted delivery of nanoparticle-based therapeutics to the
tumor. Here, we examine the in vivo distribution of nanoparticles as a function of particle size.
Mice bearing subcutaneous Neuro2A tumors (mouse neuroblastoma) received i.v. injections of
PEGylated gold particles (Aux-PEG5000 NPs) of different sizes in the submicron size range (x
= 20, 50, and 80; final hydrodynamic size ≤ 100 nm). All particles demonstrate steric stability
against physiological concentrations of salt. Histological and TEM data captured the tissue and
cellular level in vivo distribution of Aux-PEG5000 NPs in the tumor, liver, and kidney 24 h after
dosing. Aux-PEG5000 NPs entered the tumor by the enhanced permeation and retention (EPR)
effect, and primarily localized near leukocytes in the tumor interstitium regardless of particle size.
Smaller particles (Au20-PEG5000 NPs ) could infrequently enter Neuro2A cells and reside in either
vesicles or cytoplasm. Phagocytic response in the liver was largely size dependent, as reflected by
more severe sequestration (6-fold increase by stereological estimates) of Au80-PEG5000 NPs com-
pared to Au20-PEG5000 NPs by Kupffer cells. In the kidney, Au50-PEG5000 and Au80-PEG5000
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NPs had noticeably more accumulation inside renal corpuscles than Au20-PEG5000 NPs. Based
on these observations, passive tumor targeting using i.v. administered nanoparticles is optimal
when particle diameter is <70 nm to prevent RES clearance, with concomitant implications of
toxicity due to residency of particles within renal corpuscles.
2.2 Introduction
Cancer is currently the top killer in the world. With over 12 million incidents globally in 2008,
cancer incidence is projected to further increase by 69% by 2030. In economic terms, the burden
of cancer (cost of years lost from ill health, disability, or early death) outweighs all other health
concerns, such as heart diseases, HIV/AIDS, liver cirrhosis, and malaria [96]. Since the 1970s,
death rates from most common forms of cancer in the United States have not fallen, and the
total number of US deaths each year from lung and pancreatic cancers has doubled [97].
A major emphasis in nanomedicine research is the development of sub-100 nm structures to
improve the diagnosis and treatment of cancer. Early and non-invasive diagnosis of maligan-
cies, imaging of tumor profiles and contours, and selective eradication of abnormal cells without
harming healthy population are long-standing goals in cancer research [98]. In the past decade,
nanotechnology has shown enormous utility in developing tools and strategies for cancer ap-
plications, as exemplified by the creation of immunoliposomes injected i.v. for the treatment
of breast cancer [99], targeted nanosized contrast agents for imaging brain tumors [100], and
nanoparticle-based methods for the specific detection of oncological DNA and protein [101].
Yet, these technological advancements do not yield a fundamental understanding in the in-
teraction of nanosized objects with biological structures in vivo. The paucity of knowledge for
their impact on environment, safety, and health (ESH) raises the eyebrows of the public following
the growing prevalence and diversity of nano-inspired technologies. To support their continued
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Figure 2.1: Passive tumor targeting. Passive tumor targeting of nanoparticles is achieved by extravasa-
tion of nanoparticles through the leaky tumour vasculature and ineffective lymphatic drainage (enhanced
permeation and retention (EPR) effect). Over time, a concentration gradient between the tumor vascu-
lature (high) drives the irreversible accumulation of nanoparticles in the tumor interstitium (low). The
interstitial pressure increases to that of the tumor vasculature.
use in cancer applications and address EHS concerns, one possible route is to investigate the in
vivo distribution of nanostructures. Here, we explore the effect of size, a key physicochemical
property of nanoparticles, on the in vivo distribution in mice bearing solid tumors.
Tumor biology in brief
Tumors are solid lesions formed by an abnormal growth of cells. Depending on the stage of
cancer progression, nature of mutation (carcinoma, sarcoma, or lyphoma), and primary organ,
tumors can assume very hetereogenous morphological elements. Thus, developing a therapy that
can target multiple cancer types across different patient populations can be a daunting task.
Most solid tumors demonstrate common physiological characteristics, such as hypervascu-
lature (large network of vasculature), porous endothelium, and defective lymphatic drainage
system [102]. These features poses significant challenges to the accumulation of macromolecular
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therapeutics within the tumor, including (1) heterogeneous blood supply (which limits delivery
to well-perfused regions of the tumor); (2) high interstitial pressure (which reduces extravasation
of fluid and macromolecules in the high interstitial pressure regions); and (3) large transport
distances in the interstitium (which prolongs the diffusion of marcomolecules within the tumor)
[103]. If there exists a tumor targeting strategy that accounts for all these general features of
tumor biology, then this strategy is expected to be applicable to a broad class of tumors.
Passive targeting
From a seminal study in 1986, i.v. injected molecules of high molecular weight (e.g., IgG antibody,
MW = 150 kDa) would preferentially accumulate within the tumor of mouse xenograft models
than their lower molecular weight counterparts (e.g., anti-tumor protein NCS, MW = 12 kDa)
[104]. This differential tumor accumulation as a function of molecular weight emerges after 3-6
h, with the gap reaching to its maximum plateau value after 24 h. This phenomenon, now called
the “enhanced permeability and retention (EPR) effect,” universally applies to macromolecular
agents (e.g., liposomes, micelles, polymeric nanoparticles) for targeting solid tumors.
“Passive targeting” exploits the unique features of tumor biology that allow nanosized objects
to accumulate in the tumor by the EPR effect. Unlike free drugs that may diffuse randomly,
nanosized objects can penetrate into the tumor tissue via the leaky vessels (extravasation). The
porous blood vessels enables rapid fluid intake into the tumor interstitium from the blood vessels.
The dysfunctional lymphatic drainage traps the influx fluid and the nanosized objects within the
tumor interstitium, providing sufficient time for nanosized objects to engage the tumor cells (Fig.
2.1). The threshold particle size for extravasation into tumors is <400 nm, but other studies
have shown that particles with diameters <200 nm are more effective [105].
The discovery of the EPR effect represents a paradigm shift, empowering the sustained deliv-
ery of therapeutics or contrast agents (in the form of nanoparticles) within the tumor at elevated
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concentrations. It spurred the development and commercialization of nanoparticle-based thera-
petuics in the 1990s, most notably liposomes and polymer-protein conjugates, in treating multiple
cancer indications ranging from lyphoma, heptaoma, leukemia, and sarcoma [106].
Despite its proven clinical utility, the EPR effect suffers from several limitations. The random
retention of nanoparticles in the tumor due to the EPR effect is difficult to control, and can
contriubte to multiple drug resistance (the expulsion of therapeutics out of cancer cells within
the tumor) [107]. The EPR effect relies on the permeability of blood vasculature in a particular
tumor type, and permeability can be very heterogeneous even within a single tumor tissue [108].
One viable approach to overcome such limitations of passive targeting is “active targeting,” via
the surface decoration of targeting ligands on nanoparticles to engage receptors overexpressed on
cancerous cells within the tumor. In Chapter 3, we will provide a mechanistic analysis of the in
vivo fate of actively targeted nanoparticles as a function of ligand density and receptor density.
Here, we examine the mechanistic aspects of passive targeting in tumor bearing mice as a
function of particle size. In particular, we investigate the in vivo distribution of PEGylated gold
nanoparticles (used as model probes) in the tumor, liver, and kidney. Biological structures are
filled with fenestrations, allowing for the transport of nutrients and metabolic prodicts into and
out of tissues, cells, and even subcellular compartments. These gaps assume a submicron length
scale (∼100 (pores of outer mitochondrial membrane) - 102 nm (endothelial linings of tumor
vasculature)). Thus, submicron-sized nanoparticles, once injected in vivo, are expected to reach
various destinations based on their relative sizes to those of pore in different organs. Besides
transport patterns, size can also affect cellular responses. Here, we will underscore the effect of
size on phagocytosis of nanoparticles by hepatic macrophages. In Chapter 4, we will observe a
unique size range in which intake of nanoparticles by kidney mesangial cells is maximal. Results
are valuable for optimizing the design of nanoparticles for tumor targeting.
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2.3 Results and Discussion
Characterization of Aux-PEG5000 NPs
We prepare an array of PEGylated gold nanoparticles of different sizes (Fig. 1.3) as model
probes. Dynamic light scattering (DLS) measurements confirmed the initial hydrodynamic sizes
of all citrate-stabilized gold nanoparticles (Aux NPs) in deionized water (20 ≤ x ≤ 150), where
x denotes the core size of the gold core (in nm). At their unmodified forms, Aux NPs are stable
against aggregation in deionized water due to repulsion of surface negative charges. Upon the
addition of physiological levels of salt (e.g., 1× PBS), unmodified Aux NPs experienced rapid and
pronounced aggregation. The long error bars associated with the mean sizes of the unmodified
Aux NPs in 1× PBS reflected the stochastic nature of particle aggregation.
The addition of excess methoxy-PEG5000-thiol (mPEG5000-SH) to AuNPs in deionized water
led to the formation of PEGylated gold nanoparticles (Aux-PEG5000 NPs). The mean diameter
of Aux-PEG5000 NPs in 1× PBS was roughly identical to that of the same particles in water.
Thus, Aux-PEG5000 NPs of all sizes were stable against salt-induced aggregation (Fig. 2.2A).
In general, PEGylation led to an increase in the hydrodynamic size of an AuNP by ∼20-30
nm, implying that the PEG5000 layer grafted on the gold surface amounted to 10-15 nm. Polymers
tethered on surfaces experience forces due to entropy (leading to a random-walk configuration)
as well as solvent-monomer interactions (favoring a swollen configuration). The first scaling
models originated from free energy balance arguments to ascertain chain dynamics on planar
surfaces [109] [110], and these results were subsequently extended to curved surfaces [111] [112].
The average brush height (L) of the grafted polymer corona on a spherical particle (e.g., collidal
nanoparticles, micelles, star polymers) of radius R takes the following form:
L ∼ bN3/5σ1/5 (R/b)2/5
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Figure 2.2: Physicochemical characterization of Aux-PEG5000 NPs. (A) Colloidal stability. PEGylation
provides AuNPs with steric stability against salt-induced aggregation. (B) Charge shielding. PEGylation
of unmodified Aux NPs gave less negative particles. Error bars bracket one s.d. from five measurements.
The PEG monomer, (CH2CH2O), bears a molecular weight of 44 g/mol a bond length of 0.44
nm (from one C-C bond of length 0.15 nm and two C-O bonds of length 0.145 nm each). So
PEG5000 has 5000 ÷ 44 ≈ 114 monomers, and the total contour length of PEG5000 is 0.44 nm ×
114 = 50 nm. Assuming a Kuhn length b of 0.8 nm for PEG (twice its persistent length [113]),
the number of Kuhn segments in each polymer chain, N , is 50 nm ÷ 0.8 nm = 62.5. Suppose
that σ = 0.1 [114], then L for Aux-PEG5000 NPs (x = 20, 50, and 80) lies in the range of 15-30
nm. DLS measurements match reasonably well with predictions from polymer physics.
Another consequence of PEGylation is charge screening. Unmodified Aux NPs of all dimen-
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HDW (nm) ζ (mV)
Au20-PEG5000 43.1 ± 0.2 -9.62 ± 1.83
Au50-PEG5000 78.8 ± 0.2 -10.91 ± 1.33
Au80-PEG5000 97.l ± 1.9 -16.77 ± 1.14
Au100-PEG5000 121.9 ± 2.6 -18.14 ± 3.16
Au120-PEG5000 172.5 ± 6.1 -22.5 ± 3.83
Table 2.1: Physiochemical properties of Aux-PEG5000 NPs. HDW = hydrodynamic diameter in deionized water;
ζ = zeta potential in 1 mM KCl. The standard deviation originate from values due to five measurements.
sions are negatively charged due to the surface capping of citrate groups. This magnitude of
negative charge increases with x. The covalent grafting of PEG5000 gave rise to less negative
Aux-PEG5000 NPs (Fig. 2.2B). To understand charge screening in quantitative terms, we can
calculate the Debye length (κ−1) of the electrolyte in which the ζ-potential measurements were
made. For a binary electrolyte, κ−1 takes the following form:
κ−1 =
(
kBT
2z2e2c0
)1/2
e, z, c0, , kB, and T depict the elementary charge, ionic valency, ionic concentration, permittivity
of water, Boltzmann’s constant, and temperature, respectively. For 1 mM KCl at RT, κ−1 ∼ 10
nm. For unmodified Aux NPs (20 nm < x < 150 nm), κx/2 ∼ 1-7.5, indicating that the charges
are neither diffuse or concentrated near the particle surface. From above, the addition of PEG5000
increases the total size by 10-15 nm. The new κx/2 of Aux-PEG5000 NPs ∼ 2-10. PEGylation
slightly increased κx/2 and somewhat provided charge screening, but did not completely screen
the negative charges of the unmodified AuNPs (Table 2.1).
Systemic administration
Armed with this set of Aux-PEG5000 NPs, we proceed to inject them i.v. into mice bearing
subcutaneous Neuro2A tumors (mouse neuroblastoma) at the same particle concentration. This
concentration (4.5 × 1011 particles/mL) represents a careful balance between signal detectability
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and ease of administration. In a typical intravenous (i.v.) injection, only ∼1 of every 100,000
molecules of monoclonal antibodies reaches their parenchymal targets in vivo [115][116]. An
overloaded injection of concentrated particles may lead to the formation of a highly viscous
formulation, not favorable for the tolerance of the animals (see Appendix B).
After 24 h, mice were sacrificed for the collection of the tumor, liver, and kidney. In subse-
quent chapters, most in vivo distribution measurements originate from the same time point (24
h after injection) to allow for sufficient time for the onset of the EPR effect in the tumor.
Below are results from imaging studies that elucidate the in vivo distribution of the Aux-
PEG5000 NPs (x = 20, 50, and 80) at the tissue and cellular levels, as a function of particle
size 24 h after injection. Animal experiments did not include the largest two particle sizes
(x = 100 and 150) due to the emphasis on the in vivo behavior of sub-100 nm nanoparticles.
(For completeness, Chapter 4 contains data regarding the in vivo blood pharmacokinetics and
organ-level distribution of Aux-PEGy NPs in non-tumor bearing mice as a function of size.)
Tumoral distribution
In agreement with most neoplastic tissues, Neuro2A tumor (mouse neuroblastoma) contains
three compartments (vascular, interstitial, and cellular). The tumor comprises three cell types,
subcutaneously implanted Neuro2A cancerous cells, leukocytes (or tumor associated macrophages
(TAM)), and blood endothelial cells, all dispersed in a collagen-rich matrix. Due to its defective
lymphatic drainage system, continuous fluid intake from the blood capillaries into the intersititial
space gives rise to a high interstitial fluid pressure and velocity [117].
Like normal neurons, Neuro2A cells possess a large, round, and euchromatic nucleus with
a single prominent nucleolus. Such nuclei are sometimes termed owl-eye or fried-egg. Unlike
normal neurons, Neuro2A cells do not possess basophilic masses of endoplasmic reticulum in
their cytoplasm. They lack the large and extended cytoplasm characteristic of normal neurons.
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Neuro2A cells are regularly packed in the absence of connective tissues (Fig. 2.3A-C2).
Aux-PEG5000 NPs of all dimensions agglomerated in the vicinity of leukocytes, due to the
leakiness and irregularity of the tumor blood vessels (Fig. 2.3A-C1). While PEGylation was
shown to reduce non-specific uptake, the injection of nanoparticles, foreign to the mouse, trig-
gered an inflammatory response and led to their entrapment among connective tissues and leuko-
cytes. During an inflammation, activated immune cells secrete cytokines that attract more cells
to destroy the invading nanoparticles. Cationic particles are more likely to induce inflammatory
reactions than anionic and neutral species [118].
Very rarely did these particles enter the Neuro2A cells, as seen by the clarity of their cy-
toplasm. Yet, smaller particles can localize between cancerous cells. Au20-PEG5000 NPs could
slide into the thin capillary vessels separating neighboring Neuro2A cells as well as localize into
the cell cytoplasm, but not 70 and 100 nm particles. The size of pores of the tumor vasculature
may affect whether particles can enter the Neuro2A cells. Yuan et al. reported a cutoff size of
400-600 nm for fluorescently labeled liposomes (25-160 kDa) to cross the pores of vasculature of
LS174T (human colon adenocarcinoma) [119]. Hobbs et al. demonstrated the tumor dependence
of vasculature pore cutoff sizes spanning from 100 to 800 nm by injecting latex microspheres i.v.
to mice bearing subcutaneous carcinoma, hepatoma, glioma, and sarcoma tumors [120].
Based on the histological images, stereology (see supporting information) can provide semi-
quantitative estimates of the tissue level particle distribution in the tumor. More particles
concentrated near the leukocytes than Neuro2A cells for all particle sizes (Table 2.2). Given that
each mouse received the same dosage of particles, these results illustrates the independence of
the degree of inflammation as a function of particle size.
TEM reveals the subcellular localization of Aux-PEG5000 NPs following the inflammatory
response triggered by their i.v. injection. The Au20-PEG5000 NPs lied near the fenestrated en-
dothelium of the Neuro2A cells, implying their entry to the cytosol through the pores. Evidently,
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Figure 2.3: Intratumoral tissue level distribution of Aux-PEG5000 NPs. (A) Au20-PEG5000 NPs; (B)
Au50-PEG5000 NPs; (C) Au80-PEG5000 NPs. Column 1: Neuro2A cells (N2A) and leukocytes (WBC);
Column 2: Neuro2A cells. Black arrows indicate Aux-PEG5000 NPs deposited with silver. The blue
dotted line separates WBCs and N2A cells. Scale bar = 10 µm for light micrographs.
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Figure 2.4: Intratumoral cellular level distribution of Aux-PEG5000 NPs. (A) Au20-PEG5000 NPs; (B)
Au50-PEG5000 NPs; (C) Au80-PEG5000 NPs. Column 1: Neuro2A cells (N2A) and leukocytes (WBC);
Column 2: Neuro2A cells. Red arrows point to actual Aux-PEG5000 NPs. Legend: Nu = nucleus.
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L N2A L/N2A
Au20-PEG5000 4.76 1.21 3.93
Au50-PEG5000 38.17 3.44 11.10
Au80-PEG5000 46.05 17.44 2.64
Table 2.2: Areal density of Aux-PEG5000 NPs inside the tumor (# particles/mm2). Legend: N2A
= Neuro2A cells; L = leukocytes. Examples of “leukocytes” include basophils, neutrophils, basophils,
lymphocytes, monocytes, and macrophages.
the pore width is larger than the particle size. Fig. 2.4A2 demonstrates the encapsulation of
Au20-PEG5000 NPs into a vesicle inside the cytoplasm. Both electron micrographs allow an es-
timate of the heterogeneous pore widths of fenestrated endothelia. While the labeled pores in
Fig. 2.4A1 had approximate dimensions of 500 and 640 nm, the two indicated pores in Fig. 2.4
A2 measured roughly 370 and 250 nm. Thus, the average width of a pore in the endothelial cell
of Neuro2A vasculature is 440 nm.
Fig. 2.4B1-2 illustrate the cytoplasmic region of Neuro2A cells. The presence of Au50-
PEG5000 NPs in these regions was significantly lower than that of Au20-PEG5000 NPs. When
particles were visible, they usually resided inside vesicles in the cytoplasm. The same observation
prevailed in the Neuro2A cytoplasm when the mice received injections of Au80-PEG5000 NPs.
Fig. 2.4C1-2 portray a low density of particles. These four images collectively suggest a bias in
distribution of Aux-PEGy NPs away from the Neuro2A cells, consistent with the predominant
localization of particles near the leukocytes, as observed from histological studies.
Hepatic distribution
Upon administration, considerable amounts of nanoparticles often accumulate in the liver. Thus,
it is instructive to investigate the distribution of nanoparticles in the liver.
“Phagocytosis” describes the uptake of particles (traditionally larger than 0.5 µm) into cells,
via mannose receptor-, complement receptor-, Fcγ receptor, and scavenger receptor-mediated
pathways [121]. It entails the elimination of pathogens, cell debris, or foreign objects by cells
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known as macrophages. They engulf foreign material with their plasma membranes to form
phagosomes. After the content becomes degraded in a lysosome, it either departs the cell by ex-
ocytosis or remains in the cell for further processing. For lower organisms, phagocytosis is critical
for the uptake of nutrients and degradation of infectious agents. It participates in development,
tissue remodeling, and immune response. Multiple macrophages of the “reticuloendothelial sys-
tem” (RES) exist in the body, such as monocytes in lymph nodes and the spleen [122].
In the liver, the corresponding macrophages are Kupffer cells. By means of phagocytosis,
these cells recycle erythrocytes by splitting hemoglobin for bile secretion. Kupffer cells (KCs)
partially occlude the sinusoid lumen but have no functional attachments to the endothelial cells
or to the underlying hepatocytes. Their location, primarily at the periportal end of the sinusoids,
confirms that they monitor arriving blood, looking for particles to remove from blood flow.
Larger particles elicited more severe phagocytic responses. While few Au20-PEG5000 NPs were
observed near KCs, many Au50-PEG5000 and Au80-PEG5000 NPs agglomerated in their vicinity.
Moreover, larger particles were predominantly localized in the vicinity of KCs, whereas smaller
particles were more evenly distributed. While Au20-PEG5000 NPs assumed a rather even spread
among hepatocytes and KCs, Au50-PEG5000 and Au80-PEG5000 NPs resided near the KCs (Fig.
2.5A-B). Also, according to stereological measurements, more Aux-PEGy NPs localized in the
vicinity of KCs than hepatocytes or other cell types with larger particle dimensions, confirming
the presence of a phagocytic response. This response is size-dependent and increases by 6-fold
as the particle size increases from 40 to 100 nm (Table 2.3).
TEM elucidated the phagocytosis phenomenon at the cellular level. Au20-PEG5000 NPs spo-
radically dispersed in the vicinity of hepatocytes, without any particular tendency to agglomerate
near KCs (Fig. 2.6A1-2). Fig. 2.6B1 captures the phagocytosis of small clusters (3-5 particles
per cluster) of Au50-PEG5000 NPs of numerous lyzosomes inside a Kupffer cell, located between
a hepatic sinusoid (populated by an erythrocyte) and the Space of Disse. The Space of Disse
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Figure 2.5: Intrahepatic tissue level distribution of Aux-PEG5000 NPs. Phagocytosis is positively corre-
lated with particle size. (A) Au20-PEG5000 NPs; (B) Au50-PEG5000 NPs; (C) Au80-PEG5000 NPs. Black
arrows indicate Aux-PEG5000 NPs deposited with silver. Red circles indicate Kupffer cells (KCs). Scale
bar = 10 µm.
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Figure 2.6: Intrahepatic cellular level distribution of Aux-PEG5000 NPs. Phagocytosis is positively
correlated with particle size. (A) Au20-PEG5000 NPs; (B) Au50-PEG5000 NPs; (C) Au80-PEG5000 NPs.
Red arrows point to actual Aux-PEG5000 NPs. Legend: RBC = red blood cells; S = sinusoidal space; L
= lyzozymes; M = mitochondrion.
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H KC OC KC/(H+OC)
Au20-PEG5000 0.14 1.44 0.38 2.77
Au50-PEG5000 1.45 29.11 2.35 7.76
Au80-PEG5000 3.59 142.16 3.40 17.79
Table 2.3: Areal density of Aux-PEG5000 NPs inside the liver (# particles/mm2). Legend: H = hepato-
cytes; KC = Kupffer cells; OC = other cell types. Examples of “other cell types” include, but not limited
to, endothelial cells, sinusoids, erythrocytes, and lymph vessels.
is the perisinusoidal space interposed between the endothelium of the sinusoid and hepatocytes
(not shown). Fig. 2.6B2 shows the hepatocytes in close proximity to KCs, as seen by the dense
network of mitochondria, endoplasmic reticulum, and free ribosomes. These subcellular features
are indicative of heavy hepatic metabolic activities in hepatocytes. Although not physically lo-
cated within the KC, the Au50-PEG5000 NPs were still entrapped inside lyzosomes as a direct
consequence of phagocytosis. The Au80-PEG5000 NPs led to the highest level of phagocytic re-
sponse, with large particle clusters (∼10-30 particles per cluster) congregated near or within a
KC (Fig. 2.6C1-2). Following the increase in particle size, higher densities of gold particles, if
not already phagocytosed, localized in shorter distances away from the KCs.
Despite the high particle density in these clusters, the same electron micrograph shows that all
PEGylated particles remained as individual entities even in the confined geometry of lyzosomes
in KCs or hepatocytes, implying steric stability conferred by PEGylation to the Aux-PEGy NPs.
Fig. 2.5C4 offers a close-up view of the particles encapsulated inside a lyzosome within a KC.
Renal distribution
Therapeutic nanoparticles, once injected into the bloodstream, must eventually exit the body to
minimize toxicity due to their prolonged residency. Their individual components (drug payload
and delivery vehicle) are small enough to pass through the kidney tubules and depart the body via
urine excretion (a process known as “renal filtration” [123]). Whereas inulin the polysaccharides
(hydrodynamic diameter = 3 nm) can completely filter through to urine with a whole-body t1/2
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of 1.9 h [124], only 9% of the Fab’ antibody fragment can be renally filtered with a while-body
t1/2 of 4 h [125] [126]. In contrast, IgG, with a hydrodynamic diameter of 11 nm, has a much
longer t1/2 of 730 h with less than 0.1 urine/blood filterability [127] [126].
Aux-PEG5000 NPs are non-decomposable objects. Given their hydrodynamic size (≥ 40 nm),
they should remain in blood circulation for a prolonged time and not experience renal clearance
via urine excretion. It is of interest to see their accumulation patterns in the kidney, because
particles can still freely access the tissue regions adjacent to the “renal filtration” apparatus from
the bloodstream. The in vivo distribution patterns may reveal insights for the in vivo fater of
intact polymeric or lipophilic therapeutic nanoparticles prior to their disassembly.
At the tissue level, Aux-PEG5000 NPs display size-dependent accumulation in the kidney.
Au50-PEG5000 NPs demonstrated the highest areal density in the renal corpuscles (Fig. 2.7B1-
2), whereas Au20-PEG5000 and Au80-PEG5000 NPs were found in minute quantities throughout
the kidney in both medullary tubules and cortical renal corpuscles (Fig. 2.7A,C1-2). Stereological
estimates also support these observations (Table 2.4), highlighting the superior ability of Au50-
PEG5000 to localize in renal corpuscles compared to other particle sizes.
TEM provides more morphological information to ascertain the in vivo particle distribution
of the kidney at the cellular level. Consistent with stereological estimates, TEM images reflect
the general dearth of Aux-PEG5000 NPs in proximal tubule cells (Fig. 2.8B-C2). A tiny portion
of the Au20-PEG5000 NPs became clogged up in the renal tubules (Fig. 2.7A3) or were found near
the mitochondria of tubule cells (Fig. 2.8A2). Such particles are too large to be pass through the
renal filtration apparatus (with a size cutoff of 5-10 nm). At very rare instances, Au50-PEG5000
NPs localized near vesicles adjacent to the basal laminar of a proximal tubule cell (Fig. 2.8B2).
In brief, particle accumulation in renal tubules was an infrequent occurrence.
At this point, the reasons for the high retention of Au50-PEG5000 NPs in the renal corpuscles
remain unclear. TEM can provide additional ultrastructural details to address this issue. Inside
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Figure 2.7: Intrarenal tissue level distribution of Aux-PEG5000 NPs. Au50-PEG5000 NPs resulted in
the maximal deposition in renal corpuscles among all particle sizes. (A) Au20-PEG5000 NPs; (B) Au50-
PEG5000 NPs; (C) Au80-PEG5000 NPs. Column 1: Renal corpuscles; Column 2: Renal tubules. Black
arrows indicate Aux-PEG5000 NPs deposited with silver. Scale bar = 10 µm.
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Figure 2.8: Intrarenal cellular level distribution of Aux-PEG5000 NPs. Au50-PEG5000 NPs resulted in
the maximal deposition in renal corpuscles among all particle sizes. (A) Au20-PEG5000 NPs; (B) Au50-
PEG5000 NPs; (C) Au80-PEG5000 NPs. Column 1: Renal corpuscles; Column 2: Renal tubules. Red
arrows point to actual Aux-PEG5000 NPs. Legend: RBC = red blood cell; MM = mesangial matrix; FP
= foot processes; U = urinary space; P = podocytes; En = endothelial cells.
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RC T O RC/(T+O)
Au20-PEG5000 0.35 0.75 0.17 0.38
Au50-PEG5000 12.88 4.68 3.11 1.66
Au80-PEG5000 2.29 2.24 1.23 0.66
Table 2.4: Areal density of Aux-PEG5000 NPs inside the kidney (# particles/mm2). Legend: RC =
renal corpuscles; T = assorted renal tubules (e.g., proximal convoluted tubules, distal convoluted tubules,
collecting tubules); O = other tissues (e.g., blood vessels, endothelial cells).
the renal corpuscles, immersed in a mesh of matrix are mesangial cells, phagocytic cells that can
remove trapped residues and aggregated proteins from the basal lamina [128]. For our present
system, Au50-PEG5000 NPs were entrapped by these mesangial cells (Fig. 2.8B1).
For Aux-PEG5000 NPs in the renal bloodstream to come into contact with these mesangial
cells, they need to first exit the blood capillaries (known as glomerular tufts) through their
porous endothelial membrane. Incidentally, this membrane separates the mesangium matrix
(where mesangial cells lie) from the glomerular capillary bloodstream. Thus, Aux-PEG5000 NPs
must be sufficiently small to penetrate through these pores of the glomerular membranes into
the mesangium. Based on TEM measurements, such fenestrations have pore widths spanning
from 71.4 to 95.2 nm (Fig. 2.8C1). The mean diameter cutoff is 83.3 nm. The gap between
foot processes of podocytes is 59.5 nm by inspection (measured at the mean-height of the foot
processes), in good agreement with previously reported values [129] [130] [131]. These size
estimates support the notion that Au50-PEG5000 NPs (or smaller) are sufficiently small to pass
through the pores and enter the mesangium.
2.4 Conclusion
There is ever increasing research momentum to apply nanotechnology on the diagnosis and
treatment of cancer. On the treatment front, the safe, substained, and targeted delivery of
nanoparticle-based therapeutic and contrast agents to tissue and cellular destinations (e.g, cancer
cells within the tumor) are recurrent objectives for creating more efficacious cancer therapies.
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This chapter seeks to optimize the delivery of submicron-sized nanoparticles used for cancer
applications. To generate a viable strategy to maximize tumor targeting, mechanistic under-
standing in the effect of each design parameter (e.g, particle size, surface charge, polymer coat-
ing) on the in vivo behavior of nanoparticles (e.g., pharmacokinetics, distribution, toxicity) is
crucial. Here, we investigate the effect of particle size on the in vivo distribution in mice bearing
solid tumors, using PEGylated gold nanoparticles as model probes.
All gold nanoparticles contain of PEG5000 chains on their periphery, and are stable against
salt-induced aggregation at physiological conditions. Changes in hydrodynamic size and ζ-
potential of the particles before and after PEGylation match reasonably well with theoretical
predictions. The PEG chain length of 5000 represent a careful balance between circulation
time and diffusion. Particles coated with shorter PEGs may experience rapid binding by serum
proteins and subsequent clearance by macrophages, failing to reach to the tumor in adequate
amounts despite the EPR effect. Longer PEG coatings can prevent premature clearance by
opsonization, but can add tremendous hydrodynamic drag to the nanoparticle in the tumor
interstitium en route to its traversal to cancer cells within the tumor.
Passive tumor targeting
Aux-PEG5000 NPs do not contain any targeting ligands, but still reached the tumor after 24 h
after their i.v. injection due to the EPR effect. From results given in Chapter 3, a threshold tar-
geting ligand content is necessary for nanoparticles in the tumor interstitium to enter cancerous
cells. Thus, passively targeted Aux-PEG5000 NPs predominantly accumulated in the tumor inter-
stitium and in the vicinity of leukocytes, and only entered Neuro2A cells at infrequent instances,
independent of particle size. The only exception is the smallest particles (Au20-PEG5000 NPs),
which localized inside vesicles within Neuro2A cells. This is consistent with observations made
by Perrault et al. [132], who reported two size-dependent migration patterns of Aux-PEGy NPs
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inside the tumor. 24 h after dosing, Au16-PEG2000 moved further away from blood vessels and
accumulated in intracellular regions more frequently, when compared to their larger counterparts,
Au33-PEG5000 and Au84-PEG10000 NPs. Moreover, based on pharmacokinetics measurements on
submicron-sized Aux-PEGy NPs (see Chapter 4), larger particles have shorter blood circulation
times than smaller particles. Thus, passive targeting is optimal when using nanoparticles smaller
than 100 nm, for their deeper tumor penetration and longer circulation in blood.
Avoidance of RES clearance
Targeted delivery to biological destinations also requires the minimization of premature clearance.
The RES can serve as immunological barriers to the effective tumor targeting, with macrophages
or monocytes sequestering injected nanoparticles. Kupffer cells (KCs) are an important RES
cell type responsible for nanoparticle clearance. Tissue and cellular level data from this chapter
show that KCs engulfed Aux-PEG5000 NPs in a size-dependent fashion. These data agree with
the in vivo distribiution at the organ level, characterized by positive correlation between bulk
nanoparticle uptake by the RES organs (liver and spleen) and particle size (see Chapter 4).
Ogawara et al. [133] reported biodistribution data of polystyrene microspheres of 50 and 500
nm in the liver. 59% of the 50 nm particles reached KCs, whereas 71% of the 500 nm particles
arrived at KCs. Bogers et al. [134] discovered an elevated clearance for larger IgA polymers or
aggregates compared to monomeric IgA, and showed the association of IgA (hydrodynamic size
∼ 11.36 nm) to KCs and encapsulation of IgA within vesicles in KCs. The degree of phagocytic
response then translates into the speed of clearance. Sadauskas et al. [135] reported tremendous
phagocytic activity at KCs even for 2 and 40 nm AuNPs, injected i.v. at similar concentrations
to mice, although their AuNPs were not PEGylated to prevent salt-induced aggregation. Taking
our data and existing literature into cosideration, the avoidance of RES clearance by KCs sets
an upper limit of 100 nm for the nanoparticle size to optimize tumor targeting.
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Renal accumulation
Unlike the tumor and liver, few studies in the nanomedicine field have reported submicron-sized
particle accumulation in the kidney following an i.v. injection, because the kidney is regarded
merely as a blood filtration organ that removes excess salts and metabolic wastes in the form
of urine. Here, we observe size-dependent accumulation of Aux-PEG5000 NPs in the kidney, in
which Au50-PEG5000 and Au80-PEG5000 NPs resided within renal corpuscles in more appreciable
amounts than Au20-PEG5000 NPs. Foglieni et al. [136] reported the retention of locally injected
lipopolyplexes (diameter ∼ 160 nm) in the renal corpuscles but not polyplexes (diameter ∼ 93
nm), suggesting the presence of a filtration mechanism that retains nanoparticles of 100 ± 25
nm in size within renal corpuscles (to be explained in Chapter 4).
In summary, passive targeting and avoidance of RES clearance dictate that the particle size
for optimal tumor delivery should not exceed 100 nm. Armed with these results, the next step is
to promote the engagement of nanoparticles accumulated in the tumor interstitium to cancerous
cells in the tumor. In Chapter 3, we will explore the ability of Au50-PEG5000 NPs (size ∼ 70
nm) to internalize into cancerous cells via the surface attachment of targeting ligands (active
targeting). Based on the kidney imaging data, an inevitable consequence of delivering Au50-
PEG5000 NPs (with targeting ligands attached) to tumor bearing mice is their accumulation
within renal corpuscles in the kidney.
2.5 Supporting Information
In Greek, “stereo” means “a geometric object.” Stereology recreates or estimates the geometrical
properties of objects. Here, we employ basic stereology to semi-quantitatively describe the
distribution of Aux-PEG5000 NPs in different tissue compartments of the kidney, liver, and
tumor. Stereology consists of two major components, “sampling” and “measuring.”
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Sampling
While a larger number of sections are desired to achieve statistical significance, time is often
insufficient to examine each section in detail. The generation of “representative samples” is im-
perative. A sample is representative if all components possess the same probability to contribute
to the sample. Random sampling can satisfy this requirement. By the “Law of large numbers,”
the average of a large number of estimates will converge to the true value of the mean estimate.
While random sampling guarantees an equal probability of each segment of the section to be
captured, it does not preclude the likelihood of repeated sampling of the same segment. One can
employ “uniform random sampling” (URS) in which one chooses a random starting point on the
section and obtains all subsequent samples at a fixed interval. While the random starting point
ensures equal representation, the fixed intervals avoid the occurrence of “clustered sampling.”
Measuring
Simple counting methods can effectively reproduce the spatial relationships of particles. This
study focuses on the two-dimensional (areal density) distribution, but the method outlined below
is open for extension to obtain three-dimensional measurements (volume density) by taking the
section thickness into account. This is a direct application of the “Cavalieri Principle,” and is
similar to counting a population of cells using a hemacytometer.
The calculation of the areal density begins with the construction of a rectangular grid. One
then places points at each of the intersections of the grid lines and associates one of the rectan-
gular areas formed by the grid with each point. The association of one area with a point located
at each intersection allows the coverage of the entire area of the grid.
With the uniformly representative images, the next step is to introduce approximate bound-
aries to establish functional or morphological compartments in tissues captured by these images.
The experimental objectives in question will dictate the exact nature of these compartments.
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Hypothesis I: Particle injection triggers immune responses, leading to engulment by cells
of the self-defense apparatus (e.g., Kupffer cells and leukocytes). (Liver: 1. Hepatocytes; 2.
Kupffer cells; 3. Endothelial cells, erythrocytes; Tumor: 1. Leukocytes; 2. Cancerous Cells)
Hypothesis II: Size affects the particle distribution in the kidney, a natural blood filter
(Kidney: 1. Glomerulus; 2. Renal tubules; 3. Blood vessels and endothelial cells).
2.6 Materials and Methods
Assembly of Aux-PEG5000 NPs
Methoxy-PEG5000-thiol (Laysan Bio.), dissolved in deionized water, was added to 3 mL of aqueous sus-
pension of unconjugated gold colloids (Ted Pella) of a designated core size (20, 50, 80, 100, and 150 nm)
at an excess concentration of ∼9 PEG strands per nm2 of gold surface. e.g. To ensure complete coverage,
PEGylation of Au50 NPs required the addition of 10 µL of 1 mM mPEG5000-thiol (in deionized water) to
0.5 mL of aqueous suspension of 2.25× 1010 particles. All PEGylation reactions proceeded at RT for 30
min with constant stirring. To remove any unbound PEG5000, the reaction mixture was dialyzed against
deionized water using a 30 kDa Amicon MWCO membrane (Millipore) for three times.
Tumor formation and systemic delivery
Neuro2A cells were cultured in complete growth medium (DMEM supplemented with 10% FBS, 100
units/mL penicillin, and 100 units/mL streptomycin). In the right hind flank, A/J mice (Jackson Lab-
oratory) received subcutaneous implantation of Neuro2A cells (at 106 cells per mouse per 0.1 mL of
DMEM). Before injection, tumors reached 100-200 mm3 in size, as determined by caliper measurements
(0.5× l×w2). For each particle size (x = 20, 50, and 80 nm), three A/J mice received i.v. administration
of Aux-PEG5000 NPs at a concentration of 4.5 ×1011 particles per animal (formulated in 0.1 mL of D5W)
via the tail vein. Animal sacrifice by CO2 overdose took place 24 h after injection to collect the tumor,
liver, and kidney.
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Stereological sampling
Observed with a 100× objective under a light microscope, each silver-enhanced tissue slide was shifted
laterally and across the entire sample by the same distance to obtain uniformly random photographs,
captured by a built-in digital camera connected to the light microscope. The same camera, also connected
to a computer monitor, enabled the visual inspection required to ensure a consistent degree of a lateral
shift from one point on the tissue slide to another. This collection scheme yielded a total of 456 light
microscopic images for later quantification of the in vivo biodistribution of Aux-PEG5000 NPs.
Stereological measuring
Depending on the tissue, each light microscopic image was visually inspected to see whether the compart-
mentalization scheme could be applied. If so, an arbitrary border was drawn to decompose the image into
multiple compartments. Otherwise, the entire tissue was taken as a single compartment.
In each microscopic image, for each particle size i and each tissue compartment j, the number of Aux-
PEG5000 NPs was counted as nij . Meanwhile, the area of this tissue compartment, aij , was recorded.
The same procedure was repeated for all mij microscopic images that captured the particles of the same
dimension i in the same tissue compartment j. Such a counting exercise enabled the calculation of the
sum of particles of a certain dimension, i, residing in a certain tissue compartment, j, denoted as Nij .
Likewise, it also yielded the sum of area of a certain tissue compartment j that contained particles of
dimension i, Aij . The normalization of Nij by Aij led to Πij , the areal density of particles of the
dimension i per unit area of the tissue compartment j.
Πij ≡ Nij
Aij
≡
∑mij nij∑mij aij
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Chapter 3
Mechanism of Active Targeting in
Solid Tumors with Transferrin
Containing Gold Nanoparticles
3.1 Abstract
PEGylated gold nanoparticles are decorated with various amounts of human transferrin (Tf)
to give a series of Tf-targeted particles with near-constant size and ζ-potential. The effects
of Tf content on nanoparticle tumor targeting are investigated in mice bearing subcutaneous
Neuro2A tumors. Quantitative biodistributions of the nanoparticles 24 hours after tail vein,
intravenous (i.v.) injections show that the nanoparticle accumulations in the tumors and other
organs are independent of Tf. However, the nanoparticle localizations within a particular organ
are influenced by the Tf content. In tumor tissue, the content of targeting ligands significantly
influences the number of nanoparticles localized within the cancer cells. In liver tissue, high
Tf content leads to small amounts of the nanoparticles residing in hepatocytes, while most
nanoparticles remain in non-parenchymal cells. These results suggest that targeted nanoparticles
can provide greater intracellular delivery of therapeutic agents to the cancer cells within solid
tumors than their non-targeted analogs. A competitive binding model from classical kinetics,
Excerpts of this chapter are reproduced with permission from “Mechanism of active targeting in solid tumors
with transferrin containing gold nanoparticles.” Chung Hang J. Choi, Christopher A. Alabi, Paul Webster, and
Mark E. Davis. Proc. Natl. Acad. Sci. USA. 107, 3, 1235-1240 (2010).
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when used in conjunction with in vitro binding studies, provides extra insights to the mechanism
of multivalent ligand-receptor interactions.
3.2 Introduction
Targeted nanoparticle delivery of therapeutic molecules has the potential to provide safer and
more effective therapies for cancer applications [137]. Recent work has focused on understanding
the parameters that influence targeted nanoparticle behavior and the development of design rules
for creating nanoparticle-based therapeutics and imaging agents. Passive tumor targeting takes
advantage of the irregularity and leakiness of tumor vasculature to allow nanoparticle accumu-
lation in the tumor (due to the enhanced permeability and retention (EPR) effect [104] [138]).
Active targeting exploits the overexpression of surface receptors on cancer cells by providing
targeting ligands that can engage these receptors.
Active targeting
Previous studies on active targeting have utilized an assortment of ligands ranging from proteins
(antibodies [139] and their molecular fragments [140]), nucleic acids (aptamers [141]) and small
molecules (vitamins [142], peptides [143], or carbohydrates [144]). Ligand incorporation facili-
tates the entry of nanoparticles to cancer cells via receptor-mediated endocytosis, after which
they can release their drug payloads to provide a therapeutic action. Perrault et al. convinc-
ingly illustrated that PEGylated gold nanoparticles require sizes below 100 nm in diameter for
movement away from the vasculature and throughout the tumor [132]. This is a necessary con-
dition for engaging cancer cell surface receptors and attacking molecular targets within cancer
cells. Park et al. showed that antibody-targeted liposomes revealed enhanced anti-tumor effects
over their untargeted counterparts [99]. The same investigators later concluded that the anti-
body targeting does not increase tumor accumulation of liposomes over untargeted controls but
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rather elevates particle localization within cancer cells [145]. Using multimodal in vivo imag-
ing techniques, Bartlett et al. demonstrated that untargeted and transferrin-targeted polymeric
nanoparticles containing siRNA have the same whole body distribution (and kinetics) and tumor
accumulation, but the targeted particles lead to more pronounced gene inhibition within cancer
cells [146]. Very recently, with the aid of computer simulations, Schmidt and Wittrup predicted
similar tumor uptake of both targeted and untargeted liposomes of ∼50 nm in size [147].
From the above examples, the targeting ligand does not influence organ distribution, e.g., bulk
tumor localization, but rather tissue distribution, i.e., cancer cells versus non-cancer cells (such
as leukocytes and blood endothelial cells) within the tumor. These findings suggest that active
targeting of nanoparticles occurs via a different mechanism than individual targeting ligands,
e.g., antibodies. Thus, further examination of active targeting with nanoparticles is merited.
We prepared a series of gold nanoparticles with transferrin contents spanning two orders of
magnitude for comparison to untargeted particles, in order to test the mechanistic effects of the
active targeting of nanoparticles in solid tumors, as well as to delineate particle distribution
patterns due to ligand targeting at the cellular level, a level not investigated in previous organ
and tissue distribution studies.
Transferrin as a targeting ligand
Human holo-transferrin (Tf) is the targeting ligand used here to probe the effects of active
targeting. Because of rapid cell division and stringent demand for iron (for heme synthesis),
many cancer cell types have abundant expression of transferrin receptors (TfRs) [148]. Tf is a
79 kDa endogenous glycoprotein that binds to TfRs at extracellular pH (Kd = 1-100 nM [149]
[150]) and trigger receptor-mediated endocytosis [151].
Tf has a history of use as a targeting agent for cancer cells. For example, Tf-targeted, siRNA-
containing nanoparticles give pronounced inhibition of tumor growth in metastatic Ewing’s sar-
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Figure 3.1: Synthesis of Tf-PEG5000-SAc. (A) Reaction conditions: (i) SATA, 4 h, DMF, RT. (ii) DSC,
DMF/dioxane, 4 h, RT. (iii) Holo-Tf, 2 h, RT, 50 mM sodium phosphate, pH = 7.4 (iv) hydroxylamine, 2 h,
RT, 50 mM sodium phosphate, 25 mM EDTA, pH = 7.5. Step (iv) renders free -SH groups for conjugation
onto AuNPs to form Au50-PEG5000-Tfx NPs. (B) The sharp peak of the MALDI-TOF spectrum at 84
kDa confirms the identity of the expected product, mono-PEGylated Tf (Tf-PEG5000-SAc).
coma, whereas their untargeted counterparts do not [152]. The covalent conjugation of Tf onto
PEG-AuNPs at varying amounts to form transferrin-targeted, PEGylated gold nanoparticles
(Au50-PEG5000-Tfx NPs) and the i.v. injection of these particles into mice bearing subcutaneous
Neuro2A tumors provide the model system to investigate the effects of targeting ligand content
on in vivo particle distribution on organ, tissue, and cellular levels.
3.3 Results and Discussion
Synthesis and characterization of Tf-PEG5000-SAc
Fig. 3.1 illustrates the synthesis scheme for Tf-PEG5000-SAc, a PEG conjugate (MW: 5000) that
contains the targeting ligand (Tf) and an acetyl-protected sulfur group (SAc). This conjugate
decorates the surface of the gold nanoparticles to extend Tf away from the gold surface to the
nanoparticle periphery, as well as to facilitate the engagement of Tf with surface TfRs of cancer
cells within the tumor. Purification of the crude reaction mixture using hydrophobic interaction
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Figure 3.2: (A) A confocal micrograph shows the surface and internalized TfRs of Neuro2A cells stained
by antiTfR-AF555 (orange), counter-stained by DAPI (blue) (Scale bar = 20 µm). (B) Competitive
binding assay. PEGylation to form Tf-PEG5000-SAc did not drastically reduce the binding affinity of Tf.
Reported data are expressed as percent of fluorescence of cells incubated with only Tf-AF488.
chromatography (HIC) gave pure, mono-PEGylated, Tf-PEG5000-SAc, with an apparent molecu-
lar weight of 84 kDa. This PEGylation method is not site specific on the Tf, so excessive protein
PEGylation may block the active sites of Tf for binding to TfRs. Therefore, we used here only
the mono-PEGylated fraction for nanoparticle assembly.
The competitive binding of Tf-PEG5000-SAc against fluorescently tagged Tf (Tf-AF488) was
used to estimate the effects of mono-PEGylation on Tf binding affinity (Fig. 3.2), with holo-
transferrin (holo-Tf) and mPEG-SH (methoxy-PEG-thiol; MW: 5000) as positive and negative
controls. A 1:1 ratio of Tf-AF488 to free holo-Tf gives ∼45% reduction in fluorescence, implying
almost equal binding affinity of Tf-AF488 and free holo-Tf. Tf-PEG5000-SAc shows reduction in
fluorescence following the escalation in Tf-PEG5000-SAc concentration, although the magnitude
is less than that of free holo-Tf. A 1:1 ratio of Tf-AF488 to Tf-PEG5000-SAc gives ∼20% decline
in fluorescence. Thus, mono-PEGylation does alter the affinity of Tf to TfRs on Neuro2A cells,
but not to a large extent.
Furthermore, a saturation binding experiment of Tf-AF488 to TfRs of Neuro2A cells was used
to measure the affinity of Tf-PEG5000-SAc (Fig. 3.3). A Scatchard analysis of these data yields a
Kd for Tf-AF488 of 64 nM, and hence a Kd of 64 nM for free holo-Tf (based on the competitive
binding study). The estimated Kd for Tf-PEG5000-SAc is 144 nM, because Tf-PEG5000-SAc
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Figure 3.3: (A) Saturation binding of Tf-AF488 to Neuro2A cells. Error bars represent one s.d. from
duplicate experiments. (B) The slope of a Scatchard plot gives the inverse of the binding dissociation
constant, K−1d . Linear regression gives K
−1
d = 0.0157 nM
−1, and Kd (Tf-AF488) = 64 nM. Kd (Tf) ∼ Kd
(Tf-AF488) = 64 nM. Confocal micrographs show the dose-dependent binding and internalization of free
Tf-AF488 ligands (green) into Neuro2A cells at (C) 5 nM and (D) 25 nM. Scale bar = 20 µm.
Figure 3.4: (A) Assembly scheme of Au50-PEG5000-Tfx NPs. Unmodified 50nm AuNPs (I) were either
reacted with excess mPEG5000-SH to form Au50-PEG5000 NPs (II) as untargeted particles, or first reacted
with various amounts of Tf-PEG5000-SH and later excess mPEG-SH to form Au50-PEG5000-Tfx NPs (III:
2 Tf/particle; IV: 18 Tf/particle; V: 144 Tf/particle). (B) Coupling efficiency of Au50-PEG5000-Tfx
NPs. This table presents estimates of Tf content of Au50-PEG5000-Tfx NPs from the reaction of various
amounts of Tf-PEG5000-SH and 2.25× 1010 unmodified 50 nm AuNPs in a 0.5 mL aqueous solution. The
theoretical Tf content assumes perfect conjugation of Tf-PEG5000-SH added to the reaction mixture. An
ELISA assay was used to determine the amount of free Tf-PEG5000-SH, which in turn was used to deduce
the amount of Tf-PEG5000-SH bound onto Au50 NPs (by assuming a perfect mass balance). A division of
the final Tf content by the theoretical Tf content and multiplication by 100% gives the coupling efficiency.
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displays a 2.25-fold less binding affinity to TfRs when compared to free holo-Tfs.
Synthesis and characterization of Au50-PEG5000-Tfx NPs
The addition of Tf-PEG5000-SH (deprotected Tf conjugate) into an aqueous suspension of 50 nm
unmodified AuNPs (I) initiates the assembly of Au50-PEG5000-Tfx NPs (Fig. 3.4A). We selected
this gold particle size to mimic the size our siRNA-containing therapeutic nanoparticles (∼70 nm)
[146] [152] and to achieve optimal receptor-mediated endocytosis in cells amidst other particle
sizes in the 10-100 nm range [153]. Adjustment of ligand concentration during the assembly
process gave targeted nanoparticles with Tf contents spanning two orders of magnitude (III: 2
Tf/particle; IV: 18 Tf/particle; and V: 144 Tf/particle), with a coupling efficiency that decreases
with input Tf concentration from 87% (III) to 60% (V) (Fig. 3.4B). Complete PEGylation with
excess mPEG-SH followed to mask any unreacted gold surface of the nanoparticles. PEGylated
nanoparticles (II) were prepared for use as an untargeted control.
Table 3.1 lists the physicochemical properties of the nanoparticles. Hydrodynamic diameters
of Au50-PEG5000-Tfx NPs are near-constant in water and 1× PBS independent of Tf content
(∼80 nm). Their ζ-potentials in 1 mM KCl are also the same and independent of Tf content
(∼−10 mV). With an isoelectric point of 5.9 [151], Tf is negatively charged in 1× PBS (pH = 7.4),
but do not significantly change the overall particle ζ-potential. Thus, this set of nanoparticles
is well-suited to ascertain the effects of targeting ligand content on nanoparticle distribution at
relatively constant nanoparticle diameter and ζ-potential.
Stability and binding affinity of Au50-PEG5000-Tfx NPs
Particle stability in physiological conditions is a prerequisite for effective active targeting. I
aggregates rapidly in 1× PBS (Fig. 3.5). PEGylation imparts steric stability to II-V in salt
solutions, as can be seen from their near constant hydrodynamic diameter (HD) when exposed to
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NP HDwater (nm) HDPBS (nm) ZP (mV) σ (#Tf/NP)
I 49.4 ± 0.6 755.4 ± 8.3 -18.3 ± 1.2 N/A
II 73.2 ± 1.3 74.9 ± 0.9 -10.9 ± 1.3 N/A
III 77.0 ± 0.9 77.7 ± 1.5 -10.8 ± 0.9 2.1 ± 0.2
IV 78.5 ± 1.7 81.3 ± 2.9 -9.0 ± 1.7 17.5 ± 2.5
V 81.0 ± 2.5 87.5 ± 3.4 -9.9 ± 1.7 144.3 ± 15.6
Table 3.1: Physicochemical properties of Au50-PEG5000-Tfx NPs. I = Unmodified Au50 NP; II =
Au50-PEG5000 NP; III-V = Tf-PEG5000-Au50 NP of 2, 18, and 144 Tf per particle, respectively. HD =
hydrodynamic diameter; ZP = ζ-potential; σ = Tf content; N/A = not applicable. Reported data are
reported as average ± s.d. from triplicates of experiments.
Figure 3.5: Particle stability. (A) In vitro stability against salt. I showed instant aggregation after the
addition of 10× PBS at the 4th minute, yet II-V remained stable. (B) In vitro stability against serum.
PEGylation attenuated particle aggregation in 90% mouse serum.
1× PBS. Moreover, II-V do not flocculate in 90% fresh mouse serum in 1× PBS. These results
suggest that the PEGylated nanoparticles will not aggregate in vivo.
From the saturation binding experiment of Au50-PEG5000-Tfx NPs, IV-V bind to Neuro2A
cells in a fashion that depends on both Tf content and nanoparticle concentration (Fig. 3.6),
validating the successful conjugation of Tf-PEG5000-SH onto the particle surface. A Scatchard
analysis was used to estimate the Kd’s of Au50-PEG5000-Tfx NPs, assuming a homogeneous
distribution of Tf on the nanoparticle surface. The measured values of IV and V were 1.06 and
0.13 nM, respectively. If 21.33% of Tf on the particle surface are in actual contact with TfRs on
the surface of Neuro2A cells due to geometric scaling arguments (see Supporting Information), the
resultant Kd’s of IV and V are 0.23 and 0.03 nM, respectively, representing approximately 600-
fold and 4800-fold enhancement in binding affinity, respectively, compared to free Tf-PEG5000-
SAc (Kd = 144 nM). The magnitude of binding affinity enhancement also increases with the
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Figure 3.6: (A) Saturation binding of Au50-PEG5000-Tfx NPs to Neuro2A cells. Au50-PEG5000-Tfx NPs
bound in a Tf content dependent manner (III-V). Error bars indicate one s.d. from duplicate experiments.
(B) Scatchard plots yield a Kd of 1.06 and 0.13 nM for IV (left curve) and V (right curve), respectively.
The Scatchard analysis assumes 100% contact of all Tfs mounted on the surface of PEG-AuNPs.
ligand content on the particle surface. Such enhancement underscores the “multivalent effect,”
when particle curvature permits a localized surface of multiple Tfs for simultaneous interactions
with surface TfRs to trigger endocytosis. Furthermore, given the low binding affinity, the poor
signal-to-noise ratio from the binding data of III does not warrant a meaningful estimation of
the Kd for III. Provided such dilute Tf content (2 Tf per particle), in theory, the binding affinity
of III should approach that of the monovalent ligand, Tf-PEG5000-SAc (Kd = 144 nM).
In vivo tumor distribution of Au50-PEG5000-Tfx NPs
Mice bearing subcutaneous Neuro2A tumors received i.v. administrations of II-V via the tail
vein, and were sacrificed 24 hours later to collect organs for analyses. Despite the overexpression
of surface TfRs by Neuro2A cells (Fig. 3.2), at the organ level, the tumor merely amasses 2-3%
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Figure 3.7: In vivo organ level distribution. Bulk particle localization in all organs was independent of
Tf content. Gold contents are normalized to percent injected dose (% ID). Error bars indicate one s.d.
from each class of Au50-PEG5000-Tfx NP (N = 3).
ID of particles, independent of Tf content (Fig. 3.7).
At the tissue level, histological data reveals predominant localization of AuNPs in the vicinity
of leukocytes for all Tf contents (Fig. 3.8A-B1). Intracellular accumulation of nanoparticles
inside Neuro2A cells is rare (Fig. 3.8B-C1) at low Tf content (II - IV), but further increase in
Tf content to 144 Tf per particle leads to considerable nanoparticle uptake by Neuro2A cells, as
seen from isolated nanoparticles of V residing near Neuro2A cells (Fig. 3.8D1).
Electron microscopy reveals clear, Tf-content dependent, intracellular nanoparticle localiza-
tion. While II-IV mostly localize inside leukocytes (Fig. 3.8A2) or externally touch the surface
of Neuro2A cells (Fig. 3.8B-C2), clusters of V reside within large endocytic vesicles of Neuro2A
cells (Fig. 3.8D2). The abundance of mitochondria and endoplasmic reticulum (essential for
robust cellular metabolic activities) indicates nanoparticle localizations inside target Neuro2A
cells but not other leukocytes, endothelial cells, or other non-cancer cells (Fig. 3.8D3). Thus,
ligand content does not alter the extent of bulk, nanoparticle content in the tumor. Instead, it
biases the tissue and cellular distribution with increasing targeting ligand content favoring the
intracellular localization within cancer cells. These results support the work of Kirpotin et al.
54
Figure 3.8: In vivo tumor tissue and intracellular distribution. Fig. 3.8A-D1 are light micrographs
of “silver-enhanced” tumor sections (scale bar = 10 µm). Independent of Tf content, most particles
resided near leukocytes. Electron micrographs show particles either engulfed by leukocytes (Fig. 3.8A2)
or touching tangentially Neuro2A cells (Fig. 3.8B-C2, enlarged image: Fig. 3.8B3). Particles of a high
Tf content (V: 144 Tf/particle) could enter Neuro2A cells (Fig. 3.8D2; enlarged image: Fig. 3.8D3).
Enlarged TEM images show a scale bar of 500 nm. All other TEM images display a scale bar of 2 µm.
Legend: RBC = red blood cell; M = mitochondrion; Nu = nucleus; ER = endoplasmic reticulum; V =
vesicle; WBC = leukocyte; N2A = Neuro2A cell; black arrow = “silver-enhanced” AuNP.
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[145] and our previous observations from the targeted delivery of siRNA [146]. Furthermore, III
and IV demonstrate the same in vivo distribution patterns within the tumor as II. A critical Tf
content is necessary to promote intracellular accumulation of nanoparticles in cancer cells.
In vivo hepatic distribution of Au50-PEG5000-Tfx NPs
Since nanoparticles always localize in liver to some extent, we address the fate of Au50-PEG5000-
Tfx NPs in the liver. Compared to Neuro2A cells, hepatocytes have weaker expression of TfRs
(data not shown). At the organ level, Tf content does not influence the level of nanoparticle
localization in the liver (17-21% ID; Fig. 3.7).
At the tissue level, most particles (independent of Tf content) experience phagocytic uptake
by Kupffer cells (Fig. 3.9B2) or reside along hepatic sinusoids (Fig. 3.9A-D1) or in the Space
of Disse, a region between hepatocytes and blood endothelial cells that contains reticular fibers,
microvilli, and collagen (Fig. 3.9A3). Particles rarely enter hepatocytes (independent of Tf
content (Fig. 3.9A2)). Like with the tumor, Tf targeting does not affect bulk particle content
in the liver, but yields infrequent instances of accumulation inside hepatocytes given sufficiently
high Tf content. From electron micrographs, at the cellular level, IV and V reside inside vesicles
as small clusters near the hepatocyte nucleus, surrounded by mitochondria and endoplasmic
reticulum (Fig. 3.9C2-3 and 3.9D2). Yet, below the threshold Tf content, II and III never
permeate through the Space of Disse and enter hepatocytes. Thus, the Tf targeting ligand
content does not alter the extent of bulk content in the liver, it only biases particle localization
nearby and entry into hepatocytes.
Ligand multivalency
Above we establish the presence of a critical Tf ligand density that imparts nanoparticles the
ability to access intracellular locations within the tumor. Yet, Tf is an endogenous protein and
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Figure 3.9: In vivo liver tissue and intracellular distribution. Fig. 3.9A-D1 are light micrographs of
“silver-enhanced” liver sections (scale bar = 10 µm). Independent of Tf content, particles rarely entered
hepatocytes. Electron micrographs show particles either engulfed by Kupffer cells (Fig. 3.9A2) or residing
in the Space of Disse (Fig. 3.9A2, enlarged image: Fig. 3.9A3). Hepatocytes could internalize particles
of high Tf contents (IV and V; Fig. 3.9C-D2; enlarged image: Fig. 3.9C3). Enlarged TEM images show
a scale bar of 500 nm. All other TEM images display a scale bar of 2 µm. Legend: RBC = red blood
cell; D = Space of Disse; KC and red circle = Kupffer cell; S = sinusoid; M = mitochondrion; MV =
microvillus; Nu = nucleus; G = Golgi apparatus; ER = endoplasmic reticulum; En = endothelial cell; H
= hepatocyte; HA = hepatic artery; PV = hepatic portal vein; black arrow = “silver-enhanced” AuNP.
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exists in normal serum. If background Tf can compete against Au50-PEG5000-Tfx NPs for Tf
receptors, how would this affect the utility of Tf-targeted nanoparticles for clinical applications?
Classical kinetics can provide a reasonable model to address this question. According to the
competitive binding model of N different species binding the same site, the equilibrium binding
fraction, θi, of species i depends on the binding dissociation constants (K
i
d’s) and concentrations
Ci of all competitors available. The mathematical expression of θi is given below:
θi =
(Kid)
−1Ci
1 + ΣNi=1(K
i
d)
−1Ci
From Fig. 3.4 and using the geometric assumption of partial interaction with Tf receptors,
the effective Kid’s of Au50-PEG5000-Tfx NPs are 0.13 nM and 0.03 nM for x = 18 (IV) and 144
(V), respectively. For our preceding animal models, the Neuro2A tumor grew to an approximate
volume of 100 mm3 (0.1 mL) before i.v. injection. Within the tumor, the blood vasculature
volume fraction is 0.15 [138]. Thus, the tumor blood compartment has a volume of 0.015 mL. If
2% ID of Au50-PEG5000-Tfx NPs reached the tumor 24 h after injection for all values of x (Fig.
3.7), the approximate number of particles in the tumor is 4.5× 1011 × 2% = 9× 109. Thus, the
concentration of Au50-PEG5000-Tfx NPs in the tumor blood compartment is ∼1.5 nM.
The typical Tf concentration in circulating serum is ∼12.5 µM [154]. Tf has two distinct iron
binding sites. Depending on the number of Fe3+ ions bound per Tf molecule, Tf can take the
form of apo-Tf, monoferric-Tf, and diferric-Tf (a.k.a. holo-Tf), which signify the binding of zero,
one, and two Fe3+ ions, respectively. From Fig. 3.3, the Kd of holo-Tf is 64 nM. Prior data from
rabbits indicate that the corresponding Kd’s of apo-Tf and monoferric-Tf are 4600 nM and 265
nM, respectively [155]. At normal plasma iron concentrations, random distribution of the metal
on the available Tf binding sites would give rise to a population of molecules of which 50% were
apo-Tf, 40% monoferric-Tf, and 10% diferric-Tf [156].
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Figure 3.10: Competition with background Tf in serum. Langmuir isotherms of Au50-PEG5000-Tfx NPs
(x = 18 (IV) or 144 (V)) on TfRs of N2A cells. Above the threshold Tf content, V can outcompete the
background serum apo-Tf, monoferric-Tf, and diferric-Tf in binding 65% of the available TfRs. IV can
only attach to 30% of the receptors, losing the remaining receptors to the background Tf in serum.
With the Kid’s and C
i for all pertinent Tf-containing species, we can plot the equilibrium
binding curves of Au50-PEG5000-Tfx NPs (x = 18 and 144) over Tf receptors on Neuro2A cells
within the mouse tumor (Fig. 3.10). Using the above parameters, the competitive binding model
predicts an occupation of 65% of the available Tf receptors on the Neuro2A cell surface by V
particles, in great excess to those occupied by the competitive serum Tf. In contrast, IV particles
can only bind to 30% of the Tf receptors, losing the remaining receptors to background serum Tf.
From this, the intracellular localization exclusively observed for V may stem from their innate
ability to outcompete serum Tf molecules in binding to Tf receptors.
Effect of receptor density
Prior analysis till this point involves strictly one cell line, Neuro2A, to engage multivalent binding
with Au50-PEG5000-Tfx NPs. Neuro2A has an upregulated expression of surface Tf receptors
(TfRs) (Fig. 3.2A; ∼110 TfR/µm2). This value assumes that the TfR density of Neuro2A is the
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Figure 3.11: Effect of receptor density on multivalency. (A) Binding of Au50-PEG5000-Tfx NPs (x = 18
(IV) or 144 (V)) on 3T3 cells. IV bound consideraly less cells compared to Neuro2A cells. V particles
even showed negligible binding. (B) Langmuir isotherms of Au50-PEG5000-Tfx NPs (x = 18 or 144) on
TfRs of 3T3 cells. IV and V could bind to limited fraction of TfRs (<15%) due to lower TfR densities.
same as HepG2 [157] and that the diameter of a Neuro2A cell is 12 µm. What is the effect of
receptor density of tumor cells on multivalent binding by liganded nanoparticles?
We repeated in vitro binding experiments using 3T3 cells (mouse fibroblast), which have much
weaker surface TfR expression (∼21 TfR/µm2 [158]) compared to Neuro2A cells. The binding of
Tf-AF488 onto 3T3 cells revealed less overall fluorescent retention compared to Neuro2A cells,
as well as a Kd of 36 nM (data not shown). Neuro2A and 3T3 cells have similar Kd’s (64 nM
vs. 36 nM), implying that the degree of binding between monovalent Tf-AF488 and each TfR
(1:1 interaction) is consistent across cell lines and independent of TfR expression.
In vitro binding experiments using 3T3 cells with IV and V particles followed. III particles
barely bound to Neuro2A cells (Fig. 3.6), and hence were not included in the binding study with
3T3 cells (with even lower TfR densities). Due to reduced level of TfR expression, both particle
types bound to significantly less 3T3 cells compared to Neuro2A cells of the same population
(Fig. 3.11A). The increase in absorbance readings due to binding of IV was almost beyond the
detection limit of the UV-Vis spectrometer. The interaction was so weak that the binding curve
appears linear rather than hyperbolic (expected shape for a typical isotherm). Scatchard analysis
based on the binding data indicate that the Kd’s of IV and V are 9.94 nM (by extrapolation
from the linear portion of the binding curve) and 1.60 nM, respectively (data not shown). A
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comparison of the Kd’s of IV and V between the Neuro2A and 3T3 cells underscores that
the multivalent interactions for tumor targeting depends on both the ligand density on the
nanoparticles as well as the receptor density of the tumor cells. Binding enhancement due to
multivalency is highest when both ligand and receptor densities are elevated.
Another approach to evaluate the effect of receptor density on tumor targeting is to employ
the competitive binding model. By inserting the Kd’s of IV and V obtained for 3T3 cells
and applying the geometric assumption that only 21.33% of the ligands bound to TfRs, the
Langmuir isotherms demonstrated considerably an attenuated equilibrium binding fraction for
these particles compared to its counterpart curve for Neuro2A cells (Fig. 3.11B). From this
model, even V, with the highest density of Tf ligands, could only bind to <15% of the receptors,
suggesting the futility of intracellular localization of V within a 3T3 tumor (with weak TfR
expression, and assuming that it is tumorigenic).
3.4 Conclusion
In summary, our results demonstrate the use of Au50-PEG5000-Tfx NPs as imaging agents to
understand targeted nanoparticle behavior in vivo. With similar sizes and ζ-potentials, targeted
particles of different Tf contents (II-V) permit the investigation of the effect of targeting ligand
content on nanoparticle distribution in vivo. PEGylation confers steric stability against salt-
and serum-induced aggregation in vitro. Because II-V localize in cellular structures of the
tumor and liver as individual entities, it is implied that the steric stabilization occurs in vivo as
well. Despite complete nanoparticle PEGylation, the RES organs (liver and spleen) still show
significant localization (17-21% ID and 5-6% ID, respectively) in excess to that of the tumor
(2-3% ID), irrespective of Tf content. Active targeting with Au50-PEG5000-Tfx NPs leads to
nanoparticle internalization into cancer cells with abundant TfR expression (Neuro2A cells).
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These data when taken together with past tumor permeation work conducted with other
targeted nanoparticle delivery systems (dextran [99], immunoliposomes [145], and Tf-targeted
cyclodextrin [146]), support the conclusion that targeted nanoparticles in the sub-100 nm size
range will always deliver a higher payload (drug, imaging agent, or combination) into cancer
cells of the tumor than their untargeted counterparts.
Moreover, from the present study, there is a minimum targeting ligand content on the
nanoparticle that provides the sufficient condition for effective active targeting. Below this
threshold content, targeted nanoparticles manifest similar in vivo distribution patterns as un-
targeted particles on organ, tissue, and cellular levels. Rather than simplistically switching
nanoparticles from an “off” state to an “on” state, i.e., untargeted vs. targeted, our results
underscore the importance of optimizing the ligand content on the nanoparticle surface in order
to achieve effective intracellular targeting of cancer cells in solid tumors.
A competitive binding model from classical kinetics can provide additional insights into un-
derstanding the basis of multivalent interactions for tumor targeting. From this model, there
are two key criteria that govern multivalency. To start with, nanoparticles must contain suffi-
cient ligands on their periphery to compete with endogeneous ligands in background serum for
the same tumor surface receptors. From in vitro binding studies and in vivo imaging of animal
models, one can deduce the threshold surface ligand content to achieve tumor intracellular accu-
mulation. Besides this threshold ligand content, the model also predicts that nanoparticles must
interact with tumor cells with up-regulated expression of surface receptors. Further binding and
imaging data from different tumor models can ascertain the critical receptor density.
Taking this model with all other data together, multivalent interactions may be the essence
of intracellular localization of nanoparticles within the tumor, and can only happen in systems
with sufficiently high ligand content and receptor density. In other words, with sufficient amounts
of ligands, nanoparticles will target tumor cells more selectively than normal cells, and hence
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Figure 3.12: Definition sketch of a sphere of radius R levitating on top of a flat surface.
can direct the drug payload to the targeted site without harming normal cells due to off-target
effects. This selection process stems from the multivalent interactions as described above.
3.5 Supporting Information
The Kd’s obtained from the Scatchard analysis assumes that all Tf moieties immobilized on
Au50-PEG5000-Tfx NPs interact with the TfRs on the cellular surface. Due to particle curvature,
this assumption does not make much physical sense. Is there an approximation that evaluates
the actual fraction of Tf in contact with the cell surface?
Consider a sphere of radius R whose center is of a distance h away from a flat surface. The
spherical curvature dictates the appropriate length scaling (Fig. 3.12). The sphere represents a
PEGylated gold nanoparticle (II), whereas the flat surface depicts a cellular surface that have
an overexpression of TfRs. The distance between the sphere and the flat surface reflects the
approximate height of Tf. By the Pythagoras theorem, (z − h)2 + r2 = R2.
For the bottom of sphere, and performing a Taylor expansion about the origin assuming
r  R, we derive the following mathematical relationship:
z = h−R
√
1−
( r
R
)2 ≈ h−R [1− 1
2
( r
R
)2
+O
( r
R
)4] z
R
∼ 1 + 1
2
( r
R
)2
In these expressions,  = (h − R)/R = d/R and d is the distance of the thin gap between the
63
NP K100%d K
21.33%
d Binding enhancement
IV 1.06 0.23 ∼ 600 fold
V 0.13 0.03 ∼ 4800 fold
Table 3.2: Multivalency of Au50-PEG5000-Tfx NPs. Enhancement in binding affinity (from effective
Kd’s) by three orders of magnitude for IV (x = 18) and V (x = 144) highlights the effect of multivalency.
bottom of sphere and flat surface. If r ∼ R, z/R is huge and does not converge because 1/ is
huge. If r  R, z/R is small and the second term of the expansion vanishes. To account for the
curvature of the sphere, set the second term of the expansion to the same size as the first term
(i.e., order 1). This gives the relevant length scale in the radial direction that indicates contact of
the sphere with the flat surface: r = 2R1/2 = 2(dR)1/2. With the assumption of homogeneous
Tf distribution on the entire spherical surface of PEG-AuNPs (4piR2), the fraction of contact is:
pi[2(dR)1/2]2
4piR2
=
d
R
≡ 
From Table 3.1, the hydrodynamic size of II in 1× PBS is 75 nm. Tf has a Stokes-Einstein
diameter of 8 nm [159]. These two measurements (R = 37.5 nm and d = 8 nm) collectively
imply a fraction of ∼21.33% of Tf attached on each Au50-PEG5000-Tfx NP in contact with TfRs.
Because ( ≡ d/R = 0.2 < 1), the thin gap lubrication approximation is valid.
Table 3.2 displays the effective Kd’s with and without the geometric assumption. From Fig.
3.3, the Kd of a single Tf-PEG5000-SAc ligand is 144 nM. With the geometric assumption, the
multivalent enhancement in binding is up to ∼600 and ∼4800-fold for IV and V, respectively.
3.6 Materials and Methods
Synthesis of Tf-PEG5000-SAc
HO-PEG-NH2 (MW: 5000; Laysan Bio) was reacted with excess N-succinimidyl-S-acetylthio acetate
(SATA; Pierce Biotechnology, Rockford, IL) in dimethylformamide (DMF) at RT for 4 h. The prod-
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uct was reacted with excess N, N-disuccinimidyl carbonate (DSC; Pierce Biotechnology) in DMF/dioxane
at room temperature for 4 h to give NHS-PEG5000-SAc. Upon solvent removal and drying under vac-
uuo, NHS-PEG5000-SAc was reacted with human holo-transferrin (Tf; Sigma) at a 2:5 molar ratio in
50 mM sodium phosphate at RT for 2.5 h to form Tf-PEG5000-SAc. Purification involved passing the
reaction mixture through a 5 mL HiTrap Phenyl HIC column in AKTA FPLC (GE Healthcare), with 1
M ammonium sulfate as the high salt and 50 mM sodium phosphate as the low salt.
Competitive binding assay
Plated in a 24-well plate at a population of 5 × 104 2 d in advance, Neuro2A cells were incubated in
0.45 mL of OptiMEM I containing 50 nM Tf-AF488 and different amounts of Tf-PEG5000-SAc at 37
◦C
and 5% CO2 for 1 h. After rinses with 1× PBS to remove unbound Tf conjugates, cells were analyzed
with FACSCalibur (Becton Dickinson Biosciences) to quantify the mean fluorescence at 488 nm. The
Tf on both Tf-PEG5000-SAc and Tf-AF488 (Tf conjugated to AlexaFluor488) bind to and compete for
surface transferrin receptors (TfRs) of Neuro2A cells. Reported data show percent of mean fluorescence of
cells incubated with Tf-AF488 only. Analogous experiments were conducted with holo-Tf and methoxy-
PEG5000-SH (mPEG-SH; MW: 5000; Sigma-Aldrich) for comparison.
Binding of Tf-AF488 to cells
Plated in a 24-well plate at a population of 5×104 cells per well 2 d in advance, Neuro2A and 3T3 (mouse
fibroblast) cells were incubated in 0.45 mL of OptiMEM I (Invitrogen) containing various concentrations
of Tf-AF488 at 37 ◦C and 5% CO2 for 1 h. After rinses with 1× PBS to remove unbound Tf-AF488, cells
were analyzed with FACSCalibur to quantify the mean fluorescence at 488 nm. A Scatchard analysis gave
the dissociation constant (Kd) of Tf-AF488 from TfRs of cells.
Assembly of transferrin-targeted, PEGylated gold nanoparticles
The deprotection of 6 µL of 1 µg/L Tf-PEG5000-SAc in 1× PBS was performed with the addition of
54 µL of 50 mM NH2OH (in 50 mM sodium phosphate and 25 mM EDTA; pH = 7.5) at RT for 2 h.
Adding deionized water to Tf-PEG5000-SH, the deprotected Tf conjugate, yielded a 0.3 mL volume for salt
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removal by a 0.5 mL Zeba Desalt Spin Column (Thermo Scientific). Salt removal prevents salt-induced
aggregation of gold particles, yet it led to 25% loss of Tf content due to entrapment in the column.
To prepare AuNPs with increasing Tf contents, 0.5, 5, or 50 µL of desalted Tf-PEG5000-SH (15
ng/µL) was added into 0.5 mL of 50 nm unconjugated AuNPs (Ted Pella) at a concentration of 4.5×1010
particles/mL. The reaction proceeded at RT with shaking for 1 h. Complete PEGylation of the unreacted
gold surface required the introduction of 10 µL of 1 mM mPEG5000-SH into the reaction mixture, and
proceeded at RT with shaking for 30 min. The reaction mixture was centrifuged at 14,000 × g for 10 min,
followed by removal of the supernatant fraction that contained unreacted or dimerized Tf- and methoxy-
PEG5000s. Au50-PEG5000-Tfx NPs sank to the bottom of the reaction vial as a brick-red pellet. The
pellet was rinsed twice with 0.45 mL of 1× PBS for 10 min in a shaker.
0.5 mL of 50 nm AuNPs were PEGylated with 10 µL of 1 mM mPEG5000-SH at RT with shaking for
30 min. The removal of excess mPEG5000-SH yielded Au50-PEG5000 NPs as untargeted control particles.
Estimation of Tf content
A human transferrin ELISA quantitation kit (Bethyl Laboratories) was used to determine the amount of
unbound Tf-PEG5000-SH in the supernatant fractions collected from the synthesis and PBS rinse steps.
Given the initial amount of Tf-PEG5000-SH added, a mass balance indirectly yields the Tf content of
Au50-PEG5000-Tfx NPs. All reported contents are from triplicate experiments.
Particle stability in salt and serum containing solutions
To monitor particle stability in salt solutions, a pellet containing 2.25 × 1010 unmodified AuNPs, Au50-
PEG5000 NPs, or Au50-PEG5000-Tfx NPs of different Tf contents (x = 2, 18, and 144 Tf per particle)
were resuspended in 1.26 mL of deionized water in a cuvette placed inside the ZetaPals instrument. 4 min
through HD measurements, 0.14 mL of 10× PBS was added to the cuvette. Size measurements continued
for 16 min. The assessment of particle stability in serum entailed the resuspension of a pellet containing
2.25 × 1010 particles in 200 µL of 90% fresh mouse serum (collected by saphenous vein extraction from
A/J mice) in 1× PBS. A Safire2 Microplate Reader (Tecan) was used to measure the absorbance of the
AuNP-serum mixture at 37 ◦C for 1 h at 590 nm, a wavelength indicative of gold flocculation.
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Binding of Au50-PEG5000-Tfx NPs to cells
Plated in a 24-well plate at a population of 8×105 cells per well 2 d in advance, Neuro2A and 3T3 cells were
incubated in 0.2 mL of OptiMEM I containing different concentrations of Au50-PEG5000-Tfx NPs (x = 2,
18, and 144) at 37 ◦C and 5% CO2 for 1 h. After rinses with 1× PBS, a Safire2 Microplate Reader (Tecan)
was used to measure the cell absorbance at 530 nm, the plasmon peak of Au50-PEG5000 NPs. To account
for non-specific adsorption, cells were incubated with identical concentrations of Au50-PEG5000 NPs. For
Scatchard analyses to deduce the effective Kd’s of Au50-PEG5000-Tfx NPs, the free gold concentration
was quantified by Safire2 based on a calibration curve of known concentrations of Au50-PEG5000 NPs.
Reported values, after deduction of non-specific gold signals, are from duplicate experiments.
Cell lines
Neuro2A and 3T3 cells were cultured at 37 ◦C and 5% CO2 in DMEM, supplemented with 10% FBS,
100 units/mL penicillin, and 100 units/mL streptomycin. Before tumor implantation, Neuro2A cells were
washed with 1× PBS, trypsinized, and resuspended in serum-free, antibiotic-free DMEM.
Animal models
In the right hind flank, each 8-week, female A/J mice (Jackson Laboratory) received subcutaneous im-
plantation of 106 Neuro2A cells in 0.1 mL of DMEM.
Systemic administration
2 weeks after tumor implantation, four mouse groups (N = 3) received administration of Au50-PEG5000-
Tfx NPs (x = 0, 2, 18, and 144) via the tail vein (4.5 ×1011 particles in 0.1 mL of D5W). Animal sacrifice
by CO2 overdose took place 24 h after injection, followed by collection and immersion-fixation of the
tumor, liver, kidney, heart, spleen, and lung in 4% PFA in 1× PBS at 4 ◦C for 2 weeks.
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Chapter 4
Targeting Kidney Mesangium by
Nanoparticles of Defined Sizes
4.1 Abstract
Nanoparticles are being investigated for numerous medical applications, and are showing po-
tential as an emerging class of carriers for drug delivery [137] [106]. Investigations on how
physicochemical properties (e.g., size, surface charge, shape, and density of targeting ligands) of
nanoparticles enable their ability to overcome biological barriers and reach designated cellular
destinations in sufficient amounts to elicit biological efficacy are of interest. Despite proven suc-
cess in nanoparticle accumulation at cellular locations and occurrence of downstream therapeutic
effects (e.g., target gene inhibition) in a selected few organs such as tumor [160] and liver [161],
reports on effective delivery of engineered nanoparticles to other organs remain scarce. We show
that nanoparticles of ∼75 ± 25 nm diameters target the kidney mesangium. These data are the
first to show the effects of particle diameter on targeting the kidney mesangium. Since many dis-
eases originate from this area of the kidney, our findings establish design criteria for constructing
nanoparticle-based therapeutics for targeting diseases that involve the kidney mesangium.
Excerpts of this chapter are reproduced with permission from “Targeting kidney mesangium by nanoparticles
of defined sizes.” Chung Hang J. Choi, Jonathan E. Zuckerman, Paul Webster, and Mark E. Davis. Proc. Natl.
Acad. Sci. USA. 108, 16, 6656-6661 (2011).
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4.2 Introduction
Constructing nanoparticles for drug delivery requires knowledge in colloidal science and biology,
where biological constraints generally dictate the design of nanoparticle therapeutics and imaging
agents. A celebrated design criterion is the notion of “renal clearance” [123] [162]. That is,
nanoparticles will experience rapid clearance by the kidney if they are smaller than ∼10 nm in
diameter. Such clearance originates from the innate function of the kidney as a blood filter.
Renal physiology in brief
The structural and functional unit of the kidney, the nephron, consists of the renal corpuscle
and tubule system. The renal corpuscle contains a tuft of blood capillaries and support tissue
(the mesangium: Fig. 4.1A-C) called the glomerulus. A fraction of blood plasma entering the
glomerulus will pass through the “glomerular filtration apparatus” to produce an ultrafiltrate,
which will be collected by the tubule system and ultimately be processed into urine. The first
component is the glomerular endothelium with pores that have been reported to be in the range
of 80-100 nm in diameter [163]. Next, the glomerular basement membrane (GBM), a 300-350 nm
thick basal lamina rich in heparan sulfate [164] and charged proteoglycans with an average pore
size of 3 nm [165], filters small molecules by size and charge. Behind the GBM lies podocytes,
cells with interdigitating foot processes that form “filtration slits” of 32 nm in width [166]. The
glomerular filtration apparatus, taken in its entirety, possesses an effective size cutoff of 10 nm,
and is responsible for the rapid “renal clearance” of small nanoparticles.
Kidney targeting using nanoparticles
Many nanoparticle-based contrasting agents for in vivo imaging were designed to be smaller
than this size cutoff [167] [168]. Prolonged residency of nanoparticles in the kidney has been
shown to induce toxicity in the form of cell shrinkage, due to excessive nanoparticle uptake by
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Figure 4.1: Illustrations of the renal corpuscle and the mesangium. (A) This light micrograph reveals
the typical morphology of the renal cortex. Scale bar = 10 µm. (B) This close-up reveals the inner
structure of a renal corpuscle. (C) This transmission electron micrograph shows the internal structures
of the renal corpuscles. Scale bar = 10 µm. (D) This schematic diagram shows the relationship between
mesangial cells and glomerular capillaries. Legend: renal corpuscles (RC), distal convoluted tubules
(DC), proximal convoluted tubules (PC), peritubular capillaries (PTC), red blood cells (RBC), leukocytes
(WBC), mesangial matrix (MM), mesangial cells (MC), foot processes of podocytes (FP), urinary space
(U), glomerular capillary space (C), endothelial cell (EC), glomerular basement membrane (GBM), and
pores (P) of the fenestrated endothelium of glomerular capillaries. In panel C, white arrows trace the
glomerular basement membrane. In panel D, red arrows indicate the pores between the glomerular
capillaries and mesangium. If smaller than the pore width, particles can enter the mesangium from the
glomerular capillaries in the absence of GBM and podocytes as structural barriers.
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Figure 4.2: Physicochemical characterization of unmodified gold nanoparticles (Aux NPs). Precise values
of hydrodynamic diameter (HD) and ζ-potential (ZP) of Aux NPs are listed, with the predicted ζ-potential
due to Debye-Hu¨ckel electrokinetic theory.
renal cells [169][170]. Closer examination of the renal corpuscle reveals the existence of another
intriguing size cutoff that would affect the distribution pattern. Within the renal corpuscle, in
the absence of GBM and podocytes, the sole dividing barrier between the mesangium (mesangial
cells and extracellular matrix) and the glomerulus is the fenestrated endothelium (Fig. 4.1D,
modified from Sakai and Kriz [171]). Submicron-sized nanoparticles may diffuse and accumulate
indefinitely in the mesangium once they depart from the glomerulus through these pores.
Here, we illustrate the size-dependent delivery of PEGylated gold nanoparticles to the kidney
mesangium. Gold nanoparticles (AuNPs) were used here for the following reasons. They are
compatible with multiple imaging methods. As rigid and non-decomposable objects, submicron-
sized AuNPs larger than ∼10 nm cannot escape the kidney by renal clearance.
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NP x (nm) y (Da) HDwater (nm) HDPBS (nm) ZP (mV)
Au5-PEG5000 5.3 ± 0.5 5000 26.2 ± 0.3 24.8 ± 0.5 -8.44 ± 0.85
Au20-PEG5000 21.6 ± 0.2 5000 43.1 ± 0.2 41.4 ± 0.4 -9.62 ± 0.62
Au40-PEG4000 41.2 ± 0.2 4130 59.1 ± 0.3 58.6 ± 0.5 -12.34 ± 1.21
Au50-PEG5000 51.4 ± 0.2 5000 78.8 ± 0.2 76.5 ± 0.4 -10.91 ± 1.33
Au60-PEG7000 58.1 ± 0.5 7359 94.6 ± 0.5 96.2 ± 0.2 -12.51 ± 1.24
Au80-PEG10000 76.5 ± 0.3 10000 127.6 ± 2.1 128.9 ± 0.9 -8.93 ± 0.67
Au100-PEG20000 98.3 ± 0.3 20000 167.4 ± 9.6 164.3 ± 8.6 -9.67 ± 0.31
Table 4.1: Physicochemical properties of Aux-PEGy NPs. x = core diameter of AuNP; y = chain length
of grafted PEG; HD = hydrodynamic diameter; ZP = ζ-potential. The table presents data as average ±
s.d. from triplicate runs. All particle types have near-constant ZPs despite their size differences.
4.3 Results and Discussion
Assembly of Aux-PEGy NPs
Unmodified AuNPs of different sizes have zeta potentials (ζ) ranging from −11 to −28 mV (Fig.
4.2). For any charged sphere of radius R in an electrolyte, its ζ is given below, where σ, , and
κ−1 are the surface charge density, permittivity constant, and Debye length.
ζ =
σ

R
1 + κR
From this equation, ζ of charged gold spheres becomes more negative as R increases, consistent
with data shown in Fig. 4.2. For typical ζ measurements in 1 mM KCl at room temperature, κ−1
is roughly 9.8 nm, a constant independent of R. By curve fitting of the measured ζ as a function
of R, the dimensionless charge density (σ/) is approximately 3. The measured ζ values are
consistent with predictions due to classical electrokinetic theory, and suggest that unmodified
AuNPs of all sizes share the same surface charge density (σ). In other words, the larger the
unmodified AuNPs, the more negative the surface charge.
To create an array of nanoparticles with variable size and relatively constant surface charge,
we exploit the charge screening effect of poly (ethylene glycol) (PEG). This would require the
engraftment of longer PEG chains onto the larger nanoparticles. This concept prompted us to
72
Figure 4.3: Blood pharmacokinetics. All Aux-PEGy NPs revealed extended circulation times in blood.
Gold contents are normalized to percent injected dose (% ID). Error bars indicate one s.d. from each
Aux-PEGy NP class (N = 3). Exact values of blood particle concentration at 0.5, 4, and 24 h are provided.
use an assortment of PEGylated gold nanoparticles (Aux-PEGy NPs) of different core diameters
(x) and PEGs of different chain lengths (y) (Table 4.1). The engraftment procedure entailed
the use of methoxy-PEG-thiol (mPEG-SH) molecules, whose terminal thiol group can react with
the gold surface via the formation of gold-thiol covalent bonds. Careful choice of x and y gave
rise to a near-constant ζ (roughly −10 mV) for Aux-PEGy NPs of various final hydrodynamic
sizes (Table 4.1). In general, the engraftment of each additional 2000 molecular weight of PEG
onto the gold surface translates to an increase in 5 nm of the hydrodynamic diameter of Aux-
PEGy NPs. This approximate linearity between the PEG corona thickness and chain length is
consistent with previous predictions for tethered polymer brushes on spherical interfaces without
pronounced curvature [114] (see supporting information). All Aux-PEGy NPs showed colloidal
stability in 1× PBS after 24 h, with hydrodynamic sizes roughly equal to those in water.
Blood pharmacokinetics
Balb/c mice (N = 3) received single i.v. injections of each type of Aux-PEGy NPs at the same
particle concentration. From each mouse, blood was withdrawn via the saphenous vein at various
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Figure 4.4: Organ level biodistribution. Bulk particle localization in the liver, spleen, and kidney was
size dependent. Gold contents are normalized to percent injected dose (% ID). For all particle sizes, the
five organs plus blood accounted for ≥70% ID of the injected dose. Error bars indicate one s.d. from each
Aux-PEGy NP class (N = 3). The inset shows the magnification of the particle retention in the kidney.
Exact values of blood particle concentration in all organs at 24 h are provided for added clarity.
time points to evaluate for gold content using inductively coupled plasma mass spectrometry
(ICP-MS). With extensive surface engraftment of PEG (y ≥ 4000), all particles manifested
extended blood circulation with a half-life (t1/2) that spans from 7 to 38 h (Fig. 4.3). Particle
size and t1/2 were inversely correlated (Table 4.2). The simultaneous increase in x and y led
to reduction in t1/2, indicating that size-dependent internal clearance, not colloidal stability
conferred by PEGylation, played a dominant role in determining particle blood circulation.
Organ level distribution
Mice were then euthanized 24 h after injection to extract organs for detection of bulk gold
content using ICP-MS. For all particle sizes, gold content of the six organs plus the blood
samples collected at three time points summed up to ≥70% ID, thus constituting a mass balance
that accounts for the destinations of most injected Aux-PEGy NPs. Overall, the liver, spleen,
and kidney were the main sites of particle accumulation, whereas the lung, pancreas, and heart
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NP t1/2 (h) Ω (% ID) GTE (%) SI
Au5-PEG5K 48.9 0.2 ± 0.1 0 0
Au20-PEG5K 31.8 1.2 ± 0.5 50 +
Au40-PEG4K 13.8 3.0 ± 0.6 80 ++
Au50-PEG5K 13.7 4.6 ± 0.9 100 +++
Au60-PEG7K 11.4 1.9 ± 0.4 90 +++
Au80-PEG10K 8.7 0.7 ± 0.4 70 ++
Au100-PEG20K 6.8 0.5 ± 0.3 60 +
Table 4.2: In vivo characteristics of Aux-PEGy NPs. t1/2 = blood half-life; Ω = kidney bulk particle
content; GTE = glomerular targeting efficiency; SI = staining index (an arbitrary score that ranks both
the intensity and spread of the silver stain, whereby +++ and 0 are the maximum and minimum values,
respectively). The table presents in vivo data as average s.d. from three animals per particle type.
showed negligible (<0.5% ID) particle retention (Fig. 4.4). At 24 h after dosing, the liver and
spleen both showed a positive correlation between particle size and degree of particle uptake, in
agreement with previous reports that the degree of particle phagocytosis by Kupffer cells and
spleen macrophages is largely size-dependent (the larger the nanoparticles the greater the uptake
in the reticuloendothelial system (RES)) [135]. From the data shown in Fig. 4.1-4.3, the blood
nanoparticle content at 24 h appears to correlate with uptake by the RES (increased uptake by
the RES is accompanied by lower content in the blood (leading to shorter circulation half-life)).
Lastly and most importantly, the kidney revealed an unexpected size-dependent nanoparticle
retention pattern: there exists a particle size (Au50-PEG5000) at which renal accumulation was
maximal (Fig. 4.4).
Tissue level renal distribution
To understand the size-dependent accumulation in the kidney, we prepared “silver enhanced”
kidney sections to reveal the distribution of Aux-PEGy NPs at the tissue level. Gold selectively
catalyzes the reduction of silver ions and deposition of metallic silver, making nanosized objects
visible under light microscopy. Within the cortex, most particles accumulated either near resident
phagocytes within peritubular capillaries, which intertwine the cortical tubules (proximal con-
voluted tubules and distal convoluted tubules), or inside renal corpuscles. Particle accumulation
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at peritubular capillaries did not show clear size correlation (Fig. 4.5).
Particle accumulation inside renal corpuscles reveals a strong function of size. The smallest
particles (Au5-PEG5000 NPs) were virtually undetectable in the renal corpuscles, but were found
in peritubular capillaries (Fig. 4.6A). Au20-PEG5000 NPs accumulated in the renal corpuscles and
rarely in the peritubular capillaries (Fig. 4.6B). Only ∼50% of the renal corpuscles contained
Au20-PEG5000 NPs, and the staining scattered all over the extracellular space (mesangium)
outside the mesangial cells. The staining intensity appeared mild. For Au40-PEG4000 NPs,
staining within renal corpuscles became more intense. ∼80% of the renal corpuscles were stained
positive for particles and staining was closer to mesangial cells (not shown).
Similar accumulation patterns were apparent for Au50-PEG5000 NPs, except that 100% of
the renal corpuscles examined under the light microscope were stained positive for particles.
Closer inspection of each individiual renal corpuscle reveals the most intense silver staining near
mesangial cells in the largest areal fraction of the renal corpuscles among all particle sizes (Fig.
4.6C). Incidentally, this complete glomerular targeting efficiency (GTE) matches strongly with
the maximal bulk particle content in the kidney observed for Au50-PEG5000 NPs (Fig. 4.4).
Likewise, the GTE for Au60-PEG7000 NPs were close to complete (∼90%), and such particles
elicited very intense silver staining near the mesangial cells (Fig. 4.7A).
Au80-PEG10000 and Au100-PEG20000 NPs gave a GTE of 60-70%. Due to the catalytic nature
of staining, larger Aux-PEGy NPs are expected to produce more surface silver deposition. While
silver staining can confirm the presence of Aux-PEGy NPs, the intensity alone does not provide
quantitation of actual particle content. Besides intensity, the spread of staining (areal fraction
covered by silver) within the renal corpuscles is also an important measure.
We report in Table 4.2 what we denote as the “staining index (SI),” an arbitrary measure that
accounts for both intensity and spread of staining. For the highest score (i.e., +++), particles
(like Au50-PEG5000 NPs) accumulated in the highest areal fraction of the renal corpuscles, and
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Figure 4.5: Tissue level distribution in peritubular tubules. The deposition of Aux-PEGy NPs in the
cortex excluding renal corpuscles is not a function of particle size. Particles (black arrows) are located
near peritubular capillaries or in the connective tissue space between adjacent convoluted tubule cells.
Scale bar = 20 µm.
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also at the highest intensity. Typically, the same particles can achieve a high GTE, meaning that
they can be found frequently in different renal corpuscles throughout the cortex. For the lowest
score (i.e., 0), particles (like Au5-PEG5000 NPs) resided in limited areas of the renal corpuscles,
and usually at undetectable densities. Typically, the same particles can achieve a low GTE,
implying their low occurrence in different renal corpuscles throughout the cortex.
For Au80-PEG10000 NPs, silver staining was found in limited regions of renal corpuscles,
despite their intense staining, yielding an SI score of ++. The largest particles, Au100-PEG20000
NPs, barely occupied a sizeable areal fraction of the renal corpuscles, and was accompanied by
very modest staining, leading to their score of + for the SI. Overall, the staining index of the
largest nanoparticles was lower than that of Au50-PEG5000 NPs. Taken together, Au80-PEG10000
and Au100-PEG20000 NPs target 60-70% of the renal corpuscles, and within each corpuscle, a very
limited area fraction and moderately intense staining.
The histological data collectively suggest a size-dependent localization of Aux-PEGy NPs
within renal corpuscles in the kidney cortex. Because such particles do not have a constant PEG
chain length, one may question whether the distribution of nanoparticles in renal corpuscles is
PEG-dependent. To address this point, we investigated the tissue level in vivo distribution of
Au80-PEG5000 NPs (hydrodynamic size: 97.1 ± 1.9 nm; zeta potential: −16.77 ± 1.14 mV) in
renal corpuscles, noting that such particles possess a very similar hydrodynamic size of Au60-
PEG7000 NPs. Histological analysis reveals accumulation of Au80-PEG5000 NPs in the renal
corpuscles in similar intensity and area as that of Au60-PEG7000 NPs but not Au80-PEG10000
NPs, supporting that the distribution of nanoparticles in renal corpuscles is size-dependent.
Cellular level renal distribution
We employed transmission electron microscopy (TEM) to determine the intracellular localization
patterns of the nanoparticles residing in the renal cortex. In agreement with the histological data,
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Figure 4.6: Tissue level distribution in renal corpuscles. Representative light micrographs of “silver-
enhanced” kidney sections reveal size-dependent particle accumulation. (A) Au5-PEG5000 NPs were
almost undetectable. (B) Au20-PEG5000 NPs exhibited weak silver staining in limited areas of the renal
corpuscles. (C) Au50-PEG5000 NPs displayed the most intense staining in the largest area of renal corpus-
cles among all particle sizes. Silver staining (dark specks indicated by red arrows) was present in almost
every renal corpuscle observed under the light microscope, resulting in complete glomerular targeting.
The right column (scale bar = 3 µm) illustrates the magnified renal corpuscle (green box) shown in the
left column (scale bar = 10 µm).
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Figure 4.7: Tissue level distribution in renal corpuscles (continued). Representative light micrographs
of “silver-enhanced” kidney sections reveal size-dependent particle accumulation. (A) Au60-PEG7000 NPs
displayed the most intense staining in the largest area of renal corpuscles among all particle sizes. Silver
staining (dark specks indicated by red arrows) was present in almost every renal corpuscle observed under
the light microscope, resulting in complete glomerular targeting. (B) Au80-PEG10000 NPs appeared in
reduced amounts with moderate intensity. (C) Au100-PEG20000 NPs accumulated in the renal corpuscles
in minute amounts and very weak intensity, presumably due to their inability to penetrate through the
fenestrated glomerular endothelium. The right column (scale bar = 3 µm) illustrates the magnified renal
corpuscle (green box) shown in the left column (scale bar = 10 µm).
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particles of all sizes were either engulfed by resident phagocytes or remained as isolated entities
in circulation inside pertitubular blood capillaries. Particle accumulation in peritubular blood
capillaries was not size-dependent (Fig. 4.8).
Retention of particles in renal corpuscles, however, is a strong function of size (Fig. 4.9).
Smaller particles (Au20-PEG5000 NPs) entered the mesangium within renal corpuscles in minute
quantities (Fig. 4.9A). As size increases, Aux-PEGy NPs showed more association with mesangial
cells. Au50-PEG5000 NPs accumulated in multiple clusters either within mesangial cells or in the
extracellular matrix outside mesangial cells. The clustering density was the most pronounced
among all particle sizes, consistent with the histological data (Figs. 4.9C and 4.10A). Particles of
similar sizes (Au40-PEG4000 (Fig. 4.9B) and Au60-PEG7000 NPs (Fig. 4.10B) ) also demonstrated
appreciable particle accumulation in the mesangium. Larger particles (Au80-PEG10000 NPs)
only resided at the extracellular space in isolated amounts, but never inside the mesangial cells
(Fig. 4.10C). The TEM data reveal a size at which particle association with mesangial cells
was maximal (Au50-PEG5000 NPs). This particular size maximized bulk kidney particle content
and glomerular targeting. Thus, the size of Au50-PEG5000 NPs yields maximal kidney
targeting at the organ, tissue, and cellular (mesangium) levels.
Interpretation of maximal kidney targeting
The average pore diameter of the fenestrated glomerular endothelia is reported to be 80-100 nm,
roughly the hydrodynamic size of Au50-PEG5000 and Au60-PEG7000 NPs. Particles larger than
this size cutoff (Au80-PEG10000 and Au100-PEG20000 NPs) may experience steric hindrance when
permeating through the pores to enter the mesangium and access the mesangial cells. On the
contrary, smaller particles (Au20-PEG5000 and Au40-PEG4000 NPs) are freely accessible to the
mesangium. Thus, the “size exclusion” effect may account for the lower kidney particle content
and weaker glomerular targeting of the largest particles.
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Figure 4.8: Cellular level distribution in peritubular capillaries. Representative TEM microcraphs show
that particle deposition in the cortex excluding renal corpuscles is not a function of particle size. Particles
are located near peritubular capillaries or in the connective tissue space between convoluted tubule cells.
Images shown in the 2nd column (scale bar = 500 nm) are magnified versions of those shown in the 1st
column (scale bar = 2 µm).
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Figure 4.9: Cellular level distribution in renal corpuscles. Representative TEM micrographs show par-
ticle accumulation in the mesangium (mesangial cells and extracellular matrix). (A-B) A small portion
of Au20-PEG5000 and Au40-PEG4000 NPs localized in mesangial cells within the renal corpuscles. (C)
Au50-PEG5000 experienced the most prominent uptake by mesangial cells among all particle sizes. TEM
micrographs clearly depict the mesangial location in the vicinity of the glomerular filtration apparatus,
including glomerular filtration membrane (GBM) and podocytes. Images shown in the 2nd column (scale
bar = 500 nm) illustrates the magnified portion (black box) shown in the 1st column (scale bar = 2
µm). Red arrows in the right column indicate clusters of Aux-PEGy NPs. Legend: red blood cell (RBC),
mesangial cells (MC), foot processes of podocytes (FP), urinary space (U), endothelial cell (EC).
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Figure 4.10: Cellular level distribution in renal corpuscles (continued). Representative TEM micrographs
show particle accumulation in the mesangium (mesangial cells and extracellular matrix). (A-B) Au50-
PEG5000 and Au60-PEG7000 NPs experienced the most prominent uptake by mesangial cells among all
particle sizes. (C) Au80-PEG10000 NPs deposited in the mesangium in drastically reduced amounts. TEM
micrographs clearly depict the mesangial location in the vicinity of the glomerular filtration apparatus,
including glomerular filtration membrane and podocytes. Images shown in the 2nd column (scale bar =
500 nm) illustrates the magnified portion (black box) shown in the 1st column (scale bar = 2 µm). Red
arrows in the right column indicate clusters of Aux-PEGy NPs. Legend: red blood cell (RBC), mesangial
cells (MC), podocyte (Po), foot processes of podocytes (FP), urinary space (U), glomerular basement
membrane (GBM), pericyte of Bowman’s capsule (Pe), proximal convoluted tubule (PC).
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From TEM data, size-dependent uptake occurs solely at mesangial cells, which come in two
types. The first type is contractile mesangial cells, which resemble vascular smooth muscle cells
and fibroblasts that regulate surface area for glomerular filtration of fluids and mesangial vol-
ume. The second type involves mononuclear resident phagocytes derived from the bone marrow
[128]. From the ICP-MS data, particle uptake by spleen macrophages and hepatic Kupffer cells
(both of bone marrow origin) rise with increasing particle size. Below the size cutoff in the
kidney, larger particles (Au50-PEG5000 NPs) can penetrate through the endothelial pores, en-
ter the mesangium, and accumulate inside mesangial cells (likely the phagocytic type resident
macrophages). Smallest particles (Au5-PEG5000 NPs) may transiently enter the mesangium, but
may not favor prolonged retention due to lack of phagocytosis by mesangial cells. The absence
of a cellular sink may lead to their low bulk particle content.
4.4 Conclusion
This work is the first study to systematically examine the distribution of 10-150 nm nanoparticles
in the kidney from a systemic injection. From measuring blood pharmacokinetics as well as
distribution patterns at the organ, tissue, and cellular levels, the results suggest that there is
an optimal size range (Au50-PEG5000 NPs) that maximizes bulk particle uptake in the kidney,
deposition of particles in renal corpuscles within the cortex, and uptake of particles by mesangial
cells within renal corpuscles. When using nanoparticles as cancer therapeutics, accumulations
in single digit percent ID amounts in the tumor can lead to gene inhibition and tumor reduction
[146]. Thus, the accumulation of Aux-PEGy NPs (1-5% ID) in the kidney at these amounts may
be able to impart efficacy with kidney diseases.
Moreover, the lack of significant localization of residual (0.7% ID) of larger particles (Au80-
PEG10000 NPs; ∼130 nm in diameter) provides an in vivo calibration to the size of the glomerular
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x (nm) β (oligos/nm2) Σ (PEG/nm2) σ∗
20 1.4× 1013 0.400 0.196
40 8.5× 1012 0.243 0.119
50 8.1× 1012 0.231 0.113
60 7.8× 1012 0.223 0.109
80 7.1× 1012 0.203 0.099
Table 4.3: Rough estimates of PEG grafting density on Aux-PEGy NPs. β = oligonucleotide grafting
density (all entries referenced from Hill et al.); Σ = PEG grafting density (with the first entry (0.4) by
Takae et al. and all remaining entries scaled according to β); σ∗ = b2Σ = dimensionless PEG grafting
density (with the first entry (0.196) determined above and all remaining entries scaled according to Σ.)
endothelial pores. Most reported values for this pore size are derived from direct measurements
of TEM and SEM images. Sample processing for microscopy involves repeated dehydration, and
may lead to shrinkage of fine cellular features. The pore size reported here (130 nm) depicts the
glomerular endothelial morphology at physiologically relevant conditions.
4.5 Supporting Information
PEG corona thickness of Aux-PEGy NPs
Each Au20 NP can anchor 520 PEG chains of 6000 Da each [172]. This translates to a PEG
grafting density (Σ) of 0.4 PEG/nm2. The Kuhn length (b) of PEG is 0.7 nm. The dimensionless
PEG grafting density (σ∗) is σ∗ = b2Σ = (0.7 nm)2× (0.4 PEG/nm2) = 0.196. Hill et al. [173]
evaluated the grafting density of oligonucleotides (β) on submicron-sized AuNPs (10-100 nm).
If the oligonucleotide density data due to size curvature are applicable to the study of PEG
grafting, a rough estimate of PEG grafting density of Aux-PEGy NPs can be made (Table 4.3).
σ∗ is ∼0.1-0.2 (for AuNPs with size >20 nm), which represents a very high grafting density
according to Wijman and Zhulina [174]. Physically, how high is this density? According to scaling
analysis by de Gennes on grafted polymers, the brush conformation appears if σ∗ > N−6/5, where
N is the number of Kuhn polymer segments [110]. How can we estimate N?
Take Au50-PEG5000 NPs as an example. The MW of each PEG unit is 44 g/mol. The two
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Au40-PEG4K Au50-PEG5K Au60-PEG7K Au80-PEG10K
MW (g/mol) 4000 5000 7000 10000
Rmax (nm) 40 50 70 100
N 57.14 71.43 100 142.86
N−6/5 0.0078 0.0060 0.0040 0.0026
RF (nm) 7.93 9.07 11.09 13.74
D (nm) 2.29 2.35 2.39 2.50
x (nm) 40 50 60 80
x/2b 28.57 35.71 42.86 57.14
Table 4.4: Polymer parameters of grafted PEG. MW = molecular weight of grafted PEG; Rmax = bN
= contour length; N = degree of polymerization (no. of Kuhn segments); RF = bN
3/5 = Flory radius in
a good solvent; D = separation distance between adjacent PEG monomers
C-O bonds (each 0.145 nm) and C-C bond (0.15 nm) add up to 0.44 nm. The contour length
(Rmax = Nb) of a fully stretched PEG5000 coil is 5000 ÷ 44 × 0.44 nm = 50 nm. If b = 0.7
nm, then N = 71.4. Clearly, σ∗ is greater than N−6/5. Hence, PEG polymer chains fill are
overlapping with each other, with their blobs acting as hard spheres and cover the gold surface
densely. The σ∗ > N−6/5 result is also apparent for all other Aux-PEGy NPs.
Alternatively, one can calculate the footprint (D) of each PEG chain (separation distance
between each adjacent PEG chain) on the gold surface, knowing that 4piD2 = Σ. For Au50-
PEG5000 NPs, D = 2.29 nm, which is shorter than the Flory radius of PEG5000 in a good solvent
(RF = bN
3/5 = 9.07 nm). Because the RF > D result is apparent for all other Aux-PEGy NPs,
the grafted PEG chains take the “brush conformation” on the gold surface for all particle sizes.
On a planar surface, the brush height of tethered PEG corona (H) should scale linearly with
N [110] [109]. Yet, on a spherical interface, H ∼ N3/5 because the chains extended away from
the surface should be more diffuse compared to those densely packed chains near the surface,
thus shortening H. Yet, DLS measurements revealed H ∼ N (Table 4.1), not N3/5, suggesting
that the curvature effect on H is not eminent.
For σ∗ ∼ 0.1 and using self-consistence-field simulations, Dan and Tirrell [114] showed that
the curvature effect becomes less important, and that H will approach the planar limit of (H ∼
N) when x/2b >100. For Aux-PEGy NPs at hand, their values of x/2b mainly lie in the range of
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28-57 (Table 4.4), so H ∼ N0.9 according to simulation results by Dan and Tirrell. This explains
the observed approximate “linearity” between H and N even on spherical particles.
4.6 Materials and Methods
General
Unless otherwise mentioned, all poly (ethylene glycol) (PEG) raw materials were purchased from Laysan
Bio. All organic solvents were purchased from Sigma.
Synthesis of mPEG4000-SH and mPEG7000-SH
50 mg of amine-PEG3400-SH (14.7 µmol) was reacted with 40.4 mg of methoxy-PEG550-(succinimidyl
propionate) (73.5 µmol) in 50 µL of triethylamine (TEA) and 1.2 mL of anhydrous dichloromethane
(DCM) at RT with stirring for 7 h. The crude mixture was dried under vacuuo, and dialyzed against
deionized water using a 3 kDa Amicon MWCO membrane (Millipore) three times. 15 mg of amine-
PEG5000-SH (3.0 µmol) was reacted with 60 mg of methoxy-PEG2000-(succinimidyl valerate) (30.0 µmol)
in 50 µL of TEA and 1.2 mL of anhydrous DCM at RT with stirring for 16 h. The crude mixture was dried
under vacuuo, and dialyzed against deionized water using a 30 kDa Amicon MWCO membrane (Millipore)
three times. The correct fraction (7000 Da) was separated using HPLC using a TSKgel G3000SW column
(Tosoh Bioscience). Final molecular weights were confirmed by MALDI-TOF.
Assembly of PEGylated gold nanoparticles (Aux-PEGy NPs)
Methoxy-PEG-thiol (purchased or synthesized above) of a certain molecular weight (y = 4000, 5000, 7000,
10000, and 20000), dissolved in deionized water was added to 3 mL of aqueous suspension of unconjugated
gold colloids (Ted Pella) of a designated core size (x = 5, 20, 40, 50, 60, 80, and 100 nm) at an excess
concentration of ∼9 PEG strands per nm2 of gold surface. E.g., To ensure complete coverage, PEGylation
of Au50 NPs required the addition of 10 µL of 1 mM mPEG5000-thiol (in deionized water) to 0.5 mL of
aqueous suspension of 2.25 × 1010 particles. All PEGylation reactions proceeded at RT for 2 h with
constant stirring. To remove any unbound PEG, the reaction mixture was dialyzed against deionized
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water using a 30 or 100 kDa Amicon MWCO membrane (Millipore) three times.
Animal experiments
For each type of Aux-PEGy NPs, three 9-week, female Balb/c mice (Jackson Laboratory) received i.v.
injections of particles via the tail vein at a concentration of 4.5 × 1011 particles per mL, formulated in
120 µL of filtered D5W. At three consecutive time points after injection (0.5, 4, and 24 h), 30 µL of mouse
blood was drawn from each mouse via its saphenous vein using a Microvette CB 300 Capillary Blood
Collection Tube with EDTA (Sarstedt). Blood samples were stored at 4 ◦C until use. After 24 h, mice
were euthanized by CO2 overdose for the collection of the liver, kidney, lung, heart, spleen, and pancreas.
Organs were fixed in 4% PFA in 1× PBS for 3 d.
Organ level particle distribution
All excised organs underwent routine ICP-MS procedures for quantification of gold contact (see Appendix
A). Each mouse weighed ∼20 g at the time of experiment, and had a total blood volume of 1.6 mL
(average mouse volume is 77-80 µL/g).
Quantitative tissue level renal particle distribution
Fixed kidney blocks underwent routine histological procedures with silver enhancement (see Appendix
A) to generate silver enhanced, H & E counterstained sections. To estimate the glomerular targeting
efficiency (GTE) of particles to renal corpuscles from light micrographs, 300 renal corpuscles, selected
at random positions from 10 to 15 kidney sections per injected mouse, were inspected visually for the
presence of silver stains. For the staining index (SI), both the staining intensity and spread of these 300
renal corpuscles were scored.
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Chapter 5
Development of Chemical Stain for
Cyclodextrin-based Nanoparticles
5.1 Abstract
Cyclodextrin-polymer (CDP) nanoparticles represent a class of delivery vehicle with widespread
biomedical applications, owing to its low toxicity, high aqueous solubility, and superior ability
to imbibe hydrophobic moieties (drug payload). Tracking the localization patterns of CDP
nanoparticles at the tissue and cellular levels can provide valuable information of their in vivo
behavior. Here, we report the creation of a new chemical stain that can specifically recognize
CDP nanoparticles embedded in cells, tissue sections, and patient biopsies, ex vivo. Based on
an aqueous suspension of monodisperse Au5-PEG1000 nanoparticles, this stain exhibits superior
binding to the adamantane cups exposed on the periphery of CDP nanoparticles, fluorescence for
detection by confocal microscopy, as well as steric stability against salt-induced aggregation in
PBS. This chapter concludes with different applications of this stain to reveal key pharmacological
insights (e.g., intratumoral transport and dose response) of two classes of CDP nanoparticles
currently under clinical development (IT-101 and CALAA-01).
Excerpts of this chapter are reproduced with permission from “Pharmacokinetics and tumor dynamics of
the nanoparticle IT-101 from PET imaging and tumor histological measurements.” Thomas Schluep, Jungyeon
Hwang, Isabel J. Hildebrandt, Johannes Czernin, Chung Hang J. Choi, Christopher A. Alabi, Brendan C. Mack,
and Mark E. Davis. Proc. Natl. Acad. Sci. USA. 106, 27, 11394-11399 (2009). and “Evidence of RNAi in humans
from systemically administered siRNA via targeted nanoparticles.” Mark E. Davis, Jonathan E. Zuckerman,
Chung Hang J. Choi, David Seligson, Anthony Tolcher, Christopher A. Alabi, Yun Yen, Jeremy D. Heidel, and
Antoni Ribas. Nature 464, 7291, 1067-1070 (2010).
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5.2 Introduction
There are many important measures to ascertain the efficacy of nanoparticle-based therapeutics
for cancer applications. After their administration, do the nanoparticles accumulate in the
tumor? If so, will they enter the cancer cells within the tumor? Presumably they arrive at the
specific cancer cells, can they release the drug payload? And can the payload lead to obvious
reduction or stabilization of tumor growth? If so, is such growth reduction due to the mechanism
of action originally proposed for the therapeutic?
Efficient delivery of nanoparticles must take place before the encapulated drug can demon-
strate its mechanism of action. When experimental data from molecular biological analysis (e.g.,
knockdown of target gene, attenuation of protein expression) can be subject to interpretation,
microscopic evidence that illustrates the presence of the administered nanoparticles within the
tumor is more objective, and can often lend confidence to the molecular biological data (espe-
cially when the tumor does not show obvious regression). Thus, developing tools that can reveal
injected nanoparticles within tumor tissues is of much scientific and clinical merit.
This chapter features the development of a chemical stain for the specific detection of
cyclodextrin-based polymer nanoparticles. We elucidate the utility of this stain in revealing
key pharmacological insights of nanoparticle-based drug delivery vehicles, such as transport phe-
nomena and dosage. While positron emission tomography or near-infrared imaging can provide
live imaging data, they can only provide organ-level distribution data but no information about
the spatial relationship between these particles and their surrounding tissues or cells (e.g., intra-
cellular accumulation). The lack in tissue- and cellular-level resolution motivates us to create a
new stain for CDP nanoparticles in cells, tissue sections, and patient biopsies, ex vivo.
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Cyclodextrin-based pharmaceutics
Cyclodextrins (CDs) represent a series of cyclic oligosaccharides. Each CD molecule adopts an
interesting three-dimensional structure that resembles as a cone-shaped cup. The interior of the
cup is relatively apolar, but its surface displays multiple hydroxyl groups that render its high
water solubility. Also, they lack immunogenicity and are not prone to enzymatic digestion. In
light of these properties, CDs can incorporate hydrophobic moieties within their cups and form
CD inclusion complexes with high solublility in aqueous media, thus explaining their widespread
application as building blocks of macromolecular vehicles for drug delivery [175] [176].
Cyclodextrin-polymer nanoparticles
Davis and co-workers developed two drug delivery platforms by employing linear polymer chains
that contain β-CD (with 7 glucose monomers in its cyclic structure) as the backbone. In aqueous
environments, both platforms can form nanosized inclusion complexes.
The first type of conjugate consists of repeating units of β-CD and PEG as the polymer
backbone, grafted with camptothecin (CPT) as the active ingredient on their pendant chains
[177]. CPT, a hydrophobic molecule, can recognize the apolar cups of CDs on the polymer
backbone to trigger the self-assembly into a nanoparticle named IT-101. CPT is a potent anti-
neoplastic agent against many different cancer cell types [178], but suffers from poor solubility,
severe toxicity, and low clinical activity [179]. Compared to free CPT at equivalent doses,
binding CPT with the CDP-based backbone dramatically enhanced the plasma half-life and net
retention in the tumor resulting from an i.v. injection in animal models [180]. IT-101 has also
demonstrated high tolerability and antitumor activity against a broad range of tumors in mice
[181], and is now in clinical development for treatment of cancer [182].
The second type comprises repeating units of β-CD and a short cationic linker as the poly-
mer backbone, non-covalently decorated by PEG-adamantane (for stability against salt-induced
92
aggregation) and Tf-PEG-adamantane (for targeting tumor cells that overexpress Tf receptors)
[160]. The cationic polymer serves to condense strands of small interfering ribonucleic acid
(siRNA) molecules (effectors of the natural post-transcriptional gene silencing mechanism called
RNA interference (RNAi)), the main therapeutic agent, and to protect siRNA from serum degra-
dation. These nanoparticles contain siRNAs that target the M2 subunit of ribonucleotide re-
ductase (RRM2), a crucial enzyme involved in preparing nucleotides for DNA replication. The
specific sequence (denoted as siR2B+5) [183] can reduce the expression of RRM2, an anti-cancer
target protein [184]. In aqueous medium, the combination of electrostatic (between the cationic
CDP and siRNA) as well as hydrophobic foces (between adamantane and CD cups on CDP
backbone) drives the self-assembly of these ingredients into stable nanoparticles of ∼70 nm in
diameter (denoted as CALAA-01) [185]. Well tolerated in multi-dosing studies in non-human pri-
mates [186], CALAA-01 is now in use as part of the first ever human clinical trial to systemically
deliver siRNA with a targeted delivery system to patients with solid cancer [187].
5.3 Results and Discussion
Design of chemical stain
To identify the presence of cyclodextrin-containing nanoparticles in tissues, the desirable stain
should possess two properties. It should be detectable by conventional imaging modalities, and
specifically bind to cyclodextrin-containing nanoparticles (or their fragments). To satisfy both
properties, we coated AuNPs of 5 nm in diameter with thiolated PEG chains (methoxy-PEG1000-
SH). Some PEG chains contain adamantane (AD) moieties at their distal ends (Fig. 5.1).
Surface modification with gold-sulfur covalent linkages (Au-S) has been shown to yield the
most significant enhancement in fluorescence signals of 5 nm AuNPs compared to their uncapped
counterparts [188]. Surface Au(I) atoms and their coordinated ligands can engage in metal-
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Figure 5.1: Synthesis of chemical stain. (A) Synthesis of AD-dPEGTM12 -SPDP (MW: 1000). The adaman-
tane (AD) residue was inserted to one end of a short, heterofunctional PEG linker. (B) Assembly of
Au-PEG-AD. Different molar ratios of methoxy-PEG1000-SH and AD-dPEG
TM
12 -SPDP are added to an
aqueous suspension of 5 nm Au NPs to create Au5-PEG1000-ADx NPs (∼10 nm). x indicates the relative
level of hydrophobicity of the stain to bind to cyclodextrin-containing nanoparticles.
Figure 5.2: Principle of specific staining. (A) Adamantane (AD) residues are known to form inclusion
complexes with beta-cyclodextrin (β-CD). (B) Multiple Au-PEG-AD particles will specifically bind to the
surface of cyclodextrin-based nanoparticles due to AD-βCD interactions.
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Figure 5.3: Fluorescence and binding of Au5-PEG1000-AD50 NPs. (A) Emission spectra. 5 nm AuNPs
are weakly fluorescent when excited by an argon laser at 488 nm. PEGylation using gold-sulfur linkage
confers fluorescence signal to the gold particle. Emission: 500-550 nm bandpass (BP) filter. (B) The
confocal micrograph shows fluorescence of a cluster of Au5-PEG1000-AD50 NPs. Scale bar = 20 µm. (C)
This TEM image shows direct binding of Au5-PEG1000-AD50 NPs (individual dark spots) atop the surface
of IT-101, a CDP-based nanoparticle (white). Scale bar = 20 nm.
metal to ligand charge transfer (MMLCT) interactions in their excited states. Compared to
other capping ligands (e.g., triphenylphosphine), sulfur-containing ligands give more prominent
MMLCT for AuNPs [189]. Thus, the application of this gold-sulfur based stain onto tissue
sections permits visualization using confocal microscopy. In addition, TEM can reveal these
AuNPs due to their inherently high electron density.
For signal specificity, the stain displays multiple copies of AD on the AuNP periphery to
exploit the strong hydrophobic interaction between cyclodextrin cups of the nanoparticles and
adamantane (Kd = 10
−4 − 10−5 M) [190]. Fig. 5.2 is a schematic illustration of the specific
interaction between the proposed stain and a cyclodextrin-polymer (CDP) based nanoparticle.
The staining of tissue sections usually proceeds in buffered salt, which incidentally can lead
to aggregation of AuNPs. Because the fluorescence of thiol-capped AuNPs are restricted to
small sizes (≤5 nm), PEGylation provides steric stability of the stain against salt. By UV-
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Figure 5.4: Fluorescence of IT-101. (A) Structure of IT-101. The components of the parent polymer
are β-CD (blue), PEG (green), and L-cysteine (black). CPT (red) is attached to the polymer via a single
glycine amino acid linker (brown). (B) The fluorescence of IT-101 (blue) originates from CPT. Excitation
= 370 nm; emission = 440 nm. Neuro2A cells incubated with IT-101 showed uptake of IT-101 given the
intense CPT fluorescence (C), while untreated cells did not (D).
Figure 5.5: Nature of staining. (A) After incubation with β-CDP for 7 h, Neuro2A cells took up the
polymer, and were stained by Au5-PEG1000-AD50 NPs. There was no CPT fluorescence because the
polymer solution did not contain any CPT. (B) After incubation with pure CPT (for only 90 min to avoid
cytotoxicity), Neuro2A cells showed CPT fluorescence and limited gold fluorescence. There was no overlap
between both types of signals. Left = CPT (ex: 370 nm; em: 440 nm). Middle = Au5-PEG1000-AD50
(ex: 488 nm; em: 500-550 nm bandpass filter). Right = Merged image with bright field.
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Vis spectrometery and confocal microscopy, capping AuNP with thiolated PEG gave rise to a
pronounced elevation in fluorescence (Fig. 5.3A-B) when excited by an argon laser (488 nm). It
is desirable to verify the binding of the stain on CDP-based nanoparticles. We employed IT-101
as the model nanoparticle (see Fig 5.4A for its chemical structure). Incubation of IT-101 with
the chemical stain led to obvious binding on the surface of IT-101 (Fig. 5.3C).
Optimization of chemical stain
We then exploited the fluorescence of IT-101 to more accurately characterize the binding prop-
erties of Au5-PEG1000-AD NPs as a chemical stain. (CPT demonstrates fluorescence with peak
excitation and emission wavelengths of 370 and 450 nm, respectively [191]. It is thus not sur-
prising that IT-101 emits fluorescence at similar wavelengths as CPT (Fig. 5.4)).
Fig. 5.3C only revealed binding of the stain atop IT-101, but did not indicate whether the
binding was toward CPT or β-CD as hypothesized. As a hydrophobic molecule, CPT may
interact with the stain. To address this question, Neuro2A cells were incubated with either pure
β-CDP or pure CPT, rinsed with PBS, and stained by Au5-PEG1000-AD NPs (dispersed in 1×
PBS). Cells were mounted for viewing under a confocal microscope after PBS rinses to remove
any non-specifically bound stain. Fig 5.5 demonstrated that binding was due to CDP, not CPT.
While Neuro2A cells (mouse neuroblastoma) preincubated with blank β-CDP solution (without
CPT) showed gold staining, the same cells preincubated with pure CPT (no β-CDP) did not.
The above experiments set the stage to optimize the hydrophobicity required for effective
staining of IT-101 (or cyclodextrin-containing nanoparticles) in biological tissues or cells. While
Au5-PEG1000-AD NPs must display sufficient AD residues to interact with CDP-based nanopar-
ticles, they cannot be too hydrophobic to maintain solubility in the salt buffer for staining tissue
sections. We prepared Au5-PEG1000-ADx (x = 0, 25, 50) NPs by tuning the molar ratios of AD-
dPEGTM12 -SPDP and mPEG1000-SH (Fig. 5.2) added to an aqueous suspension of 5 nm AuNPs.
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For instance, the preparation of Au5-PEG1000-AD25 and Au5-PEG1000-AD50 NPs entails the ad-
dition of AD-dPEGTM12 -SPDP and mPEG1000-SH in a molar ratio of 1:3 and 1:1, respectively.
Au5-PEG1000-AD0 NPs served as negative control to verify the need of AD for effective staining.
Fig. 5.6 presents staining data of Au5-PEG1000-ADx NPs on Neuro2A cells pretreated with the
same concentration of IT-101. Clearly, the colocalization of IT-101 and Au5-PEG1000-ADx NPs
fluorescence signals increased with AD content of the stain. This colocalization suggests that the
chemical stain stains for IT-101 as a self-assembled particle, not merely CDP fragments without
CPT. For future experiments covered in this thesis, we shall adopt Au5-PEG1000-AD50 NPs as
the default chemical stain unless otherwise mentioned. (Results shown in Fig. 5.3 and Fig. 5.5
also entailed the use of Au5-PEG1000-AD50 NPs).
Generality of chemical stain
Results illustrated thus far anchor upon the use of Au5-PEG1000-AD50 NPs to stain only one
type of cyclodextrin-polymer nanoparticle (IT-101) in biological specimens. Is is possible to
apply this stain to other CDP-based nanoparticles, say CALAA-01 (Fig. 5.7)?
Unlike IT-101, CALAA-01 exhibits mulitple copies of the targeting ligands (human trans-
ferrin; Tf) on its periphery to target surface receptors of cancer cells, and may block effective
binding between AD and CD cups. We developed an ELISA-like assay to show that binding of
the chemical stain to CALAA-01 is specific and dose-dependent (Fig. 5.8A-C). In brief, CALAA-
01 nanoparticles at a constant concentration were deposited into an ELISA plate pre-coated with
antibodies against human Tf. After rinsing away excess CALAA-01, the application of different
concentrations of Au5-PEG1000-AD50 NPs to the ELISA plate followed. Despite repeated rinsing
to remove non-specifically bound Au5-PEG1000-AD50 NPs, the ELISA plate retained the stain
in a dose-dependent fashion, as evidenced by the gradual increase in red color (by inspection)
as well as absorbance reading at 520 nm (peak absorbance of Au5-PEG1000-AD50). As negative
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Figure 5.6: Optimization of staining. N2A cells were pretreated with IT-101 at 37 ◦C for 7 h, rinsed with
1× PBS, and stained for IT-101 using the same concentration of (A) Au5-PEG1000-AD0, (B) Au5-PEG1000-
AD25, and (C) Au-PEG-AD50 NPs. The colocalization of IT-101 and Au5-PEG1000-ADx NPs fluorescence
signals increased with AD content. Staining due to Au5-PEG1000-AD50 NPs showed overlapping with IT-
101 fluorescence signals. Left = CPT (ex: 370 nm; em: 440 nm). Middle = Au5-PEG1000-ADx NPs (ex:
488 nm; em: 500-550 nm bandpass filter). Right = Merged image with bright field.
Figure 5.7: Composition of CALAA-01. (A) The delivery components are (i) a linear, catioinic
cyclodextrin-containing polymer (CDP), (ii) an adamantane-PEG conjugate (AD-PEG5000), and (iii)
an AD-PEG conjugate with an human transferrin protein (Tf) connected to the other end of AD (AD-
PEG5000-Tf). These partsr will condense with siRNA (sequence shown) that specifically cleaves the
mRNA encoding the M2 subunit of ribonucleotide reductase (RRM2). (B) The mixing of all compo-
nents triggers the self-assembly of CALAA-01 nanoparticles of 70 nm in size. In this TEM image, the
CALAA-01 nanoparticle appears dark due to staining of siRNA by uranyl acetate.
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Figure 5.8: Binding of CALAA-01. (A) This schematic representation depicts the design of the ELISA-
like binding assay. Blue circle = human transferrin (Tf); wavy line = PEG5000; Y-shape = antibody
against Tf pre-coated on the ELISA plate (black horizontal line). (B) After depositing CALAA-01
nanoparticles onto the ELISA plate (precoated with anti-Tf), Au5-PEG1000-AD50 NPs showed dose-
dependent binding (red color originates from the applied gold stain). Control Au5-PEG1000-AD0 NPs led
to no binding independent of concentration. (C) Direct absorbance readout at 520 nm from the ELISA
plate indicates dose-dependent staining by Au5-PEG1000-AD50 NPs. (D) This cryo-TEM image shows
binding of isolated Au5-PEG1000-AD50 NPs atop a CALAA-01 NP. Scale bar = 100 nm.
control, no Au5-PEG1000-AD50 NPs were retained when no CALAA-01 was deposited in the
ELISA plate beforehand, indicating the hydrophobic interaction between CD cups and AD as
the nature of binding (data not shown). Furthermore, cryo-TEM delineates binding of isolated
Au5-PEG1000-AD50 NPs atop a CALAA-01 nanoparticle (Fig. 5.8D).
Upon confirmation using the ELISA-like assay, an additional validation study to show the
binding of Au5-PEG1000-AD50 NPs followed. Mice bearing subcutaneous Neuro2A tumors re-
ceived i.v. injections of Tf-targeted, (Cy3)siRNA-containing, CDP-based nanoparticles. These
nanoparticles are virtually the same as CALAA-01, except they contain a control siRNA se-
quence that targets the firefly luciferase gene (siGL3). Some of these siRNA strands contain
a Cy3 moiety at the 5’ end of the sense strand. Subsequent animal sacrifice allowed for the
extraction of tumor. TEM confirmed the presence of such nanoparticles in Neuro2A cells within
the tumor, confirming the successful intracellular delivery by targeted nanoparticles (Fig. 5.9).
100
Figure 5.9: TEM revealed localization of targeted CDP nanoparticles (containing Cy3-siGL3) inside
Neuro2A cells of the mouse subcutaneous tumor. (A) The proximity of targeted nanoparticles to the
nucleus shows their intracellular localization. (B) Expanded view. Nu = nucleus, rib = ribosome, ER =
endoplasmic reticulum, V = vesicle, black arrow = nanoparticles. Scale bar = 500 nm.
Confocal microscopy of the same tumor tisuses followed, used in conjunction with Au5-
PEG1000-AD50 NPs. Like the staining of tumor tissues from previous IT-101 experiments, there
was significant overlap of fluorescent signals due to Au5-PEG1000-AD50 NPs and Cy3-siRNA. The
presence of gold fluorescence signals must accompany those of Cy3-siRNA, not vice versa (Fig.
5.10). This suggests that intracellular accumulation of targeted nanoparticles in Neuro2A cells
within the tumor, and that Cy3-siRNA might have been released due to nanoparticle disassembly
within Neuro2A cells. As negative control, Neuro2A tumors from mice injected with D5W failed
to show any fluorescence of either Au5-PEG1000-AD50 NPs or Cy3-siRNA (data not shown).
Application of chemical stain
In summary, Au5-PEG1000-AD50 NPs can detect CDP-based NPs. Below are some applications
of the stain to reveal pharmacological insights of nanoparticle-based therapeutics.
Intratumoral transport of IT-101
Schluep et al. [182] employed positron emission tomography (PET) to track the in vivo dis-
tribution pattern of radioactively labeled IT-101 in tumor-bearing mice as a function of time,
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Figure 5.10: Confocal microscopy of the same Neuro2A tumor tissue as shown in Fig. 5.9. Au5-PEG1000-
AD50 NPs bound to Cy3-siRNA containing, CDP-based targeted nanoparticles, whose localization was
strictly intracellular. Left = Cy3-siGL3 (ex: 540 nm; em: 560-610 nm bandpass filter). Middle = Au5-
PEG1000-AD50 (ex: 488 nm; em: 500-550 nm bandpass filter). Right = Merged image with bright field.
and discovered a more elevated label concentration in the tumor interstitium than that in blood
plasma after 24 h. Moreover, they noted a gradual increase in label concentration in the tumor
up to the 24th hour. Such dynamics of IT-101 tumor retention underscore the EPR effect and
indicate that the majority of the nanoparticles stay intact in circulation and do not considerably
disassemble into individual CDP strands. The same authors also utilized compartmental model-
ing to support the validity of the PET data, indicating that the apparent permeability of IT-101
out of blood vessels correspond to that of a nanoparticle of 37 nm in size, in close agreement to
the hydrodynamic diameter of IT-101 (∼30 nm). Taken this together, the authors proposed a
“sink” in which IT-101 nanoparticles could accumulate within the tumor.
However, PET and mathematical modelling data cannot provide any morphological informa-
tion of the precise location of this “sink” within the tumor. For general tumor-bearing animal
models, prior studies attributed the nature of this “sink” for untargeted nanoparticles (e.g.,
dextran-coated iron oxide nanoparticles [192], long-circulating liposomes [145], and PEGylated
gold nanoparticles [193]) to tumor vascular endothelial cells, tumor-associated macrophages, tu-
mor stroma in the extracellular space. CDP nanoparticles are different from the above three
particle types, because they contain hydrophobic pockets within the CD molecules for interac-
tion with lipid rafts of cell membranes [175]. Will they reflect a different intratumoral fate?
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Figure 5.11: Intracellular sink of IT-101. Mice bearing Neuro2A tumors received injections of IT-101.
Animal sacrifice 24 h later permits the extraction of tumors, whose cryosections were stained for the
presence of IT-101 using Au5-PEG1000-AD50 NPs. From this representative confocal micrograph, IT-101
accumulated in Neuro2A cells within the tumor, indicating Neuro2A cells as the biological “sinks” for
IT-101. Left = CPT (ex: 370 nm; em: 440 nm). Middle = Au5-PEG1000-AD50 NPs (ex: 488 nm; em:
500-550 nm bandpass filter). Right = Merged image with bright field.
Our chemical stain could clarify the nature of this biological “sink” for CDP-based nanopar-
ticles. Mice bearing subcutaneous Neuro2A tumors received i.v. injections of IT-101. 24 h later,
animal sacrifice took place to permit tumor extraction. Staining tumor cryosections with Au5-
PEG1000-AD50 NPs revealed prominent colocalization of fluorescence signals due to CPT and
Au5-PEG1000-AD50 NPs that bind to CDs (Fig. 5.11). IT-101, not just released CPT, was inside
tumor Neuro2A cells. Thus, the “sink” for IT-101 within the tumor arose from the internaliza-
tion by cancerous cells, in stark contrast to intratumoral fate of other untargeted nanoparticles
listed above. Perhaps tumor cell internalization is a unique “sink” to CDP-based nanoparticles
due to their surface properties. This “sink” may explain why the amounts of IT-101 and CPT
in the tumor remained relatively constant for several days after an i.v. injection [194].
Dose-dependent accumulation of CALAA-01 in patients
Therapeutics that are designed to engage RNA interference (RNAi) pathways have the potential
to provide new, major ways of imparting therapy to patients [195] [196].
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A key obstacle with applying siRNAs in mammals is their intracellular delivery to specific
tissues and organs that express the target gene, via the use of clinically compatible methods
of administration. Several delivery vehicles have been combined with siRNAs to improve their
delivery in animals, and early clinical data are beginning to emerge.
Davis et al. is now conducting the first, to their knowledge, in-human siRNA phase I clinical
trial involving the systemic administration of siRNA to patients with solid cancers using a tar-
geted, nanoparticle delivery system (clinical trial registration number: NCT00689065) [160][187].
Patients with solid cancers refractory to standard-of-care therapies are administered doses of
CALAA-01 nanoparticles on days 1, 3, 8, and 10 of a 21-day cycle by a 30-min i.v. infusion.
We investigated biopsies from three metastatic melanoma patients (A, B, and C), who re-
ceived CALAA-01 doses of 18, 24, and 30 mg/m2 siRNA, respectively. Given the highly ex-
perimental nature of this protocol, the regulatory process at both the local and federal levels
explicitly precluded a provision for mandatory biopsies in all patients. Therefore, biopsies were
obtained on a voluntary basis. Biopsies in these three patients were collected after the final dose
of cycle 1 (denoted Apost, Bpost and C1post) and compared to archived tissue (denoted Apre, Bpre
and C1pre). Patient C continued therapy beyond one cycle and provided another set of biopsy
material (C2pre that was obtained approximately 1 month after the final dose of cycle 1, and
C2post that was collected on the day of the final dose of cycle 2).
Sections of the tumor tissue were stained for the presence of CALAA-01 nanoparticles using
Au5-PEG1000-AD50 NPs. Samples A, B and C1, analyzed in a blinded fashion, demonstrated a
heterogeneous distribution of nanoparticles only in post-dosing tumor tissue (Fig. 5.12). The
nanoparticles could localize intracellularly in tumor tissue and were not found in the adjacent
epidermis. In these biopsies, TEM images were dominated by melanosomes [197], inhibiting the
identification of the nanoparticles (data not shown). Samples C1post and C2post reveal the highest
number and intensity of stained regions. Bpost exhibits a decreased amount of staining relative
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Figure 5.12: Detection of CALAA-01 nanoparticles in human tumors. Confocal micrographs of post-
treatment biopsy sections from patients A, B, and C demonstrate the dose-dependent accumulation of
CALAA-01 nanoparticles. epi, epidermis, m, melanophage; s, skin side; t, tumor side. Left = Au5-
PEG1000-AD50 (ex: 488 nm; em: 500-550 nm bandpass filter), green. Middle = DAPI counter stain, blue.
Right = Merged image with bright field.
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to samples C1post and C2post. Apost does not reveal the presence of the stain. All pre-dosing
samples are completely negative for the stain (data not shown). We do not know how long the
nanoparticles reside within the cells and release siRNA. Because the nanoparticles are observed
in the sample C1post and not the sample C2pre, they must disassemble within 1 month.
From the same tumor tissues used for staining with Au5-PEG1000-AD50 NPs, downstream
molecular biological and immunohistochemical analyses reflected notable decrease in RRM2 ex-
pression at both mRNA and protein levels due to the RRM2-specific siRNA. Moreover, results
from a modified 5’-RNA-ligand-mediated RACE (5’-RLM-RACE) PCR technique showed that
the delivered siRNA induces the desired mRNA cleavage in both C2pre and C2post tumor biop-
sies (data not shown). Taken these results together, this is the first direct evidence of an RNAi
mechanism of action in a human (patient C) from systematically administered siRNA.
In summary, systemically administered siRNA, when encapsulated in targeted nanoparticles,
can accumulate in melanoma cells within patient tumors. This is the first example of a dose-
dependent accumulation of targeted nanoparticles in tumors of humans from systemic injections
for nanoparticles of any type. siRNA delivered by the CALAA-01 platform can engage the RNAi
machinery in a solid human tumor. Thus, siRNA can be a gene-specific therapeutic for humans.
5.4 Conclusion
Cyclodextrins have a long history of usage in drug delivery formulations, with the first patient
treated with CD-containing pharamaceutics back in 1953 [198]. CDs can enhance water solubility
of hydrophobic drugs by forming non-covalent, water-soluble inclusion complexes. They can also
improve safety and bioavailability. Due to these attractive properties, multiple pharmaceutics
based on CD-polymer (CDP) conjugates have emerged into the market since the 1980s.
As a cancer treatment modality, nanocarriers like CDP-based nanoparticles can protect the
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drug payload from premature degradation as well as enhance their retention into solid tumors
and intracellular localization. To ascertain their therapeutic efficacy, it is essential to track their
in vivo pharmacological behavior of nanoparticles besides downstream biological effects (e.g.,
toxicity, immune response, tumor regression, gene inhibition at mRNA and protein levels). For
pharmacological effects, pertinent parameters include blood pharmacokinetics and organ-level
distribution, as well as retention kinetics and transport within the target tumor tissue.
The precise tracking of pharmacological behavior in animal models via live imaging generally
necessitates the chemical attachment of fluorophores, quantum dots, or radioactive labels on the
carrier polymer and/or drug payload, with the assumption that such addition of labels would
not drastically affect the self-assembly of nanoparticles as well as their resultant physicochemical
properties. For patient use, moreover, regulatory authorities do not permit the inclusion of labels
owing to their potential toxicity arisen from indefinite accumulation in the body. Thus, the only
viable option to acquire pharmacological data in a clinical setting is through ex vivo analysis by
microscopy of tumor biopsies collected from patients.
Here, we report the design and optimization of a chemical stain that specifically recognizes
CDP nanoparticles ex vivo. The stain comprises a 5 nm gold nanoparticle core, with its surfce
decorated with multiple copies of adamantane and PEG chains via gold-sulfur linkages on the
periphery. Such design confers the chemical stain three properties: (1) pronounced fluorescence
for detection by confocal microscopy, (2) strong binding to hydrophobic cyclodextrin cups of
CDP nanoparticles, and (3) steric stability against salt-induced aggregation. The application of
this chemical stain (Au5-PEG1000-AD50 NPs) ex vivo to treated cells or tumor cryosections that
contain administered CDP nanoparticles allows for their detection. This stain reveals intracellu-
lar accumulation of CDP nanoparticles (IT-101 and CALAA-01) in cells, animal tumor tissues,
and patient tumor biopsies, and thus warrants the extraction of key in vivo pharmacological
information (such as intratumoral transport and dose response) in an ex vivo setting.
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5.5 Materials and Methods
Synthesis of SPDP-dPEGTM12 -AD
To a solution of SPDP-dPEGTM12 -NHS (100 mg, 0.11 mmol; Quanta Biodesign) in 3 mL of anhydrous
dichloromethane was added adamantanemethylamine (0.11 mmol, 21 µL). The solution was stirred for
16 h at RT, after which the solvent was removed and the product dried under vacuuo. (MALDI-TOF)
[M+Na]+ 984.08, [M+K]+ 1000.16.
Assembly of Au5-PEG1000-ADx NPs
To identify the optimal amount of adamantane (AD) required for staining, different molar ratios of SPDP-
dPEGTM12 -AD and methoxy-PEG1000-SH (Laysan Bio) was added to aqueous suspensions of 5 nm gold
nanoparticles (Nanopartz). To make Au5-PEG1000-AD25 NPs, mPEG1000-thiol (21 µg, 21 nmol) and
SPDP-dPEGTM12 -AD (8 µg, 7 nmol) were added to 1 mL of pre-sonicated gold suspension (1013 particles
per mL). For Au5-PEG1000-AD50 NPs, mPEG1000-thiol (14 µg, 14 nmol) and SPDP-dPEGTM12 -AD (16 µg,
14 nmol) were added instead. As negative control, Au5-PEG1000-AD0 (no AD) NPs were also prepared
by adding only mPEG1000-thiol (28 µg, 28 nmol).
Independent of AD content, the reaction mixture was vortexed at RT for 30 min and diluted to 4
mL with deionized water. The resulting 4 mL solution was diafiltered twice with a 10 kDa membrane
(Millipore), resuspended to 1 mL of 1× PBS, and stored at 4 ◦C for future use.
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In vitro transfection of IT-101
5×104 Neuro2A cells were cultured on 625 mm2 cover-slips pre-deposited in a 6-well plate for 2 d at 37 ◦C
and 5% CO2 in complete growth medium (DMEM medium supplemented with 10% FBS, 100 units/mL
penicillin, and 100 units/mL streptomycin).
On the day of transfection, the cells received transfection of 30 µg polymer/mL of IT-101 in complete
growth medium for 7 h at 37 ◦C and 5% CO2.
Nature of IT-101 staining by Au5-PEG1000-AD50 NPs
Neuro2A cells on cover-slips were incubated with pure cyclodextrin polymer (CDP) for 7 h. As another
control, the same experiment was repeated with pure camptothecin (CPT). To prevent cytotoxic effects,
the transfection with CPT lasted for 90 min. Cells transfected with CDP and CPT were stained by
Au5-PEG1000-AD50 NPs and mounted for confocal microscopy.
Tumor formation and systemic IT-101 delivery
Neuro2A-Luc cells were cultured in complete growth medium (DMEM supplemented with 10% FBS,
100 units/mL penicillin, and 100 units/mL streptomycin). In the right hind flank, immunodeficient
(NOD.CB17-Prkdcscid/J) mice (Jackson Laboratory) received subcutaneous implantation of N2A cells
(at 106 cells per mouse per 0.1 mL of DMEM). Before injection, tumors reached 100-200 mm3 in size,
as determined by caliper measurements (0.5 × l × w2). Two mice received i.v. administration of IT-101
(10 mg polymer/kg animal; formulated in 0.1 mL of D5W) via the tail-vein. As controls, two other mice
received i.v. injections of 0.1 mL of D5W. Animal sacrifice by CO2 overdose took place 24 h after injection
to collect tumors for confocal microscopy.
ELISA-like binding of CALAA-01 by Au5-PEG1000-AD50 NPs
The entire procedure was conducted at RT with mild shaking on a plate shaker. Into each well of a 96-well
ELISA plate was coated with 0.1 mL of coating buffer (10 µg/mL mouse IgG against human transferrin
(Bethyl Laboratories) in 50 mM carbonate-bicarbonate buffer, pH = 9.6) for 1 h. Three rinses with 0.1
mL of wash buffer (50 mM Tris, 140 mM NaCl, 0.05% Tween 20, pH = 8) followed to remove unbound
antibodies. Next, blocking by adding 0.2 mL of blocking buffer (50 mM Tris, 140 mM NaCl, 1% bovine
serum albumin, pH = 8) took place for 1 h, followed by three brief rinses. After that, each well was
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loaded with 0.1 mL of either targeted CDP particle solution (0.5 mol% AD-PEG5000-Tf in 1× PBS) or
1× PBS (negative control) and incubated for 2 h. After five rinses to remove unbound targeted particles,
each well was loaded with 0.1 mL of staining solution (Au5-PEG1000-AD50 or Au5-PEG1000 NPs) and
incubated for 2 h. Upon five rinses to remove unbound stain, each well was loaded with 0.1 mL of 1×
PBS for absorbance measurement at 520 nm (surface plasmonic peak for Au5-PEG1000-AD50 NPs) using
a Safire2 Microplate Reader (Tecan). Reported values are mean absorbance from duplicate experiments.
Cryo-TEM of complex of CALAA-01 and Au5-PEG1000-AD50 NPs
Au5-PEG1000-AD50 NPs were added to CALAA-01 nanoparticles and allowed to incubate for 1 h prior to
cryo-TEM analysis. An automated climate-controlled plunge-freezer (Vitrobot, FEI) was used for sample
vitrification. In here, humidity was set at 100% to minimize evaporation and temperature was set at 21
◦C. A glow discharged Quantifoil holey carbon grid (EMS) was loaded into this chamber and 5 µL of
sample was applied onto the grid. Blotting time was set at 1 s and drain time at 1 s before the sample was
plunged into the center of a Vitrobot cup filled with liquid ethane. The grid was then quickly transferred
into the outer ring containing liquid nitrogen and stored in a grid box under liquid nitrogen for later
analysis. Vitrified sample was loaded onto a pre-vacuumed and pre-cooled (with liquid nitrogen) Cryo
sample holder. The holder was then inserted into Techni FEI T12 TEM for imaging.
Systemic delivery of siRNA-containing CDP nanoparticles
Two NOD.CB17-Prkdcscid/J mice bearing subcutaneous Neuro2A tumors (prepared identically as for
IT-101 delivery) received i.v. administration of siRNA-containing CDP nanoparticles (5 mg siRNA/kg
animal; formulated in 0.1 mL of D5W) via the tail-vein. The model siRNA sequence, siGL3 (sense: 5’-
CUUACGCUGAGUACUUCGAdTdT-3’; anti-sense: 5’-UCGAAGUACUCAGCGUAAGdTdT-3’), used
here targets the mRNA encoding the firefly luciferase gene (Integrated DNA Technologies). 20% of the
siGL3 molecules in the formulation contain a Cy3 residue at the 5’ end of the sense strand. Two other
control mice received i.v. injections of 0.1 mL of D5W. Animal sacrifice by CO2 overdose took place 24
h after injection to collect tumors for confocal microscopy (for Au-PEG-AD50 staining) and TEM.
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Chapter 6
Conclusion
Falling between individual molecules and the corresponding bulk materials, the unique size of
nanomaterials opens the possibility of interaction with biological tissues, spurring the emergence
of the field of bionanotechnology and the creation of nanoparticle-based therapeutics, in vitro
diagnostics, and in vivo contrast agents.
The application of nanotechnology to drug delivery has exerted considerable impact on
medicine in the past few decades. Using nanotechnology, one can prolong the circulation of
hydrophobic small molecules or macromolecules in blood plasma, tailor their delivery to specific
tissues or intracellular locations, and even visualize sites of drug delivery by combining therapeu-
tic agents with imaging modalities [199]. Over 20 nanoparticle-based therapeutics are in clinical
use, and numerous others are at various stages of preclinical and clinical development. With the
gradual shrinkage of pipelines from pharmaceutical companies as well as the imminent release
of several blockbuster drugs from patent [200], nanoparticle-based therapeutics are expected to
play an ever increasingly important role in the modern medicine landscape.
Despite advances in using different drug payload and delivery vehicles to target different
diseases, the nanomedicine field still lacks consensual and mechanistic understanding in how
therapeutic nanoparticles can reach targeted biological sites in vivo. This thesis establishes
design criteria of nanoparticle properties (e.g., hydrodynamic size, surface charge, targeting
ligand density, hydrophobicity, electrophoretic mobility, porosity) to achieve effective delivery
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of therapeutics. To examine the in vivo “structure-function” relationships of nanoparticles in
a mechanistic fashion, all studies involve the adjustment of one nanoparticle physicochemical
parameter, while keeping all other parameters constant.
The thesis concerns the pharmacological fate of nanoparticles following their systemic admin-
istrations into living systems. While such “fate” largely depends on nanoparticle physicochemical
parameters, the route of administration is also a crucial factor. Clinical drug delivery applica-
tions mainly employ the systemic route, for its significant advantages over other options. Local
injections (i.e., subcutaneous or intratumoral) are not useful for targeting metastatic tumors, and
cannot overcome the intratumoral pressure gradient due to fast tumor proliferation. Oral delivery
of protein-based nanoparticles suffers from degradation in gastrointestinal acid, low absorption,
hepatic first-pass metabolism, and a significant initial increase in drug concentration.
Normal mice received systemic administrations of PEGylated gold nanoparticles (Aux-PEGy
NPs) in the submicron size range (100 ∼ 102 nm) as model probes. Metallic nanoparticles
generally exhibit strong Mie scattering, and permits for detection by dynamic light scattering
(DLS) for the determination of hydrodynamic diameter and zeta potential, two key colloidal
physicochemical properties open to manipulation in all mechanistic studies.
One fundamental advantage of gold is its versatility: it is compatibile with the application of
multiple imaging modalities. The collective use of inductively coupled plasma mass spectrome-
tery (ICP-MS), histology with silver enhancement, and transmission electron microscopy (TEM)
permits the ex vivo tracking of blood pharmacokinetics as well as distribution of Aux-PEGy
NPs at the organ, tissue, and cellular levels, respectively, all resulting from the injection into
the same animal (Fig. 1.2). The covalent attachment of PEG chains onto the particle surface
(PEGylation) confers aqueous solubility, steric stability against physiological amounts of salt and
serum, and enhanced plasma circulation to the nanoparticles.
Here, most distribution studies utilize organs extracted mice sacrificed 24 h after injection of
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Aux-PEGy NPs. For the onset of the enhanced permeation and retention (EPR) effect to target
tumors passively (Chapter 2), 24 h represents a typical duration for the plasma concentration
gradient to pump injected nanoparticles into the tumor through the blood endothelial pores.
Thus, results from these distribution studies indicate an “eqilibrium” pattern of nanoparticles.
Future work may include studies conducted at earlier or later time points (e.g., 30 min, 4 h, or
2 d after injection) to characterize the dynamics of particle accumulation.
The avoidance of reticuloendothelial system (RES) uptake has long been a key consideration
in designing nanoparticles to achieve prolonged circulation. PEGylation is a viable strategy
to sterically protect nanoparticles from aggregation due to the non-specific binding of serum
complement proteins (e.g., opsonins) that can trigger RES clearance. Yet, the engraftment of
PEG chains onto larger particles is not sufficient to curb RES uptake. RES uptake seems to
largely depend on particle size, not PEG chain length. At the organ level, particle accumulation
in the liver and spleen correlates positively with particle size (Fig. 4.4). At both tissue and
cellular levels, hepatic macrophages (Kupffer cells) and the spleen (both members of the RES)
are responsible for clearing larger nanoparticles by phagocytic uptake (Fig. 2.5), leading to the
premature clearance of nanoparticles from blood circulation (Fig. 4.3).
In this thesis, model probes are nearly spherical. Material anisotropy may provide another
solution to attenuate RES uptake besides PEGylation. Particle geometry, not size, can dictate to
the uptake of micro- and nanosized objects by macrophages in vitro [201] [202] [203]. Within an-
imal models, PEGylated gold nanorods demonstrate more effective evasion of uptake by the liver
and spleen than PEGylated gold nanoparticles [204]. Improvements in fabrication techniques
to control particle geometry and anisotropic material assembly at the nanoscale [205] lead to
the creation of more interesting shapes (e.g., nanodiamond [206], nanofullerene [207], nanocube
[208]), and may encourage careful elucidation of the effect of particle geometry on RES clearance.
As a point of digression, nanosized objects with different physicochemical and structural
113
properties can possess different blood contact properties, compatibility issues, stimulatory and
supressive responses of the immune system when delivered systemically to animal models [209].
The exposure of nanoparticles to cultured cells and tissues can also induce oxidative stress,
triggering the production of inflammatory cytokines and reactive oxygen species (ROS) [210].
As particles decrease in size, the fraction of atoms exposed to the particle surface increases,
causing discontinuous crystal planes and structural defects. Defects can serve as reactive sites
for the production of ROS, and can cause downstream toxicity as these particles interact with
biological tissues. Toxic effects may include mitochondrial perturbation, inflammation, protein
denaturation, and DNA damage [211]. At present, there exist no universal standards for assessing
the immune toxicity of nanoparticles. Whereas European authorities mandate the application of
immune function tests as an initial screen for immunotoxicity, the US and Japanese guidelines
adopt the “as-needed approach”, recommending such tests only when prior evidence indicates a
need [212] [213]. Global representatives from industry, academia, and government agencies must
jointly establish acceptable standards to determine in vivo toxicity. Possible assay criteria may
include blood chemistry, hematology, histopathology, and immunogenicity.
Back to the in vivo distribution problem, kidneys of normal mice demonstrate unexpected
retention patterns of Aux-PEGy NPs. While particle accumulation nearby the renal peritubular
capillaries show no clear dependence on size (Figs. 4.5 and 4.8), there exists a unique hydro-
dynamic size (ca. 75 ± 25 nm) that can maximize nanoparticle accumulation in the kidney
mesangium, at the organ (Fig. 4.4), tissue (Fig. 4.6), and cellular levels (Fig. 4.9). This max-
ima (up to 5% of injected dose) originates from a delicate balance between two physiological
processes at work: uptake of mesangial cells and filtration by the perforated endothelium of the
glomerular capillaries. This is the first example of passively targeting the kidney mesangium
(and its associated mesangial cells) using nanoparticles of controlled size, and opens the possi-
bility of designing nanoparticle-based therapeutics for treatment of diseases specifically at the
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kidney mesangium (e.g., diabetic nephropathy [214], IgA glomerulonephritis [215], mesangial
sclerosis [216]). Moreover, to enhance delivery into mesangial cells, therapeutic nanoparticles of
75 ± 25 nm in diameter can even contain ligands that target surface receptors (e.g., mannose
[217], pro(renin) [218]). Furthermore, nanoparticle of different sizes for kidney passive target-
ing all possess a weakly negative surface charge (ca. −10 mV). Because the kidney is both a
size- and charge-selective filter (Fig. 4.1), renal nanoparticle accumulation is also expected to
depend on the surface charge of the nanoparticle. Follow-up studies will investigate the fate
of positive nanoparticles within the mesangium. One possiblity is that positive nanoparticles
may irreversibly bind to the strongly negative glomerular basement membrane (GBM) without
entering the mesangium. Another possibility is that such nanoparticles will non-specifically bind
to negatively charged cell membranes of some other organs, drastically reducing their retention
in the kidney. There has not been a careful study that mechanistically examines the effect of
surface charge on blood pharmacokinetics and in vivo distribution. From the above, mechanistic
studies show the fate of i.v. administered nanoparticles in the liver, spleen, and kidney, chief or-
gans of retention for normal mice. Their results can be extended to examine the pharmacological
behavior of nanoparticle-based therapeutics in disease animal models (e.g., cancer).
In tumor-bearing animals, the in vivo distribution patterns of the liver and kidney are similar
to those observed in normal mice. In Chapter 2, because PEGylated gold nanoparticles of
different sizes have PEG coatings of the same length (PEG5000), they do not have the same
ζ-potential (unlike Chapter 4). The liver (most notably Kupffer cells) removes Aux-PEG5000
NPs in a size-dependent fashion (Fig. 2.5), whereas the renal corpuscles are the sinks for particle
deposition (Fig. 2.7). In the tumor, regardless of the particle size, i.v. injected Aux-PEG5000
NPs slowly accumulate in the interstitium by the enhanced permeation and retention (EPR)
effect (Fig. 2.1), and constantly lie in the vicinity of leukocytes (Fig. 2.3). Under extremely rare
instances do the smaller nanoparticles (ca. 40 nm) enter the cancerous cells and get entrapped
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in vesicles. For therapeutic nanoparticles to maximize their efficacy, they need to arrive at
specific intracellular locations of cancer cells. Mechanical methods employ physical forces to
directly deliver nanoparticles into intracellular locations (e.g., nuclei, cytoplasm). Microinjection
uses capillary forces to insert nanoparticles under an optical microscope [219]. While capillary
forces are sufficiently gentle to ensure cell viability, microinjection is low-throughput, technically
demanding, and expensive. Electroporation uses a high-voltage electric field to transiently create
hydrophilic perforations in the cell membrane, facilitating the diffusion of nanoparticles into the
cell [220]. While electric forces can deliver multiple nanoparticle types to multiple cell lines,
the strong pulses can cause cell death. Viral-based platforms (e.g., adenovirus or lentivrus)
can deliver nucleic acids with high efficiency, but their intractability due to random insertions
into the host genome induces toxicity that limits their potential for safe clinical applications
[221]. Because this thesis emphasizes on cellular targeting via systemic injections of non-viral
nanoparticles, both mechanical and viral delivery strategies are beyond the scope of this thesis.
In Chapter 3, we examine the mechanism of active targeting of cancer cells by injecting
PEGylated gold nanoparticles (Au50-PEG5000-Tfx NPs) that contain various amounts of human
transferrin (a targeting ligand that engages the transferrin receptors in cancer cells within the
tumor) into mice bearing subcutaneous tumors. To allow for a mechanistic analysis, all Au50-
PEG5000-Tfx NPs share a near-constant size and surface charge (ca. 75 nm and −10 mV)
although their ligand content spans two orders of magnitude (Fig. 3.4). With multiple copies
of transferrin ligands, these nanoparticles can bind to transferrin receptors overexpressed on
cancer cells at a much higher affinity than the free transferrin counterpart (multivalency effect;
Fig. 3.6). At the organ level, targeted nanoparticles accumulate in the bulk tumor (due the
EPR effect) by the same magnitude (2% ID), independent of ligand content (Fig. 3.7). At
the tissue and cellular levels, they can only internalize into cancer cells (specifically endosomal
vesicles) in significant amounts above a threshold ligand content (between 18 and 144 ligands per
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nanoparticle) (Fig. 3.8). Below this threshold, targeted nanoparticles behave very similarly to
their untargeted counterparts, and would not target cancer cell receptors effectively. In the liver
(whereby hepatocytes only express transferrin receptors much more weakly than cancer cells),
targeted nanoparticles rarely deposit inside hepatocytes even above the same threshold ligand
content (Fig. 3.9). Most nanoparticles experience phagocytic clearance by Kupffer cells, thus
explaining the high bulk retention in the liver (ca. 18% ID). Thus, active targeting does not
affect the bulk localization of nanoparticles in the tumor, but only affects their internalization
into target cells provided a sufficiently high ligand content to engage surface cell receptors. From
modeling based on simple classical kinetics, effective receptor-ligand binding can be possible when
both nanoparticle ligand content and cell receptor density are high (Fig. 3.10). In summary, we
elucidate the mechanism of active targeting in vivo by fixing the particle size and surface charge,
and by using tumors derived from only one cell line. Future work can explore the mechanism using
nanoparticles of a different size and surface charge, tumor models with different expression levels
of cancer cell surface receptors, as well as different ligand-receptor systems to test the generality
of this ligand/receptor content threshold for effective internalization into target cancer cells.
Based on fluid mechanical grounds, Aux-PEGy NPs as model probes can validly mimic the in
vivo flow pattern of therapeutic nanoparticles of the same size (Appendix B) despite their much
higher density compared to actual therapeutic nanoparticles (cyclodextrin, lipid, polymer, nucleic
acid). While the bulk accumulation in the tumor is somewhat limited (2% ID), an interesting
observation is that therapeutic nanoparticles can still lead to appreciable tumor regression and
gene inhibition in animal models [152] [146]. A possible interpretation is that, with its enormous
drug payload (ca. 2000 siRNA strands per nanoparticle), nanoparticles can impart their intended
therapeutic action despite a tiny fraction reaching intracellular locations.
In Chapter 5, we apply mechanistic insights derived from model gold nanoparticle probes
(Chapter 3) to understand the delivery of actual therapeutic nanoparticles. Over the past
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decade, Davis and colleagues have created two types of cyclodextrin-polymer (CDP) nanoparti-
cle conjugates to encapsulate drug payloads based on small molecules (camptothecin; CPT) and
nucleic acids (siRNAs). Both delivery systems (IT-101 and CALAA-01) are currently under clin-
ical development. The investigatation of the pharmacological fate of both types of CDP-based
nanoparticles calls for the creation of a sterically stable, water-compatible, and fluorescent chem-
ical stain (Fig. 5.1). Based on PEGylated gold nanoparticles with surface decoration of multiple
adamantane moieties (Au5-PEG1000-AD50 NPs), this chemical stain specifically can bind to the
cyclodextrin cups of the CDP nanoparticles embedded in transfected cells (Fig. 5.6), tumor sam-
ples from animals (Fig. 5.10), and patient tumor biopsies (Fig. 5.12), ex vivo. The application of
chemical stain permits the analysis of in vivo behavior of CDP-based therapeutic nanoparticles.
In tumor-bearing animals, IT-101 nanoparticles are shown to passively target the tumor and ac-
cumulate inside cancer cells 24 h after injection, with its fluorescence signals of the chemical stain
colocalizing to those of CPT. This suggests the successful delivery of CPT to cancer cells by the
CDP nanoparticle platform in great abundance, in stark contrast to the delivery of free CPT that
has short blood circulation (Fig. 5.11). From tumor biopsies collected from melanoma patients,
staining shows that CALAA-01 nanoparticles can selectively target the tumor (at times arrive at
intracellular locations) without accumulating in the skin. Interestingly, with human transferrin
as targeting ligands, they accumulate in the tumor and enter cells in a dose-depedent fashion,
whereby the dose of infusion positively correlates to the degree of accumulation (Fig. 5.12). Be-
cause melanoma cells highly express surface transferrin receptors, this “dose response” in human
tumor biopsies is the first ever reported for targeted nanoparticles of any type, underscoring the
utility of the CDP nanoparticle platform to achieve targeted delivery of siRNAs to intracellular
locations in humans. With regards to this thesis, moreoever, dose-response is consistent with the
mechanism of active targeting in that CALAA-01 nanoparticles (with the same hydrodynamic
size as Au50-PEG5000-Tf144 NPs) contain an average of 133 Tf moieties per nanoparticle, above
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the threshold ligand content required for significant internalization into cancer cells as predicted
by mechanistic studies illustred in Chapter 3.
In Chapter 5, the chemical stain is fluorescent due to the coupling of sulfur atoms from
PEG1000 chains to surface gold atoms of Au5-PEG1000-AD50 NPs. Gold nanoparticles were the
preferred material to construct the cyclodextrin stain because of their high electron density for
detection by TEM. This fluorescence intensity, however, is very weak for sensitive detection under
confocal microscopy. From our initial idea, Au5-PEG1000-AD50 NPs can bind to and reveal the
presence of CDP nanoparticles at the tissue level (using confocal microscopy) as well as cellular
level (using TEM). Unfortunately, the binding of the chemical stain to CDP nanoparticles to
tissue sections for TEM imaging is unsuccessful, perhaps due to the poor penetration through
the heavily polymerized Epon tissue block. Epon is a material of choice for enhanced morphology
in tissue sections, but does not necessarily favor antigenic binding. Other tissue block materials
(e.g., Lowicryl) or tissue-embedding methods are possible to enhance binding, but suffer from
poor tissue morphology. Thus, if TEM is unnecessary for the imaging studies, a new approach to
utilize more powerful contrast agents, such as quantum dots (for elevated fluorescence and atten-
uated tissue autofluorescence) [222] and second harmonic generation nanoprobes (for enhanced
quantum yield and less quenching) [223], is needed for viewing under confocal microscopy.
Chapter 5 illustrates the ex vivo detection of CDP nanoparticles in tissue sections. At the
forefront of imaging is the real-time, in vivo tracking of pharmacological events (following the ad-
ministration of therapeutics) in a precise, sensitive, longitudinal (for prolonged imaging), highly
resolved, and quantitative fashion, accompanied by an assortment of nanoparticle-based contrast
agents. As another key component in the field of bionanotechnology besides drug delivery, in
vivo imaging constitutes an indispensable tool in cancer research, clinical trials, and medical
practice. Fluorescence imaging stays in the mainsteam, but the development of imaging tech-
niques based on bioluminescent, optical, photoacoustic properties is underway. While current
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imaging technologies focus on tumor detection, future improved imaging systems will display
the expression/activity of biomarker molecules, shed light on biological processes that influence
drug pharmacodynamics, and provide simultaneous detection and ablation of tumors. The ma-
jor stumbling block of nanoparticle-based in vivo imaging agents is their low target-to-noise
ratio. The development of targeting strategies (passive and active) empowers the design and
optimization of nanoparticle-based probes with augmented accumulation in tumors and subdued
clearance (e.g., macrophage uptake by RES organs, non-specific tissue extravasation, and renal
elimination). As a result, only 5% of the injected contrast agent can reach the target biolog-
ical destination in appreciable amounts [224]. Clearly, effective in vivo targeting is of crucial
importance in improving technologies for drug delivery and molecular imaging.
Ultimately, the success of nanoparticles for in vivo biomedical applications relies upon their
ability to overcome biological barriers. Ongoing fundamental research to highlight structure-
function relationships between nanoparticle physicochemical properties and pharmacological be-
havior is crucial to yield additional insights to tackle unanswered questions and overcome tech-
nical bottlenecks. Quantitative measurements on the kinetics, amount, mechanisms, and tra-
jectories of in vivo nanoparticle trafficking are still in lack. More sophisticated material and
bioconjugate chemistry methods are much required to fabricate nanosized objects with more
fine-tuned properties and in a high throughput manner. Realization of these future goals, in
conjunction with more comprehensive understanding in the pathophysiology of different disease
types, will steer the rational design of more potent nanoparticle-based therapeutics and imaging
agents to diagnose and combat human malignancies.
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Appendix A
List of Common Methods
Animal manipulations are performed with sterile methods, in compliance with NIH Guidelines
for Animal Care and approved by the Caltech Institutional Animal Care and Use Committee.
Dynamic light scattering (DLS)
Hydrodynamic diameter (HD) and ζ-potential (ZP) of AuNPs were measured using ZetaPals
(Brookhaven Instruments Corporation). For HD measurements, the particle pellet was resus-
pended in 1.2 mL of deionized water or 1× PBS. Using the Smoluchowski model, reported HDs
are average values from 3 runs of 3 min each. The refractive index of Aux-PEGy NPs is taken
as 0.47, the common refractive index of gold. For ZP analysis, the pellet was re-suspended in
1.4 mL of 1 mM KCl. The pH of solution is set as 5.3 (pH of 1 mM KCl). Using the HD values
measured above, reported ZPs are average values from 10 runs each with a target residual of
0.012 measured at a conductance of 320 ± 32 µS.
Inductively coupled plasma mass spectrometry (ICP-MS)
Homogenized organs were oxidized in 0.5 mL of acid mixture (70% HNO3 and 35% HCl at a 3:1
volume ratio) in a microwave until they fully dissolved. After adding 20.5 mL of deionized water,
the sample was centrifuged at 3200× g for 15 min to remove cell debris, leaving the supernatant
for gold content analysis using HP 4500 ICP-MS (Agilent). Nebulization occurred with a flow of
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1.3 L/min of argon using a Babbington type nebulizer in a pyrex Scott-type spray chamber. The
argon plasma power was 1200 W with a flow of 15 L/min and an auxiliary flow of 1.1 L/min.
A calibration curve of various concentrations of Aux-PEGy NPs was used to measure the gold
content, using 2.5% HNO3 and 0.42% HCl as the blank solvent and tissues from uninjected mice
to account for background organ gold content.
Histology with silver enhancement
PFA-fixed tissue blocks (∼1 cm3) were dehydrated using an increasing ethanol gradient and
absolute xylene, followed by embedding in molten paraffin overnight. Semithin tissue sections of
3-5 µm thick were generated using an RM 2165 microtome (Leica) and mounted on Superfrost
poly-L-lysine coated glass slides (Fisher). Deparrifinized sections were rehydrated with a reducing
ethanol gradient and rinsed with deionized water for 5 times, dried, and stained for AuNPs using
the Silver Enhancement Kit for Light and Electron Microscopy (Ted Pella) in the dark for 20
min at RT. After rinsing with running tap water for 2 min, sections were counter-stained with
Gill’s 3 hematoxylin and 1% eosin (in 95% ethanol) for 40 s each, dehydrated, and mounted with
Permount for viewing under an Axioplan 2 light microscope (Zeiss) with a 40× objective.
Confocal immunofluorescence microscopy
Cells pretreated with IT-101 were fixed with 4% PFA (in 1× PBS) at RT for 15 min and
permeabilized with pre-chilled acetone at −20 ◦C for 10 min. Alternatively, 2 cm3 tissue blocks
were fixed in 4% PFA for 3 d, immersed in 5% sucrose and 30% sucrose for 2 h each, and
embedded in 9% gelatin (in 1× PBS). The gradual freezing of gelatin tissue blocks from RT to
−80 ◦C allowed the generation of 10 µm-thick cryosections using a microtome at −25 ◦C. Sections
were rinsed with 1× PBS to remove any surface gelatin and fixed with pre-chilled acetone at
−20 ◦C for 20 min to permeabilize the cell membrane.
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To detect any intracellular CDP-based nanoparticles, fixed and permeabilized cells or tissue
sections were stained by Au5-PEG1000-AD50 NPs (resuspended in 1× PBS at a concentration of
1.5 × 1011 particles/mL). This staining solution may also contain fluorescently labeled antibodies
or nucleic acids at appropriate dilutions (e.g., 1 µg/mL). Staining proceeded in the dark at RT
for 2 h. After brief rinses with 1× PBS, slides were dried gently and mounted with Mowiol 4-88
(in 33% glycerol in 1× PBS) or ProLong Gold antifade reagent with DAPI (Invitrogen).
A Zeiss LSM 510 inverted confocal scanning microscope (with a Plan-Neofluar ×40/0.75
objective and up to 2× optical zoom) was used to collect the images. The excitation wavelengths
of DAPI/CPT, Au5-PEG1000-AD50 NPs, and Cy3/AlexaFluor 555 (for labeling antibodies and
nucleic acids) are 740 nm (two-photon laser), 488 nm (argon laser), and 543 nm (HeNe laser),
respectively. Their corresponding emission filters are 400-460 nm, bandpass (BP) 500-550 nm
infrared radiation (IR), and BP 560-610 nm IR, respectively. The measured resolution at which
images were acquired is 512×512 pixels, and the image bit-depth is 8-bit. The Zeiss LSM Image
Browser Software allows the extraction of images.
Transmission electron microscopy (TEM)
Fixed tissue blocks (∼1 mm3) were fixed in 2.5% glutaraldehyde (in 0.1 M sodium cacodylate,
pH = 7.4) for 2 h, stained by 1% OsO4 at 4
◦C for 2 h, and 0.9% OsO4 and 0.3% K3Fe(CN)6
at 4 ◦C for 2 h. Dehydration with an increasing ethanol gradient and propylene oxide enabled
tissue embedding in Epon 812 resins (Electron Microscopy Sciences). Using a Diatome Ultra
45◦ diamond knife (EMS) on an Ultracut UCT ultramicrotome (Leica), 80 nm thick sections
were deposited on carbon and formvar-coated, 200-mesh, nickel grids (EMS). Sections were
stained with 0.2 µm-filtered 3% uranyl acetate (SPI Supplies) and Reynolds lead citrate [225]
for visualization under a 120 kV BioTwin CM120 TEM (Philips).
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Appendix B
Theoretical Considerations
An advantage of employing Aux-PEGy NPs as model agents to optimize drug delivery processes
lies in their ability to mimic the flow patterns of actual therapeutic nanoparticles. Here, we
seek to justify the validity of using Aux-PEGy NPs with simple arguments from fluid mechanics.
Unless otherwise mentioned, this section assumes spherical geometry for Aux-PEGy NPs.
A measure of the flow characteristics around a particle of radius R is the particle Reynolds
number (Rep), a ratio between the inertial and viscous forces acting on the particle due to its
surrounding flow. Let ρ and µ be the density and viscosity of the fluid, and U be the imposed
velocity field in tumor blood capillaries. If the Aux-PEGy NPs and the actual therapeutic particle
have the same size, their Rep should be identical. Thus, the fluid flow around both particle types
should have the same qualitative behavior. At body temperature, for water, ρ = 992.2 kg/m3
and µ = 6.53 × 10−4 Pa · s. The average blood flow in a tumor tissue is 10−2 m/s [226]. For an
Au50-PEG5000 NP (∼75 nm), Rep = 5× 10−4  1, indicating low Re flow.
Rep =
ρUR
µ
The particle Pe´clet number (Pe) describes nature of particle movement under an imposed
velocity. It compares the relative importance of convection and diffusion. For a spherical particle,
the Stokes-Einstein relationship gives an expression for D, diffusion coefficient, and hence Pe.
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C is the Cunningham slip correction factor that accounts for the breakdown of the no-slip
boundary condition at the particle surface as the particle dimension approaches the mean free
path of solvent molecules. At body temperature, and using C = 5 for a 75 nm particle, Pe =
8, implying that particle motion is largely due to the influence of convective forces. Because Pe
solely depends on hydrodynamic size of the particle, both Aux-PEGy NPs and actual therapeutic
particles of the same size are pushed along the blood capillaries by convective forces.
Pe =
UR
D
=
UR
kTC/6piµR
=
6piµUR2
kTC
The Stokes number (St) is the ratio of stop distance to the characteristic length scale of flow,
L. τ is the stopping time due to its encounter of an obstacle. A gold particle (ρp = 19300 kg/m
3)
is much denser than any carbohydrate- or polymer-based actual therapeutic particle (e.g., ρp =
1000 kg/m3 for β-cyclodextrins). The former should bear a higher inertial force to follow the
streamline of blood flow in tumor capillaries than the latter. Based on histology images of the
Neuro2A tumor, each turn in blood vessel (L) is around 5 µm width. St for Aux-PEGy NPs
is about 10−4  1. For the actual therapeutic particle, St is 5 × 10−5. Becauses St  1 for
Aux-PEGy NPs and therapeutic nanoparticles, both will trace the fluid streamlines of tumor
capillaries closely as they bypass irregular obstacles of the vasculature.
St =
Uτ
L
=
2U
9µL
CR2ρp
For all studies with Aux-PEGy NPs discussed above, the i.v. injection concentration was
kept constantly at 4.5× 1011 particles per 0.1 mL of D5W per animal. Despite the dense surface
engraftment of PEG chains (σ = 0.1), the i.v. administration of Aux-PEGy NPs into animals at
this concentration is not difficult. What governs the viscosity of this suspension?
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In a given volume V that contains n spherical particles of radius R and volume vs, the volume
fraction of spheres, φ, is given below. Given an injection formulation of Au50-PEG5000 NPs (R
= 37.5 nm), φ ∼ 10−3  1. Thus, the suspension is considered dilute. The effective viscosity,
µeff , due to the introduction of a dilute suspension of uncharged, force-and torque-free colloidal
particles (roughly appropriate for weakly charged Aux-PEGy NPs) under symmetric straining
motion in a Newtonian fluid is given below [227]:
φ =
nvs
V
=
n
V
(
4
3
piR3
)
µeff
µ
= 1 +
5
2
φ
The order φ correction of µ stems from the additional deviatoric viscous dissipation. This
equation assumes a similar density between the sphere (ρs) and surrounding fluid (ρf ), and does
not necessarily apply to the much denser gold particle suspension. To verify mathematically,
consider the Cauchy momentum equation in the low Reynolds number regime (Rep  1), where
g is the constant force of gravity acting on the sphere due to the density discrepancy:
0 = ∇ · σ − δρg =⇒
∫
σijdV =
∫
dσik
dxk
xjdV +
∫
∆ρgixjdV
As gi is a constant vector and hence can be pulled out of the volume integral, the right integral
identically equals zero. This step ultimately leads to the derivation of Einstein’s original µeff
expression. The discrepancy in density between spheres and fluid is still permissible. This makes
physical sense because, as a body force, gravity always act in the normal direction and never
exerts any deviatoric stress to shear the spheres horizontally with the fluid. The sedimentation
of the spheres and the shearing of fluid due to the suspension are orthogonal to each other.
The order φ correction to µeff is very limited because φ 1!
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